
Access from the University of Nottingham repository:
http://eprints.nottingham.ac.uk/41038/1/Raj%20Gandhi%20revised%20thesis.pdf

Copyright and reuse:

The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

This article is made available under the University of Nottingham End User licence and may be reused according to the conditions of the licence. For more details see:
http://eprints.nottingham.ac.uk/end_user_agreement.pdf

For more information, please contact eprints@nottingham.ac.uk
The role of polyadenylation in the induction of inflammatory genes

Raj Gandhi BSc & ARCS

Thesis submitted for the degree of Doctor of Philosophy

September 2016
Declaration

Except where acknowledged in the text, I declare that this thesis is my own work and is based on research that was undertaken by me in the School of Pharmacy, Faculty of Science, The University of Nottingham.
Acknowledgements

First and foremost, I give thanks to my primary supervisor Dr. Cornelia de Moor. She supported me at every step, always made time for me whenever I needed it, and was sympathetic during times of difficulty. I feel very, very fortunate to have been her student. I would also like to thank Dr. Catherine Jopling for her advice and Dr. Graeme Thorn for being so patient and giving me so much help in understanding the bioinformatics parts of my project. I am grateful to Dr. Anna Piccinini and Dr. Sadaf Ashraf for filling in huge gaps in my knowledge about inflammation and osteoarthritis, and to Dr. Sunir Malla for help with the TAIL-seq work. I thank Dr. Richa Singhana and Kathryn Williams for proofreading.

Dr. Hannah Parker was my “big sister” in the lab from my first day, and I am very grateful for all her help and for her friendship. My project was made all the more enjoyable/bearable by the members of the Gene Regulation and RNA Biology group, especially Jialiang Lin, Kathryn Williams, Dr. Richa Singhana, Aimée Parsons, Dan Smalley, and Hibah Al-Masmoum. Barbara Rampersad was a wonderful technician.

Mike Thomas, James Williamson, Will Hawley, Tom Upton, and Jamie Ware were some of the best of friends I could have hoped to make in Nottingham. Regularly meeting up for board games nights was instrumental in the maintenance of my sanity. I am thankful to Jess Beaver, my personal trainer and friend, through whom I discovered my hobby of fitness and formed goals that gave me a sense of purpose and meaning. Yes, my life is that sad. I give thanks to my girlfriend Janay Gibbons for helping me to keep my head screwed on towards the end when it started loosening.

Lastly, I am grateful to my parents and I thank my beloved siblings Vikram Gandhi, Krishna Gandhi, and Catherine Soskice-Gandhi for their love and support, especially through tough times.
Abstract

Polyadenylation is a universal step in the production of all metazoan mRNAs except histone mRNA. Despite being universal, previous experiments have implicated it in the regulation of inflammation. An inflammatory system using RAW 264.7 murine macrophage cells was established with bacterial lipopolysaccharide (LPS) used as a stimulus. After improving the poly(A) tail test (PAT) method of measuring poly(A) tail lengths, it was applied to inflammatory mRNAs during the inflammatory response. Poly(A) tail length was shown to vary over the course of the inflammatory response, and for Tnf, this was even true of initial poly(A) tail size, which is widely believed to be uniform for the majority of mRNAs. The adenosine analogue cordycepin (3’-deoxyadenosine) was shown to have anti-inflammatory effects on mRNA, in line with existing literature, and is likely to be the anti-inflammatory component of Cordyceps militaris ethanol extract. Inhibition of either import of cordycepin into cells or phosphorylation of cordycepin was sufficient to abolish its anti-inflammatory effects. Adenosine treatment led to repression of Il1b mRNA, but did not repress other mRNAs tested that were cordycepin-sensitive. This suggests that cordycepin does not simply act by mimicking the effect of adenosine, and that the two compounds have distinct modes of action. Inhibiting deamination of cordycepin potentiated its effects. We also observed that pre-mRNA levels of inflammatory genes were decreased by cordycepin treatment, indicative of effects on transcription. Other groups have reported that cordycepin interferes with NF-κB signalling. As NF-κB is an important transcription factor for the induction of inflammatory genes, this would provide a basis for explaining our observation that cordycepin represses at the transcriptional level. However, we did not observe any changes in NF-κB signalling, with degradation of IκBα completely unimpeached by cordycepin treatment. Notably, cordycepin did shorten the Tnf poly(A) tail, and the
observed inhibition of polyadenylation is consistent with observations that
cordycepin led to decreased efficiencies of mRNA 3’ cleavage and transcription
termination for Tnf. Such effects on polyadenylation and 3’ processing of mRNA
were hypothesised to particularly affect unstable mRNAs that depend on longer
poly(A) tails for avoiding decay and/or mRNAs with a high rate of transcription.
However, comparison of microarray data to data from RNA-seq of RNA from 4-
thiouridine labelling experiments showed that cordycepin-sensitivity did not
correlate with mRNA stability or transcription rate. Long noncoding RNAs (IncRNAs)
were found to be enriched in cordycepin-treated cells. If some of those IncRNAs
have regulatory roles in inflammation, cordycepin’s effects may be mediated
through them. Lastly, cordycepin significantly altered pain behaviour in a rat model
of osteoarthritis (OA), supporting its continued use as a lead compound for
exploration of new OA therapeutics.
Abstract........................................................................................................................................... i
List of figures....................................................................................................................................... vii
List of tables ......................................................................................................................................... xi
List of abbreviations ........................................................................................................................... xii
1 Introduction ........................................................................................................................................ 1
  1.1 Polyadenylation ............................................................................................................................ 2
    1.1.1 Mechanics of nuclear polyadenylation .................................................................................. 2
    1.1.2 Control of poly(A) tail length .............................................................................................. 5
    1.1.3 Poly(A) polymerases and other types of polyadenylation .................................................. 8
      1.1.3.1 Cytoplasmic polyadenylation ....................................................................................... 10
      1.1.3.2 Mitochondrial polyadenylation .................................................................................... 12
    1.1.4 Biological importance and role of the poly(A) tail ............................................................ 13
    1.1.5 Alternative polyadenylation ................................................................................................. 17
    1.1.6 Measuring poly(A) tails ....................................................................................................... 17
  1.2 Cordycepin ...................................................................................................................................... 24
    1.2.1 Cordycepin and transcription ................................................................................................ 24
    1.2.2 Cordycepin and mTOR signalling ...................................................................................... 25
    1.2.3 Cordycepin and polyadenylation ......................................................................................... 27
      1.2.3.1 Polyadenylation and cordycepin’s mechanism ............................................................... 29
  1.3 Inflammation ............................................................................................................................... 30
    1.3.1 Inflammation and pain ......................................................................................................... 31
    1.3.2 Macrophages ....................................................................................................................... 32
      1.3.2.1 Macrophage receptors and signalling .......................................................................... 34
        1.3.2.1.1 LPS signalling through TLR4 ................................................................................ 35
          1.3.2.1.1.1 MyD88-dependent pathway ......................................................................... 36
          1.3.2.1.1.2 TRIF-dependent pathway ........................................................................... 38
        1.3.2.1.2 NF-κB signalling in inflammation ......................................................................... 39
          1.3.2.1.3 Regulation of inflammatory cytokine mRNA stability .................................. 42
    1.3.3 Anti-inflammatory effects of cordycepin .............................................................................. 45
  1.4 Osteoarthritis – a therapeutic application of cordycepin? ......................................................... 47
  1.5 Project aims and outcomes ......................................................................................................... 51
2 Materials and methods ................................................................................................................... 53
2.1 Cell work .................................................................................................................. 53
   2.1.1 Cell culture ........................................................................................................ 53
   2.1.2 Cell stimulation with lipopolysaccharide (LPS) and treatments with compounds .................................................................................................................. 53
   2.1.3 Preparation of fungal ethanol extracts for use in cell culture ........ 54
   2.1.3.1 Assessing cordycepin and 3’ deoxyinosine concentration in fungal extracts by liquid chromatography/mass spectrometry (LC/MS) (performed by Wahyu Utami) ............................................................................. 55
2.2 RNA work .................................................................................................................. 56
   2.2.1 RNA isolation ..................................................................................................... 56
   2.2.2 RNA isolation from nuclear and cytoplasmic fractions ........................................ 57
   2.2.3 4-thiouridine labelling for nascent mRNA capture performed by Richa Singania 58
   2.2.4 Reverse transcription quantitative PCR (RT-qPCR) ............................................. 60
   2.2.5 Microarray analysis (data analysis performed by Graeme Thorn) ......... 63
   2.2.6 Poly(A) tail measurement ................................................................................... 64
   2.2.7 High throughput poly(A) tail measurement: TAIL-seq .............................. 74
2.3 Protein work .............................................................................................................. 80
   2.3.1 Western blot analysis ........................................................................................ 80
2.4 Animal work .............................................................................................................. 81
   2.4.1 Rat osteoarthritis model pain behaviour assessment by James Burston 81
   2.4.2 RNA isolation from rat synovia ......................................................................... 81
3 Optimising and developing methodologies for poly(A) tail measurements....... 83
   3.1 Deadenylation by oligo (dT)/RNase H treatment ................................................. 83
   3.2 Appraising different ligation strategies ................................................................. 86
   3.3 Identifying artefacts ............................................................................................... 91
   3.4 High-throughput poly(A) tail measurements – TAIL-seq ................................. 96
   3.5 Discussion ............................................................................................................. 104
4 Inflammation and polyadenylation in RAW 264.7 cells ................................... 105
   4.1 Developing the inflammatory system .................................................................... 106
   4.2 Time courses and poly(A) tails ............................................................................ 108
   4.3 Discussion ............................................................................................................. 114
List of figures

Chapter 1 - Introduction

Figure 1.1 The poly(A) tail allows for formation of the closed-loop complex which enhances recruitment of translation initiation factors 13

Figure 1.2 Life cycle of an mRNA 16

Figure 1.3 Schematic overview of the RNA ligation-mediated PAT procedure 20

Figure 1.4 Overview of the TAIL-seq library generation procedure 23

Figure 1.5 Chemical structure of cordycepin 25

Figure 1.6 Simplified PI3 kinase/Akt signalling pathway showing proposed interaction with cordycepin 26

Figure 1.7 TLR4 signalling through the MyD88 pathway 38

Figure 1.8 NF-κB activation downstream of the MyD88 pathway following LPS binding to TLR4 40

Figure 1.9 Simplified p38 signalling pathway overview 43

Figure 1.10 Changes in knee physiology in osteoarthritis 49

Chapter 2 - Materials and methods

Figure 2.1 Mechanism of RNA ligation 67

Figure 2.2 Overview of sPAT ligation 70

Figure 2.3 Overview of the TAIL-seq library generation procedure 74
Chapter 3 - Optimising and developing methodologies for poly(A) tail measurements

Figure 3.1  Incomplete deadenylation using NEB RNase H was addressed by increasing oligo (dT) and RNase H quantities 85

Figure 3.2  RL2 PAT yields more consistent results with a range of input RNA quantities, and more efficient cDNA generation 87

Figure 3.3  The L2T ligation improves sPAT compared to the T4 Rnl2 sPAT ligation 89

Figure 3.4  RL2-PAT results in greater efficiency of cDNA generation 90

Figure 3.5  An increase in PCR product:formamide ratio increases the prevalence of suspected multimeric bands 92

Figure 3.6  Artefactual species are multimers and can be removed through fully denaturing PAGE 94

Figure 3.7  Addition of oligo (dT) to PAT-PCR products can remove multimer species 95

Figure 3.8  Only unligated RA3 oligo is recovered after the streptavidin pulldown 97

Figure 3.9  Increasing RNase T1 digestion time results in shorter RNA fragments 102

Figure 3.10  Changing the 3’ adapter ligation strategy and increasing the RNase T1 digest duration resulted in successful amplification of a library 103
Chapter 4 - Inflammation and polyadenylation in RAW 264.7 cells

Figure 4.1  Serum withdrawal prior to LPS stimulation results in a more pronounced response 107

Figure 4.2  LPS stimulation of RAW 264.7 cells induces expression of inflammatory genes 109

Figure 4.3  Tnf and Cxcl2 poly(A) tails change in size over the course of their inductions by LPS 111

Figure 4.4  Initial Tnf poly(A) tail size is variable 113

Chapter 5 - Cordycepin and macrophages

Figure 5.1  Ethanol extracts from C. militaris and O. sinensis exhibited similar repressive effects to those of cordycepin 117

Figure 5.2  Cordycepin represses inflammatory gene expression 119

Figure 5.3  Administering cordycepin 10 minutes after LPS causes the same repression as a 1 hour pretreatment 121

Figure 5.4  Cordycepin represses at the transcriptional level 122

Figure 5.5  Pentostatin potentiates cordycepin’s repressive effect on inflammatory gene expression 123

Figure 5.6  Inhibiting import of cordycepin or its phosphorylation abrogates its repression of inflammatory genes 126

Figure 5.7  Cordycepin effects can be persistent 128

Figure 5.8  Cordycepin shortens the Tnf poly(A) tail 129

Figure 5.9  Cordycepin causes defects in transcription termination and mRNA 3’ cleavage 130
The effects of cordycepin on mRNA 3’ processing are not shared by adenosine and are unlikely to be mediated extracellularly.

IκBα degradation is not prevented by cordycepin.

Chapter 6 - High-throughput analysis of cordycepin-treated RAW 264.7 cells

94 RNAs with a >2-fold increase after LPS treatment are >2-fold downregulated by cordycepin.

Cordycepin sensitivity is independent of mRNA stability and transcription rate.

IncRNAs are enriched in RNAs that are upregulated by cordycepin treatment.

Cordycepin in a rat model of osteoarthritis

Cordycepin alters pain behaviour in a rat osteoarthritic model.

After killing the rat, the synovium must be quickly removed and chilled to avoid RNA degradation.

No significant differences observed in assessed inflammatory gene mRNA levels in rat ipsilateral synovia between treatment groups.

No global poly(A) tail length differences were observed between rat groups in ipsilateral synovial RNA samples.
List of tables

Table 1.1 List of general polyadenylation factors thought to function in most cell types 3

Table 2.1 List of PAT primers 72

Table 2.2 List of TAIL-seq primers 78

Table 2.3 List of qPCR primers 79

Table 2.4 List of rat qPCR primers used 82

Table 3.1 The ligation used in the PAT workflow successfully generated cDNA for TAIL-seq 99

Table 5.1 *Cordyceps militaris* extract contains significant quantities of cordycepin while *Cordyceps sinensis* extract does not 117

Table 6.1 Immune and inflammatory GO terms are the most significantly enriched in genes downregulated by cordycepin 138
### List of abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3' UTR</td>
<td>3' untranslated region</td>
</tr>
<tr>
<td>32P-pCp</td>
<td>[5'-32P]Cytidine 3',5'-bis(phosphate)</td>
</tr>
<tr>
<td>4EBP1</td>
<td>eIF4E-binding protein</td>
</tr>
<tr>
<td>4SU</td>
<td>4-thiouridine</td>
</tr>
<tr>
<td>5' UTR</td>
<td>5' untranslated region</td>
</tr>
<tr>
<td>ADA</td>
<td>Adenosine deaminase</td>
</tr>
<tr>
<td>AMP</td>
<td>Adenosine monophosphate</td>
</tr>
<tr>
<td>AMPK</td>
<td>AMP-activated protein kinase</td>
</tr>
<tr>
<td>AP-1</td>
<td>Activator protein 1</td>
</tr>
<tr>
<td>APA</td>
<td>Alternative polyadenylation</td>
</tr>
<tr>
<td>ARE</td>
<td>AU-rich element</td>
</tr>
<tr>
<td>ARE-BP</td>
<td>ARE-binding protein</td>
</tr>
<tr>
<td>ASM</td>
<td>Airway smooth muscle</td>
</tr>
<tr>
<td>ATF2</td>
<td>Activating transcription factor 2</td>
</tr>
<tr>
<td>ATP</td>
<td>Adenosine triphosphate</td>
</tr>
<tr>
<td>BCP</td>
<td>Basic calcium phosphate</td>
</tr>
<tr>
<td>BDNF</td>
<td>Brain-derived neurotrophic factor</td>
</tr>
<tr>
<td>BM-MSC</td>
<td>Bone marrow mesenchymal stem cell</td>
</tr>
<tr>
<td>cAMP</td>
<td>Cyclic AMP</td>
</tr>
<tr>
<td>CBP</td>
<td>CREB binding protein</td>
</tr>
<tr>
<td>CDE</td>
<td>Constitutive decay element</td>
</tr>
<tr>
<td>cDNA</td>
<td>complementary DNA</td>
</tr>
<tr>
<td>CF Iim</td>
<td>Mammalian cleavage factor II</td>
</tr>
<tr>
<td>CF Im</td>
<td>Mammalian cleavage factor I</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>CNS</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>CPEB</td>
<td>Cytoplasmic polyadenylation element binding protein</td>
</tr>
<tr>
<td>CPPD</td>
<td>Calcium pyrophosphate dehydrate</td>
</tr>
<tr>
<td>CPSF</td>
<td>Cleavage and polyadenylation specificity factor</td>
</tr>
<tr>
<td>CREB</td>
<td>cAMP response element-binding protein</td>
</tr>
<tr>
<td>CstF</td>
<td>Cleavage stimulating factor</td>
</tr>
<tr>
<td>DAMP</td>
<td>Danger-associated molecular pattern</td>
</tr>
<tr>
<td>DEG</td>
<td>Differentially expressed gene</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco's modified Eagle medium</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulfoxide</td>
</tr>
<tr>
<td>dNTP</td>
<td>Deoxynucleoside triphosphate</td>
</tr>
<tr>
<td>DTT</td>
<td>Dithiothreitol</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylenediaminetetraacetic acid</td>
</tr>
<tr>
<td>EGF</td>
<td>Epidermal growth factor</td>
</tr>
<tr>
<td>EGTA</td>
<td>Ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid</td>
</tr>
<tr>
<td>eIF4E</td>
<td>Eukaryotic translation initiation factor 4E</td>
</tr>
<tr>
<td>ERK</td>
<td>Extracellular signal-regulated kinase</td>
</tr>
<tr>
<td>FBP</td>
<td>Foetal bovine serum</td>
</tr>
<tr>
<td>FLS</td>
<td>Fibroblast-like synoviocytes</td>
</tr>
<tr>
<td>FPKM</td>
<td>Fragments per kilobase per million mapped reads</td>
</tr>
<tr>
<td>GPI</td>
<td>Glycosylphosphatidylinositol</td>
</tr>
<tr>
<td>HEPES</td>
<td>4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid</td>
</tr>
<tr>
<td>HMGB1</td>
<td>High mobility group box 1</td>
</tr>
<tr>
<td>HSC</td>
<td>Haematopoietic stem cell</td>
</tr>
<tr>
<td>IDD</td>
<td>Intervertebral disc degeneration</td>
</tr>
<tr>
<td>Term</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>IFNγ</td>
<td>Interferon gamma</td>
</tr>
<tr>
<td>IKK</td>
<td>IκB kinase</td>
</tr>
<tr>
<td>IL-1R</td>
<td>IL-1 receptor, type I</td>
</tr>
<tr>
<td>IL-1β</td>
<td>Interleukin 1 beta</td>
</tr>
<tr>
<td>IP</td>
<td>Immunoprecipitation</td>
</tr>
<tr>
<td>IRAK</td>
<td>IL-1 receptor-associated kinase</td>
</tr>
<tr>
<td>IRF</td>
<td>Interferon regulatory factor</td>
</tr>
<tr>
<td>ITu</td>
<td>5-Iodotubericidin</td>
</tr>
<tr>
<td>IκBα</td>
<td>Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha</td>
</tr>
<tr>
<td>JNK</td>
<td>Jun N-terminal kinase</td>
</tr>
<tr>
<td>KSRP</td>
<td>KH-type splicing regulatory protein</td>
</tr>
<tr>
<td>LBP</td>
<td>Lipopolysaccharide binding protein</td>
</tr>
<tr>
<td>IncRNA</td>
<td>Long non-coding RNA</td>
</tr>
<tr>
<td>LPS</td>
<td>Lipopolysaccharide</td>
</tr>
<tr>
<td>MAP3K7</td>
<td>Mitogen-activated protein kinase kinase kinase 7</td>
</tr>
<tr>
<td>MAPK</td>
<td>Mitogen-activated protein kinase</td>
</tr>
<tr>
<td>MD-2</td>
<td>Myeloid differentiation protein 2</td>
</tr>
<tr>
<td>MEK</td>
<td>MAPK Erk kinase</td>
</tr>
<tr>
<td>MIA</td>
<td>Monosodium iodoacetate</td>
</tr>
<tr>
<td>MK2</td>
<td>MAPK-activated protein kinase 2</td>
</tr>
<tr>
<td>mRNA</td>
<td>Messenger RNA</td>
</tr>
<tr>
<td>mTOR</td>
<td>Mammalian target of Rapamycin</td>
</tr>
<tr>
<td>MyD88</td>
<td>Myeloid differentiation primary response gene 88</td>
</tr>
<tr>
<td>NBTI</td>
<td>S-(4-Nitrobenzyl)-6-thioinosine</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>nCPAP</td>
<td>Non-canonical poly(A) polymerase</td>
</tr>
<tr>
<td>NEMO</td>
<td>NF-κB essential modulator</td>
</tr>
<tr>
<td>NF-κB</td>
<td>Nuclear factor kappa-light-chain-enhancer of activated B cells</td>
</tr>
<tr>
<td>NGF</td>
<td>Neural growth factor</td>
</tr>
<tr>
<td>NLS</td>
<td>Nuclear localisation signal</td>
</tr>
<tr>
<td>NMDA</td>
<td>N-methyl-D-aspartate</td>
</tr>
<tr>
<td>NMDAR</td>
<td>NMDA receptor</td>
</tr>
<tr>
<td>NOD2</td>
<td>Nucleotide-binding oligomerisation domain-containing protein 2</td>
</tr>
<tr>
<td>NP</td>
<td>Nucleus pulposus</td>
</tr>
<tr>
<td>NPM1</td>
<td>Nucleophosmin</td>
</tr>
<tr>
<td>OA</td>
<td>Osteoarthritis</td>
</tr>
<tr>
<td>PABP</td>
<td>Poly(A) binding protein</td>
</tr>
<tr>
<td>PAMP</td>
<td>Pathogen-associated molecular pattern</td>
</tr>
<tr>
<td>PAP</td>
<td>Poly(A) polymerase</td>
</tr>
<tr>
<td>PARN</td>
<td>Poly(A) ribonuclease</td>
</tr>
<tr>
<td>PAT</td>
<td>Poly(A) tail test</td>
</tr>
<tr>
<td>PBE</td>
<td>Pumilio binding element</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate-buffered saline</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PEG</td>
<td>Polyethylene glycol</td>
</tr>
<tr>
<td>PGE2</td>
<td>Prostaglandin E₂</td>
</tr>
<tr>
<td>PI3-kinase</td>
<td>Phosphoinositide 3-kinase</td>
</tr>
<tr>
<td>PKAc</td>
<td>Catalytic subunit of protein kinase A</td>
</tr>
<tr>
<td>PLE</td>
<td>Poly(A) limiting element</td>
</tr>
<tr>
<td>PMSF</td>
<td>Phenylmethylsulfonyl fluoride</td>
</tr>
</tbody>
</table>
PNK  Polynucleotide kinase
PP2A  Protein phosphatase 2A
PRR  Pattern recognition receptor
PTM  Post-translational modification
PUM2  Pumilio
PWT  Paw withdrawal threshold
RHD  Rel homology domain
RIG-I  Retinoic acid-inducible gene 1
RIP1  Receptor-interacting protein 1
RNAP II  RNA polymerase II
ROS  Reactive oxygen species
rRNA  Ribosomal RNA
RT-qPCR  Reverse transcription quantitative PCR
SAPK  Stress-activated protein kinase
SARM  Sterile α and HEAT-Armadillo motifs-containing protein
SDS  Sodium dodecyl sulfate
SDS-PAGE  SDS-polyacrylamide gel electrophoresis
TAD  Transactivation domain
TAK1  Transforming growth factor β-activated kinase 1
TANK  TRAF family member-associated NF-κB activator
TBE  Tris/Borate/EDTA
TBK1  TANK binding kinase 1
TGF-β1  Transforming growth factor beta 1
TIF-I  Transcription Initiation Factor I
TIR  Toll/IL1R homology
<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>TIRAP</td>
<td>TIR domain-containing adapter protein</td>
</tr>
<tr>
<td>TLR</td>
<td>Toll-like receptor</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumour necrosis factor</td>
</tr>
<tr>
<td>TNFR1</td>
<td>TNF receptor-1</td>
</tr>
<tr>
<td>TRAF6</td>
<td>TNF receptor-associated factor 6</td>
</tr>
<tr>
<td>TRAM</td>
<td>TRIF-related adapter molecule</td>
</tr>
<tr>
<td>TRAMP complex</td>
<td>Trf4p/Air2p/Mtr4p polyadenylation complex</td>
</tr>
<tr>
<td>TRIF</td>
<td>TIR domain-containing adapter inducing IFN-β</td>
</tr>
<tr>
<td>tRNA</td>
<td>Transfer RNA</td>
</tr>
<tr>
<td>TTP</td>
<td>Tristetraprolin</td>
</tr>
<tr>
<td>U2AF</td>
<td>U2 auxiliary factor</td>
</tr>
<tr>
<td>UBC13</td>
<td>Ubiquitin-conjugating enzyme 13</td>
</tr>
<tr>
<td>UBF</td>
<td>Upstream binding factor</td>
</tr>
<tr>
<td>UEV1A</td>
<td>Ubiquitin-conjugating enzyme variant 1 isoform A</td>
</tr>
</tbody>
</table>
1 Introduction

There are many forms of gene regulation at the epigenetic, transcriptional, and post-transcriptional levels. One of the key steps in posttranscriptional gene regulation is the 3’ processing of mRNA. It is an integral step in the production of a mature eukaryotic mRNA transcript. It involves cleavage of the mRNA 20-40 nt downstream of a poly(A) signal in the 3’ UTR, followed by the addition of a poly(A) tail at the point of cleavage (Proudfoot 2011). This happens for all metazoan mRNAs with the exception of histone mRNA. The poly(A) tail facilitates export of transcripts from the nucleus, aids mRNA association with factors that promote translation initiation, and serves a protective role for the mRNA (Matthew Brook and Gray 2012; Burgess et al. 2010; Kahvejian et al. 2005). While mRNA 3’ processing is a universal process, it was recently suggested that it may have a specific role in regulating inflammation (Kondrashov et al. 2012). Inflammation is a key part of the innate mammalian immune system, mediating host defence against pathogenic threats and responding to tissue damage. It must be carefully regulated in order to respond sufficiently to resolve threats and damage, but not be so active that it causes collateral damage to the host. In the case of the latter, inflammatory diseases result (Barnes et al. 2010; Karin 2006; Puntenmann, Taylor, and Mayr 2011; Hummasti and Hotamisligil 2010).

Cordycepin, an adenosine analogue, is a polyadenylation inhibitor derived from caterpillar fungi prized in Far Eastern traditional medicine. Cordycepin is said to have anti-inflammatory properties (among many others), and this has been shown both in cell culture systems as well as animal disease models (X. Yang et al. 2015; H. Kim et al. 2011; Rottenberg et al. 2005; H. G. Kim et al. 2006; Shin, Lee, et al. 2009; Y. Li et al. 2016). Briefly, this project aimed to investigate the role of polyadenylation in the inflammatory response, and to gain insight into how cordycepin’s anti-inflammatory
effects are mediated – whether through inhibition of polyadenylation or through other mechanisms.

1.1 Polyadenylation

1.1.1 Mechanics of nuclear polyadenylation

In metazoan gene expression, 3’ cleavage and polyadenylation of pre-mRNA at the end of transcription is a critical step. With the exception of histone mRNA, it occurs for all transcribed mRNAs. Sequences in the 3’ UTR are recognised and bound by various processing factors following which a cleavage reaction occurs, yielding two fragments. The 5’ fragment yielded is polyadenylated immediately 3’ of the site of cleavage, i.e. a chain of adenosine phosphate residues (the poly(A) tail), is added to produce the mature mRNA molecule. The 3’ fragment of the cleavage reaction is degraded (Proudfoot 2011; Kuehner, Pearson, and Moore 2011). While there is variation e.g. between yeast and metazoan systems, there is significant similarity and homology between proteins that participate in the process (Shatkin and Manley 2000; Zhao, Hyman, and Moore 1999). Here, I will describe the metazoan system.

Polyadenylation is governed by cis-elements in the 3’UTR which interact with a host of trans-acting factors that facilitate the cleavage and polyadenylation reactions (Tian and Graber 2012). These factors, summarised in Table 1.1, include the cleavage and polyadenylation specificity factor (CPSF), cleavage factors Im and IIm (CF Im and CF IIm, respectively), cleavage stimulating factor (CstF), Symplekin, WDR33, FIP1L1, and a poly (A) polymerase (PAP). In cases for which commonly used names differ from official HUGO gene nomenclature, I will use the official names, but both sets of names are shown in Table 1.1.

A consensus hexamer, most commonly AAUAAA, is found some 15-30 nt upstream of the cleavage site in the mRNA 3’ UTR. This sequence is recognised by WDR33 and
CPSF4 (Chan et al. 2014; Schönemann et al. 2014), and not by CPSF1, as previously thought (Keller et al. 1991; Murthy and Manley 1995). An upstream element (usually UGUA) associates with CF Im (Q. Yang, Gilmartin, and Doublié 2011), and a U/GU-rich element located 20-40 nt downstream of the cleavage site associates with CstF (Takagaki and Manley 1997; Perez Canadillas et al. 2003; Beyer, Dandekar, and Keller 1997). Symplekin is thought to serve as a scaffolding protein that links CstF and CPSF (Takagaki and Manley 2000). Two constituent proteins of CF IIm, CLP1 and PCF11, were found to be present in the 3’ processing complex at very low levels (substoichiometric) compared to CPSF, CstF, and CF Im (Shi et al. 2009).

<table>
<thead>
<tr>
<th>Protein Name</th>
<th>Other names</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPSF complex</td>
<td></td>
</tr>
<tr>
<td>CPSF1</td>
<td>CPSF160</td>
</tr>
<tr>
<td>CPSF2</td>
<td>CPSF100</td>
</tr>
<tr>
<td>CPSF3</td>
<td>CPSF73</td>
</tr>
<tr>
<td>CPSF4</td>
<td>CPSF30</td>
</tr>
<tr>
<td>FIP1L1</td>
<td>hFip1</td>
</tr>
<tr>
<td>CstF complex</td>
<td></td>
</tr>
<tr>
<td>CTF1</td>
<td>CstF50</td>
</tr>
<tr>
<td>CTF2</td>
<td>CstF64</td>
</tr>
<tr>
<td>CTF3</td>
<td>CstF77</td>
</tr>
<tr>
<td>CF Im complex</td>
<td></td>
</tr>
<tr>
<td>CPSF6</td>
<td>CF Im 68</td>
</tr>
<tr>
<td>CPSF7</td>
<td>CF Im 59</td>
</tr>
<tr>
<td>NUDT21</td>
<td>CF Im 25; CPSF5</td>
</tr>
<tr>
<td>CF IIm complex</td>
<td></td>
</tr>
<tr>
<td>PCF11</td>
<td>hPcf11</td>
</tr>
<tr>
<td>CLP1</td>
<td>hClp1</td>
</tr>
<tr>
<td>Other Known Polyadenylation Factors</td>
<td></td>
</tr>
<tr>
<td>SYMPK</td>
<td>Symplekin</td>
</tr>
<tr>
<td>PAPOLG</td>
<td>PAP-γ</td>
</tr>
<tr>
<td>PAPOLA</td>
<td>PAP-α</td>
</tr>
<tr>
<td>PABPC1</td>
<td></td>
</tr>
<tr>
<td>PABPC4</td>
<td></td>
</tr>
<tr>
<td>PABPN1</td>
<td></td>
</tr>
<tr>
<td>WDR33</td>
<td></td>
</tr>
</tbody>
</table>

Table 1.1. List of general polyadenylation factors thought to function in most cell types. Official HGNC names for *Homo sapiens* are given in the first column, synonyms are given in the second column. Table adapted from (Shi et al. 2009)
Addition of antibodies against CLP1 to HeLa nuclear extracts reduced cleavage activity, but not polyadenylation activity (de Vries et al. 2000). Together, these findings suggest that Cf Ilm may transiently associate with the rest of the 3’ processing machinery to stimulate cleavage activity, possibly by linking CPSF and CF Im (de Vries et al. 2000). The exonuclease Xrn2 degrades the 3’ product after mRNA cleavage, resulting in transcriptional termination (West, Gromak, and Proudfoot 2004). Further data from HeLa cells demonstrates roles for PCF11 in mediating efficient transcription termination and degradation of the 3’ cleavage product (West and Proudfoot 2008). In mammals, a distal G-rich auxiliary downstream element has also been identified, although it is not clear which factor(s) it interacts with. Lastly, most cleavage sites have a CA dinucleotide immediately 5’ of the cleavage site (with mRNA being cleaved immediately after the A). This dinucleotide sequence can be clinically relevant e.g. in the case of the human prothrombin gene. The prothrombin mRNA 3’ UTR has a CG dinucleotide, rather than the more common CA, which has been shown to result in a lower efficiency of cleavage in vitro (F. Chen, MacDonald, and Wilusf 1995). In ~1-2% of the Caucasian population the CG dinucleotide is mutated to CA, and is thought to be a cause of thrombophilia experienced by individuals with the mutation (Poort et al. 1996; Cattaneo et al. 1999). In these cases, the processing of the prothrombin mRNA is enhanced, as seen in cell culture conditions and transgenic mice (Gehring et al. 2001; Danckwardt et al. 2004; Kuwahara, Kurachi, and Kurachi 2004). The resulting increase in prothrombin expression (at the level of both mRNA and protein) provided the basis for a model to explain the contribution of the mutation to the pathogenesis of thrombophilia.

While CPSF3 was reported to be the endonuclease that performs the cleavage (Mandel et al. 2006), it seems both CPSF3 and CPSF2 contribute to endonucleolytic activity (Kolev et al. 2008). Upon cleavage of the mRNA, a poly(A) polymerase
processively adds adenosine phosphate residues to form the poly(A) tail, typically thought to be 200-250 nt in length. The polyadenylation reaction is stimulated by FIP1L1 (Kaufmann et al. 2004). There are a number of canonical and non-canonical poly(A) polymerases (ncPAPs), which are discussed in section 1.1.3. PABPN1, a poly(A) binding protein (PABP), stimulates poly(A) tail extension and is thought to have a role in controlling its length (Kuhn et al. 2009). Nucleophosmin (NPM1) deposition on the poly(A) tail is also involved in poly(A) tail length control, with NPM1 knockdown resulting in hyperadenylation of mRNA in HeLa cells (Sagawa et al. 2011).

1.1.2 Control of poly(A) tail length

It is generally thought that a new mRNA is made in the nucleus with a poly(A) tail of 200-250 nt. The mechanism proposed for the control of the length involves interactions between CPSF, the poly(A) polymerase (PAP) doing the polyadenylation, and PABPN1 (Kuhn et al. 2009). Initially, binding of PABPN1 to the nascent poly(A) tail and of CPSF to the poly(A) signal allows them to stimulate PAP activity. However, once the critical length is reached (~250 nt), PABPN1 then disrupts stimulation of PAP by CPSF, and so PABPN1 is proposed to perform the role of measuring and limiting the length of the poly(A) tail. PABPN1 has also been shown to have a role in splicing. While splicing is generally understood to occur co-transcriptionally (Tilgner et al. 2012; Carrillo Oesterreich, Preibisch, and Neugebauer 2010; Khodor et al. 2011; Ameur et al. 2011), some splicing occurs following polyadenylation. In human cells, PABPN1 depletion decreased the splicing efficiency of a subset of pre-mRNAs that undergo splicing after polyadenylation (Muniz, Davidson, and West 2015). Knockdown of PAPOLA and PAPOLG also decreased the splicing efficiency, even for a synthetic construct whose cleavage and polyadenylation did not depend on cellular machinery i.e. the poly(A) polymerases’ role in facilitating splicing was independent
of the process of polyadenylation. IP experiments also showed PABPN1 depletion reduced association of splicing factors with terminal introns. 

The RNA binding protein ZC3H14 is important in neural function (Pak et al. 2011) and also has a role in controlling poly(A) tail lengths (Kelly et al. 2014). In mouse neuroblastoma cells, depletion of Pabpn1 led to shortening of total poly(A) tail length, while depletion of ZC3H14 led to longer poly(A) tails. Adult survival of flies lacking Nab2 (orthologue of ZC3H14) was very low, but those that did survive exhibited defects in development and locomotion. These could be rescued by neuron-specific transgenic expression of human ZC3H14, indicating an evolutionarily conserved role of this RNA binding protein. In yeast, the PABPs Pab2 and Nab2 have opposing roles in the nuclear decay of pre-mRNA (Grenier St-Sauveur et al. 2013). Pab2 facilitates exosomal degradation of pre-mRNA while Nab2 impedes it, affording the pre-mRNA more time to complete posttranscriptional splicing, ‘escape’ the Pab2-mediated exosomal decay, and be exported into the cytoplasm. Thus, nuclear PABPs can influence poly(A) tail length but can also serve other roles in regulating gene expression. 

While the 250 nt length in animals is generally accepted as the initial poly(A) tail size of a newly transcribed mRNA, there appear to be a few exceptions to the rule. Mammalian histone mRNA completely lacks a poly(A) tail (Marzluff, Wagner, and Duronio 2008; Marzluff 2005). eNOS mRNA in endothelial cells has been shown to be differentially polyadenylated in the nucleus in response to certain stimuli (Weber et al. 2005; Kosmidou et al. 2007). Under basal conditions, eNOS mRNA has a short poly(A) tail of <25 nt, but in response to statins or laminar shear stress, the mRNA is synthesised with a much longer poly(A) tail. The longer eNOS poly(A) tail is accompanied by greater mRNA half-life, greater representation of the mRNA in
higher polysome fractions (suggestive of increased translational activity), and greater mRNA levels in the cytoplasm (Weber et al. 2005; Kosmidou et al. 2007).

A cis element termed the poly(A) limiting element (PLE) was found in the terminal exon of a number of mRNAs whose initial poly(A) tail sizes were discrete and limited to <20 nt (Das Gupta et al. 1998; Gu, Das Gupta, and Schoenberg 1999). The PLE was originally identified in Xenopus albumin pre-mRNA, but placing the PLE-containing part of the mRNA into a β-globin reporter construct transfected into mouse fibroblasts produced β-globin mRNA with <20 nt poly(A) tails, indicating conservation of the limiting mechanism between species (Das Gupta et al. 1998).

Other mRNAs with PLE sequences and <20 nt poly(A) tails include transferrin and HIV-EP2, and removal of the PLE sequence in reporter constructs led to mRNAs with long poly(A) tails (Gu, Das Gupta, and Schoenberg 1999). It was later found that U2 auxiliary factor (U2AF) binds to the PLE and has a role in modulating poly(A) tail length control by the PLE (Gu and Schoenberg 2003). Interestingly, it was found that the PLE increases mRNA levels in the cytoplasm by enhancing the efficiency of mRNA 3’ processing in reporter constructs. PLE-containing RNA was cleaved in HeLa nuclear extract 80% faster than control RNA (J. Peng, Murray, and Schoenberg 2005). Furthermore, PLE-containing β-globin mRNA with a short tail <20 nt was shown to be as stable as non-PLE-containing β-globin mRNA with a poly(A) tail size of 100-200 nt. These β-globin reporter constructs had the last part of the terminal exon removed and a synthetic polyadenylation element added at this point. Thus, regulatory elements in the β-globin 3’ UTR (which confer considerable mRNA stability (Peixeiro et al. 2011)) would not be present, and therefore would not be able to influence the stability of the mRNA produced.
1.1.3 Poly(A) polymerases and other types of polyadenylation

In humans, 8 poly(A) polymerase (PAP) enzymes have been identified. The three canonical PAP enzymes are PAPα, PAPβ, and PAPγ (PAPOLA, PAPOLB, and PAPOLG respectively), with PAPOLA and PAPOLG thought to be the two main enzymes involved in nuclear polyadenylation of mRNA. Non-canonical PAPs (ncPAPs) include MTPAP (mitochondrial PAP), TUT1 (STAR-PAP), PAPD4 (GLD2), PAPD5 (GLD4), and PAPD7. Canonical PAPs are nuclear enzymes, as are some ncPAPs. However, a number of ncPAPs perform roles outside of the nucleus. Additionally, some ncPAPs also have terminal nucleotidyl transferase activity that is not limited to addition of adenosines. PAPD4 is a cytoplasmic PAP with importance in germline development and synaptic plasticity in a number of species (Sartain et al. 2011; Kwak et al. 2008; Rouhana et al. 2005; Benoit et al. 2008; Barnard et al. 2004). MTPAP is the only known mitochondrial PAP, and polyadenylates mitochondrial RNAs. PAPD5 polyadenylates aberrant pre-rRNA to bring about its degradation (Shcherbik et al. 2010), uridylates histone mRNA to bring about its degradation (Mullen and Marzluff 2008), and performs 3’ oligoadenylation for snoRNAs with possible implications for their stability (Berndt et al. 2012). PAPD5 is also implicated in the regulation of TP53 (p53) mRNA levels and protein expression (Burns and Richter 2008), which might be a cytoplasmic role (more on this in section 1.1.3.1). In yeast, the Trf4p/Air2p/Mtr4p polyadenylation (TRAMP) complex is a nuclear surveillance complex that serves to polyadenylate aberrant nuclear transcripts, leading to their exosomal degradation (Wyers et al. 2005; Vaňáčová et al. 2005; LaCava et al. 2005). This role of polyadenylation (performed by Trf4p – a non-canonical PAP and orthologue of PAPD5) appears to be more in line with polyadenylation’s prokaryotic origins, in which it promotes degradation. In mammals, a TRAMP-like complex includes PAPD5, demonstrating evolutionary conservation of the decay mechanism and a role for this
non-canonical PAP (Sudo et al. 2016; Shcherbik et al. 2010). It should be noted, however, that the phenomenon of polyadenylation in the nucleus to mediate exosomal decay of aberrant transcripts is not exclusively performed by ncPAPs. Work in human cells has revealed an exosomal nuclear decay pathway in which PAPα and PAPγ (canonical PAPs), together with PABPN1 and exosomal subunits, perform this role (Bresson and Conrad 2013). Since these poly(A) polymerases appear to have multiple roles, it is conceivable that these depend on binding partners. It was noted that this decay pathway did not affect efficiently exported RNAs. A model could therefore be constructed wherein the coupling of 3’ processing to nuclear export takes RNAs away from the polyadenylation-dependent degradative nuclear environment, and into the cytoplasm where the poly(A) tail serves other roles. A subset of long noncoding RNAs (IncRNAs) were among those found to be subject to this PABPN1-involved, polyadenylation-dependent turnover (Beaulieu et al. 2012). Further work is required for characterisation of PAPD7.

A cytoplasmic role of Trf4-1 for promoting decay in *Drosophila* was recently reported (Harnisch et al. 2016). 3’ mRNA decay intermediates were found to have terminal oligoadenylation i.e. the mRNA had already experienced some 3’ decay such that its 3’ end was upstream of the poly(A) site, but then non-template As had been added to this end. These modifications were due to the cytoplasmic activity of Trf4-1, and knockdown of Trf4-1 and the Dcp2 decapping enzyme led to a significant accumulation of 3’ decay intermediates cf Dcp2 knockdown alone, illustrating the role of Trf4-1 in promoting decay. Some ncPAPs are capable of performing 3’ end uridylation of mRNA, and are thus classed as terminal nucleotidyl transferases (TUTs) (Lim et al. 2014; Kwak and Wickens 2007; Rissland, Mikulasova, and Norbury 2007; Martin and Keller 2007). Terminal uridylation of mRNA is another modification that can influence cytoplasmic mRNA decay. In yeast and mammalian systems, it
promotes decay (Slevin et al. 2014; Malecki et al. 2013), while it may have the opposite function in *Arabidopsis* (Sement et al. 2013). Uridylation can occur after the poly(A) tail, with shorter tails being better substrates for uridylation than longer tails (Lim et al. 2014). Non-polyadenylated mRNAs like siRNA-directed cleavage products and histone mRNA decay intermediates can also be uridylated (Slevin et al. 2014; Shen and Goodman 2004).

1.1.3.1 Cytoplasmic polyadenylation

Polyadenylation can occur in the cytoplasm for mRNAs that have already been transcribed and exported from the nucleus via the process of cytoplasmic polyadenylation. Generally, the role of cytoplasmic polyadenylation is to ‘activate’ translation of certain mRNAs that are stored in the cytoplasm in a repressed state with a short poly(A) tail (Weill et al. 2012; Villalba, Coll, and Gebauer 2011). For an mRNA to be regulated in this way, it would have to (after export from the nucleus) recruit deadenylases and factors that repress translation, be stored in the cytoplasm, and then be recognised by cytoplasmic polyadenylation machinery. This process is governed by interplay between cis elements in the 3’ UTR and trans-acting factors (Charlesworth, Meijer, and de Moor 2013). These include the same poly(A) signal as is used in nuclear polyadenylation (recognised by cytoplasmic CPSF complex), the cytoplasmic polyadenylation element (CPE) (recognised by CPE binding proteins (CPEBs)), and the Pumilio binding element (PBE) (bound by Pumilio (PUM2)).

Cytoplasmic polyadenylation was originally found in germ cell and embryonic development across a number of different species, and is known to play crucial roles in these processes (Sartain et al. 2011; Luitjens et al. 2000; Wilt 1973; Fox, Sheets, and Wickens 1989; Standart and Dale 1993; Vassalli et al. 1989; Lim et al. 2016).
However, cytoplasmic polyadenylation has also been found to play roles in somatic cells, with the nervous system being one example. N-methyl-D-aspartate (NMDA) is an agonist for the NMDA receptor (NMDAR). NMDAR is thought to be important in synaptic plasticity and memory (F. Li and Tsien 2009). Treating mammalian neurons with NMDA led to a rapid increase in poly(A) tail size of NR2A mRNA. This increase was reduced by PAPD4 depletion, and NMDA treatment promoted phosphorylation of CPEB and dissociation of poly(A) ribonuclease (PARN) – these are both events associated with the transition from a repressed to activated state of mRNAs regulated by cytoplasmic polyadenylation. Additionally, PAPD4 has been shown to be important in Drosophila for long-term memory (Kwak et al. 2008), and Orb2 (Drosophila somatic CPEB) is required for asymmetric cell division during neurogenesis (Hafer et al. 2011).

Cytoplasmic polyadenylation is also important in the regulation of cell cycle. In HeLa cells, total mRNA and mRNA with short poly(A) tails were separated into fractions for cells in S phase and cells in G2/M phase (Novoa et al. 2010). The ratio of total to short poly(A) tail for each mRNA was then evaluated and compared between cells from the two different phases. Hundreds of mRNAs displayed a change in this ratio, and polyadenylation of some of these transcripts was affected by knockdown of CPEB1 and CPEB4. A more recent study in HeLa cells compared differentially expressed genes (DEGs) between S and M phases (J.-E. Park et al. 2016). A small set of key cell cycle regulators, including CDK1, experienced a significant decrease in poly(A) tail length in M phase, with coincident translational repression. However, this group represented just 8 genes out of the 777 DEGs, suggesting greater importance of polyadenylation-independent regulation of gene expression in the cell cycle. In mouse primary fibroblasts, cells’ ability to enter senescence was prevented by knockdown or ablation of CPEB1 (Groisman et al. 2006; Burns and Richter 2008).
Additionally, translational activation of TP53 (p53) – a master cell cycle regulator and tumour suppressor – mRNA was found to be dependent on CPEB1, and knockdown of CPEB1 led to TP53 mRNA with short poly(A) tails. PAPD5 was found to be associated with CPEB1 and TP53 mRNA, and knockdown of PAPD5 reduced TP53 mRNA polyadenylation and protein expression (Burns and Richter 2008). Taken together, these data implicate cytoplasmic polyadenylation in the regulation of the cell cycle and specifically TP53 mRNA.

The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is an important transcription factor in the process of inflammation (see sections 1.3.2.1.1 and 1.3.2.1.3). A kinase upstream of NF-κB activation is mitogen-activated protein kinase kinase kinase 7 (MAP3K7 or TAK1). TAK1 has been shown to be regulated by CPEB, with CPEB-depleted macrophages displaying elevated production of pro-inflammatory cytokines (Ivshina et al. 2015). In this way, CPEB plays an important role in the control of the inflammatory response, although polyadenylation was not implicated in the study.

1.1.3.2 Mitochondrial polyadenylation

In mammals, mitochondrial RNAs are produced as polycistronic RNAs that are then processed by endoribonucleases to yield separate, intronless mRNAs. For several mitochondrial mRNAs, this cleavage leaves a 3’ end with an incomplete stop codon, with either a terminal UA or just U (S. Anderson et al. 1981). For these mRNAs, polyadenylation, performed by MTPAP, completes the UAA stop codon (Nagaike et al. 2005). A homozygous MTPAP mutation (N478D) in fibroblasts led to loss of polyadenylation but retention of oligoadenylation (Wilson et al. 2014). The enzyme was shown to have severely compromised polyadenylation activity in vitro. Fibroblasts with the mutation displayed a reduction in protein synthesis, and
reduction in levels of oxidative phosphorylation complexes I and IV. The loss of mitochondrial transcript polyadenylation and decreased levels of oxidative phosphorylation complexes I and IV was rescued by overexpression of wild-type MTPAP. So mitochondrial polyadenylation is an important posttranscriptional regulatory mechanism, and its dysregulation can lead to decreased mitochondrial protein synthesis and reduction in respiratory chain complexes.

1.1.4 Biological importance and role of the poly(A) tail

PABPs, through binding the poly(A) tail, perform a number of biologically important roles. Normally, they facilitate export of mRNAs from the nucleus. However, PABPN1 can also enhance the decay of some hyperadenylated mRNAs that are not efficiently exported.

Figure 1.1. The poly(A) tail allows for formation of the closed-loop complex which enhances recruitment of translation initiation factors.

Adapted from Charlesworth et al. 2013
mRNAs are generally bound by the cytoplasmic poly(A) binding protein, PABPC1, on the poly(A) tail, while the 5’ cap is bound by eIF4E, as part of the cap binding complex, comprising eIF4E, eIF4G, and eIF4A (Mangus et al. 2003). Interactions between eIF4G and PABP facilitate formation of the closed-loop complex (Figure 1.1). This complex is important for the formation of ribosomal initiation complexes (Kahvejian et al. 2005).

Most eukaryotic mRNA degradation is thought to require shortening of the poly(A) tail (deadenylation) by deadenylase complexes (PAN2-PAN3, Ccr4-Not) to some critical length, whereupon the mRNA then becomes susceptible either to decapping (i.e. hydrolytic removal of the mRNA 5’ cap structure) followed by 5’-3’ exonucleolytic decay (C.-Y. A. Chen and Shyu 2011), or exosomal decay in the 3’-5’ direction. Some mRNAs contain regulatory cis elements that increase deadenylation and decay rates. AU-rich elements are a well-studied example of such sequences, and are found in many mRNAs encoding growth factors and inflammatory mediators (P. Anderson 2010; Stumpo, Lai, and Blackshear 2010; Khabar 2010). The AU-rich sequence UUAUUUAU, for example, is bound by tristetraprolin (TTP) in TNF mRNA and mediates instability (Stoecklin et al. 2004; Mahtani et al. 2001) – see section 1.3.2.1.3 for more detail. This sequence also appears to play a role in TNF translational repression (Han, Brown, and Beutler 1990; Kontoyiannis et al. 1999), discussed more in section 1.3.2.1.1.

Data from TAIL-seq, a high throughput poly(A) tail analysis technique, revealed that poly(A) tail length correlated positively with mRNA half-life (Chang et al. 2014). However, it did not correlate with ribosome binding. Rather, data suggested that a very short or no poly(A) tail was detrimental for translation, but beyond a critical length of ~25 nt, further increases in poly(A) tail size had no bearing on translation.
High throughput analysis in Arabidopsis showed a modest negative correlation between poly(A) tail length and mRNA half-life (Kappel et al. 2015). Data yielded from PAL-seq, a similar technique to TAIL-seq, found either weak negative or variable correlations between poly(A) tail length and mRNA half-life in 3T3, HeLa, and yeast (Subtelny et al. 2014). PAL-seq data also showed that a strong positive correlation between poly(A) tail length and translational efficiency did exist for cells in early developmental stages, but not for cells that had passed this phase. This fits with existing knowledge that non-polyadenylated, maternally-derived mRNAs in Xenopus oocytes can be translationally unmasked and activated by cytoplasmic polyadenylation. It should be noted, however, that in these cases, translational efficiency was inferred from ribosome binding i.e. translation initiation. Changes in the rate of translation elongation are not considered, so these correlations rest on the assumption that translation elongation is constant and independent of poly(A) tail length changes, which may not be the case. A third, similar recently published technique, PAT-seq, found little or no correlation between mean poly(A) tail length for a given mRNA and its read count or protein abundance (Harrison et al. 2015).

In an in vitro decay system, it was shown that PABP depletion led to a several-fold increase in the decay rate of mRNAs (Bernstein, Peltz, and Ross 1989). This could be rescued by addition of exogenous PABP, and the decay rate of non-polyadenylated RNA was independent of the presence of PABP. Thus, the poly(A) tail and PABP, together, have a protective role, and it could be the case that the closed-loop complex reduces accessibility of the mRNA ends to decay machinery. However, the relationship between PABP and mRNA turnover is more complex than that, as it can also promote deadenylation and therefore decay, via TOB1 recruitment (Ezzeddine, Chen, and Shyu 2012). In summary, the poly(A) tail, through interaction with PABP, is important for nuclear export, translation, and mRNA lifetime.
Figure 1.2. Life cycle of an mRNA. As RNA polymerase II (RNAP II) transcribes the DNA, the nascent mRNA is subject to splicing. The poly(A) signal and nearby cis elements are recognised by mRNA 3’ processing machinery that cleaves the mRNA and polyadenylates the 5’ fragment. The 3’ product is degraded. The poly(A) tail is bound by poly(A) binding protein (PABP) and the mRNA is exported from the nucleus where it can adopt the closed-loop formation, favouring translation. The poly(A) tail can be removed by deadenylation and restored through cytoplasmic polyadenylation. Once shortened beyond a critical length, it is subject to degradation either by decapping and 5’-3’ exonucleolytic decay by XRN1, or by 3’-5’ exosomal decay.
1.1.5 Alternative polyadenylation

Some mRNAs have multiple poly(A) sites, and so cleavage and polyadenylation can take place at different sites to yield different products. This process is termed alternative polyadenylation (APA), of which there are four main types:

1. APA at tandem 3’ UTR sites
2. APA at alternative terminal exons
3. APA at intronic sites
4. APA at exonic CDS sites

APA at tandem 3’ UTR sites (1) produces mRNAs that vary solely in the length of their 3’ UTR, but are otherwise identical. The other three types of APA produce mRNAs which differ in both coding and 3’ UTR sequences. APA at alternative terminal exons (2), while termed APA, is a result of alternative splicing, which determines the terminal exon of the transcript. APA at cryptic poly(A) site in an intron or exon (3 and 4) can lead to production of truncated protein isoforms with altered coding and 3’ UTR sequence.

Research has implicated APA and its regulation in cancer (Xia et al. 2014; Mayr et al. 2009; Sandberg et al. 2008). Specifically, this generally involves a switch to proximal poly(A) sites, resulting in shorter 3’ UTRs which lack regulatory sequences e.g. miRNA binding sites for negative regulation. APA is also found to be important in the immune system, with T-cell activation leading to global 3’UTR shortening (Gruber et al. 2014). APA changes are also relevant in the activation of macrophages (Shell et al. 2005), and PTGS2 (COX2) regulation (Cornett and Lutz 2014; Hall-Pogar et al. 2007).

1.1.6 Measuring poly(A) tails

Given the importance of poly(A) tails, tools and techniques have been developed in order to study them and assess length. However, accurately studying poly(A) tail
length is not a simple task. If comparing full length mRNAs, differences in poly(A) tail sizes can be difficult to detect, given that these would be on a much smaller scale relative to the entire length of the mRNA. Traditional replication-based sequencing methods are not suitable for use in determining poly(A) tail lengths due to problems with slippage on homopolymeric sequences (Viguera et al. 2001; Clarke et al. 2001).

Briefly described below are some of the commonly used methods, which include northern blotting, poly(A) tail test (PAT), and 3’ end labelling.

**Northern blotting:**

1) A DNA probe that anneals at a known position of the 3’ UTR of the mRNA of interest (e.g. 300 nt upstream of the cleavage site) is allowed to hybridise to the RNA. RNase H treatment will then cleave at the site of hybridisation between RNA and the DNA probe, yielding fragments whose lengths are equal to 300 nt (distance between where the probe annealed and the cleavage site) plus the length of the poly(A) tail (which may vary across a range in the pool of mRNAs).

2) The above is done, but, in addition to the specific oligo, oligo (dT) is added to the reaction, and so the poly(A) tail is removed. The product of the RNase H treatment should just be 300 nt. Only a single product should be produced (since the region of variable size – the poly(A) tail – has been removed).

3) Cleavage products are cleaned up, run on a gel and visualised by northern blotting. The difference in size between the polyadenylated and deadenylated samples corresponds to the length of the poly(A) tail.

This method has the advantage of specificity, but requires the use of radiation, high starting input of RNA, and lacks sensitivity, with mRNAs of low abundance being difficult to detect using this method. Also, the image quality is inferior to that of
agarose gels (see below), and the oligo (dT) has the potential to anneal to A-rich tracts instead of the poly(A) tail, leading to cleavage at an unintended location.

**Poly(A) test (PAT):**

There are a number of different PCR-based poly(A) test (PAT) methods, including RACE-PAT, ePAT, sPAT, and Klenow PAT, of which some are described in a recent review (Jalkanen, Coleman, and Wilusz 2014). The one described here is RNA **ligation-mediated PAT (Figure 1.3):**

1) RNA is prepared in duplicate – one set is subjected to an RNase H/oligo (dT) treatment to remove poly(A) tails (deadenylated sample). The other set is untreated, and so retains poly(A) tails of mRNAs (non-deadenylated sample).

2) RNA has a DNA adapter ligated to its 3’ end (“PAT anchor”).

3) An oligo complementary to the PAT anchor (“PAT-R1”) is used to perform a specific reverse-transcription reaction to synthesise cDNA from all RNA to which the PAT anchor was successfully ligated.

4) A PCR reaction is done, using a forward primer than anneals in the 3’UTR (at a known location), and PAT-R1 as the reverse primer. The PCR product length will be equal to the sum of the distance between the forward primer priming site and the cleavage site; the length of the poly(A) tail (for non-deadenylated samples); and the length of the ligated PAT anchor sequence. Deadenylated samples should give rise to a single PCR product.

5) PCR products are run on an agarose gel and visualised under UV by EtBr or SYBR Safe stain. The difference in size between deadenylated and non-deadenylated samples corresponds to the size of the poly(A) tail.
Step one: ligation

5’  AAAAA...AAA  PAT anchor  3’

Step two: reverse transcription to cDNA

5’  AAAAA...AAA  PAT anchor  3’

complementary strand synthesis

5’  AAAAAAAA  TT TT TT TT  3’

3’

Step three: PCR

5’  5’ UTR  Coding sequence  3’ UTR  AAA...AAAA  PAT anchor  3’

PCR products:

Due to heterogeneity in poly(A) tail lengths of different mRNA molecules, a range of PCR products will be formed.

Figure 1.3. Schematic overview of the RNA ligation-mediated PAT procedure. A 3’-blocked adapter ("PAT anchor") is ligated to the 3’ ends of RNA. Reverse transcription is done using a primer complementary to PAT anchor (PAT-R1) to generate PAT cDNA. PCR is performed using a forward primer that anneals to the 3’ UTR of the gene of interest, and PAT-R1 as the reverse primer. The PCR products are analysed on an agarose gel.
This technique is more sensitive than northern blotting due to the amplification involved in the PCR, and does not require the use of radiation. The image quality obtained on the agarose gel is superior to that of a northern gel. However, high input RNA quantities are still required, especially if oligo (dT)/RNase H treatment is to be done, and the use of PCR can lead to artefacts and off-target amplification.

3’ End-labelling

1) A radioactive pCp base is ligated to the 3’ end of total RNA.
2) A cocktail of RNases digests all RNA that is not poly(A).
3) Free poly(A) tails are then run on a long TBE-urea PAGE gel, and then placed in a cassette with a phosphorimaging screen at -80°C for up to a week.
4) The screen is then imaged on the phosphorimager.

This technique allows for the measurement of global poly(A) tail sizes within a sample. It requires a much lower input quantity of RNA than the other two methods, but is a long process and uses radiation. No information on the poly(A) tails of individual mRNAs is obtained, unless a purification step is performed on the RNA to isolate a specific mRNA (Schoenberg et al. 1989). This requires a very high starting quantity of RNA, however, and use of the technique is limited to highly abundant mRNAs.

The methods discussed have their advantages and disadvantages. Our group primarily uses PAT and 3’ end-labelling, results and optimisation of which can be found in later sections. A significant limitation of these methods is that they do not yield high-throughput genome-wide data. PAT can only be done for a single mRNA i.e. one forward primer per tube. 3’ end labelling only provides a single result – the entire mix of poly(A) tails in a sample, with no way of separating the data into which poly(A) tails came from which mRNAs. Simply using RNA-seq is not an option, as
homopolymeric sequences result in slippage of the DNA polymerase, leading to misalignment and replication errors (Viguera et al. 2001; Clarke et al. 2001).

During the course of my project, other groups developed and published novel techniques for this very purpose of high-throughput poly(A) tail measurement. TAIL-seq, whose methodology is described briefly in Figure 1.4, requires a very large input quantity of RNA, but yields genome-wide distribution of poly(A) tail sizes within an RNA sample.

Other high throughput techniques exist including PAL-seq, PAT-seq, and mTAIL-seq (Harrison et al. 2015; Subtelny et al. 2014; Lim et al. 2016). These techniques use either a splint oligo with T bases (to anneal to poly(A) tails) for 3’ adapter ligation, or a similar oligo with T bases which serves as the template to extend the 3’ end of the mRNA to which it is annealed. In either case, this results in biasing towards polyadenylated mRNAs, and so mRNAs that are deadenylated or have non-A terminal modifications such as uridylation or guanylation will not be represented in the library. PAL-seq requires non-conventional use of the Illumina instrument in such a way that voids the manufacturer guarantee. While PAT-seq provides information on gene expression, poly(A) site usage, and changes in poly(A) tail length distribution, it does not yield data on actual poly(A) tail size. TAIL-seq has limitations of its own, but none of the above apply to it.
Figure 1.4. Overview of the TAIL-seq library generation procedure. Total RNA is subjected to two rRNA-removal steps and then has a biotinylated adapter ligated to the 3’ end of RNAs. This is then subjected to a partial RNase T1 digest, following which the 3’-most fragment of all digested RNAs (which has the biotinylated sequence) is purified by streptavidin pulldown, 5’-phosphorylated, and run on a gel for size selection (300-1000 nt). This size-selected, 5’-phosphorylated RNA then has the 5’ adapter ligated and is reverse transcribed to cDNA. PCR is then done using primers that have overhanging index sequences.
1.2 Cordycepin

Cordycepin (3'-deoxyadenosine) is an adenosine analogue that lacks the 3' hydroxyl group (Figure 1.5), and therefore functions as a chain terminator if phosphorylated and incorporated into a growing polynucleotide chain. It is extracted from parasitic caterpillar fungi that have been used in Far Eastern traditional medicine for treating a range of ailments, with its purported benefits including anti-inflammatory, anti-diabetic, anti-cancer, and anti-obesity properties, among others (Jeong et al. 2010b; Takahashi et al. 2012; S.-J. Lee et al. 2010). Over the last two decades, evidence has started to emerge to support the potential therapeutic benefits of both purified cordycepin itself, and extracts prepared from the entire fungus.

1.2.1 Cordycepin and transcription

As an adenosine analogue, it is conceivable that cordycepin triphosphate could be used by RNA polymerase II in place of ATP, thereby terminating transcription. Indeed, this was found to occur in vitro (Desrosiers et al. 1976; Shigeura and Boxer 1964), but data from cells were at odds with these findings. Incubation of HeLa cells with cordycepin revealed that pre-mRNA levels (produced by RNA polymerase II) were not significantly affected by cordycepin, suggesting that transcription is unaffected (Siev, Weinberg, and Penman 1969; Penman, Rosbash, and Penman 1970). More recently, it was confirmed that cordycepin indeed does not affect the transcription of housekeeping mRNAs in tissue culture (Kondrashov et al. 2012). Therefore, cordycepin is not an inhibitor of mRNA transcription in intact cells.

Previous data also showed that 45S pre-rRNA (produced by RNA polymerase I) was significantly decreased in cordycepin-treated cells, at concentrations of cordycepin that had no effect on pre-mRNA. To attempt to explain these findings, which were not limited to HeLa cells, the sensitivity of both RNA polymerases I and II were
compared *in vitro* (Desrosiers et al. 1976). However, both enzymes were determined to be sensitive to cordycepin with similar kinetic values obtained for both. The varying effects of cordycepin on the production of different RNA types could therefore not be ascribed to the intrinsic susceptibility of the polymerases. More recent findings on the effects of cordycepin on signal transduction suggest that the sensitivity of RNA pol I to cordycepin may be mediated by effects on signal transduction.

1.2.2 Cordycepin and mTOR signalling

As mentioned, cordycepin treatment in HeLa cells led to decreased levels of pre-rRNA. It should be noted that this reduction was accompanied by a decrease in tRNA levels. In more recent years, cordycepin has been found to inhibit mammalian target of rapamycin (mTOR) signalling (Wong et al. 2010). A simplified overview of mTOR signalling, and cordycepin’s proposed involvement, is shown in Figure 1.6.

**Figure 1.5. Chemical structure of cordycepin.** The only difference between the structure of adenosine and cordycepin is the absence of the 3’ hydroxyl group in cordycepin. This property would make it a chain terminator, if incorporated into a growing polynucleotide strand.
Corydcepin was found to activate AMP-activated protein kinase (AMPK) and cause dephosphorylation of eIF4E-binding protein (4EBP1). Dephosphorylated 4EBP1 binds eIF4E, thereby inhibiting its binding to the mRNA 5' cap structure to initiate translation. mTORC1 phosphorylates 4EBP1 to relieve this repression and facilitate translation initiation. This was blocked by cordycepin.

**Figure 1.6. Simplified PI3 kinase/Akt signalling pathway showing proposed interaction with cordycepin.** Cordycepin appears to inhibit mTOR signalling via activation of AMPK, but the detailed mechanism by which this occurs is unknown. See references for more detail (Memmott and Dennis 2009; Huang and Manning 2009; Wong et al. 2010).
mTOR signalling plays a role in the activities of RNA polymerases I and III (Mayer and Grummt 2006). Initiation of transcription by Pol I is dependent upon Transcription Initiation Factor I (TIF-I) A, TIF-IB/SL1, and Upstream Binding Factor (UBF). Signalling through the mTOR pathway leads to phosphorylation of UBF and TIF-IA, enabling their association with Pol I. Inhibition of mTOR signalling leads to both inactivation of TIF-IA and partial nuclear exclusion. Therefore, reduced Pol I transcription through inhibition of mTOR signalling provides a plausible model to account for the previously observed reduction in pre-rRNA. The same can apply for the observation of decreased tRNA levels, following cordycepin treatment. Pol III is responsible for production of tRNA, and mTOR signalling is also involved in its activity. In yeast, the TOR inhibitor rapamycin was shown to decrease Pol III activity, which was determined to occur through the negative regulator Maf1 (Zaragoza et al. 1998; Oficjalska-Pham et al. 2006). Maf1 represses Pol III activity when in a dephosphorylated state. Rapamycin treatment leads to dephosphorylation of Maf1, which results in its accumulation in the nucleus and facilitates repression of Pol III. This phenomenon was later found to be true in humans, as well, with mTORC1 directly phosphorylating human MAF1 (which represses Pol III in a hypophosphorylated state, as in yeast) (Michels et al. 2010; Shor et al. 2010). To summarise, reduction in levels of pre-rRNA and tRNA, but not pre-mRNA, following cordycepin treatment could be explained by its more recently discovered inhibitory effects on mTOR signalling.

1.2.3 Cordycepin and polyadenylation

As mentioned above, cordycepin does not inhibit transcription in cells (Penman, Rosbash, and Penman 1970; Siev, Weinberg, and Penman 1969). It was, however, shown to be an efficient chain terminator of polyadenylation (Rose, Bell, and Jacob 1977). Its status as a known polyadenylation inhibitor was exploited in several
studies for studying mRNA 3' processing. Through the use of cordycepin triphosphate for \textit{in vitro} polyadenylation reactions, insight was gained into the cleavage and polyadenylation of mRNA (Ryner and Manley 1987; Zarkower et al. 1986), and it was also determined that a complex exists that recognises the poly(A) signal and is required for cleavage and polyadenylation (Zarkower and Wickens 1987). This study also found that this complex is normally transient but becomes stabilised when associated with cleaved RNA with a cordycepin-terminated tail.

Another study made the same observation, noting that this stabilisation of the complex was observed both with cordycepin and non-hydrolysable ATP analogues (Zhang and Cole 1987). With \textit{in vitro} effects well established, data from a number of cell types show reduced poly(A) tail size following cordycepin treatment, confirming that effects on polyadenylation are present (Ioannidis et al. 1999; Kondrashov et al. 2012; Wong et al. 2010).

Since polyadenylation is required for nearly all mRNAs, it is surprising that inhibiting this process can cause a specific reduction in the expression of inflammatory genes (Kondrashov et al. 2012). In human primary airway smooth muscle (ASM) cells treated with tumour necrosis factor (TNF), inflammatory gene expression measured by RT-qPCR was greatly increased. Pretreatment of the cells with cordycepin resulted in a much lower degree of induction in the mRNA levels of such genes, while housekeeping mRNA levels were unaffected. Other adenosine analogues were tested in place of cordycepin, and only the one that was also known to be a polyadenylation chain terminator was able to replicate its effects. In addition, knocking down poly(A) polymerase α (PAPOLA) also reduced the expression of inflammatory genes.
1.2.3.1 Polyadenylation and cordycepin’s mechanism

Removal of the poly(A) tail is often the first and rate-limiting step in the process of mRNA decay (C.-Y. A. Chen and Shyu 2011), and many inflammatory mRNAs are inherently unstable owing to regulatory sequences in their 3’ UTRs (P. Anderson 2010; Stumpo, Lai, and Blackshear 2010). Therefore, if cordycepin inhibits polyadenylation (thus shortening or even removing the rate-limiting step of deadenylation), it could be hypothesised that intrinsically unstable mRNAs (like those produced from inflammatory genes) would be particularly sensitive. This model provides an explanation for the specificity of cordycepin’s effects in reducing the induction of inflammatory genes (Kondrashov et al. 2012).

Another model can be formed around the observation that cordycepin arrests the cleavage complex in vitro (Zarkower and Wickens 1987). In stabilising the 3’ processing complex, cordycepin-terminated RNAs may be sequestering the constituent factors, thereby preventing proper processing of other transcripts. This hypothesis is further supported by the finding that cordycepin caused transcription termination defects – a sign of decreased pre-mRNA cleavage efficiency (Luo, Johnson, and Bentley 2006; West, Proudfoot, and Dye 2008; Richard and Manley 2009). For genes being induced (e.g. inflammatory genes in response to an inflammatory stimulus), mRNA production could be hampered by a reduced availability of 3’ processing factors if they have high processing factor requirements. Such requirements could either be due to suboptimal cis elements around the poly(A) site; or simply because transcription becomes so fast that very many factors are required to process the large number of nascent transcripts. Additionally, there is evidence to show that proper mRNA 3’ processing is required for efficient recycling of transcription factors to the promoter to initiate the next round of transcription (Mapendano et al. 2010). By interfering with 3’ processing, cordycepin
may inhibit transcription of affected genes. In this way, cordycepin could specifically inhibit the induction of any genes for which rapid transcriptional increase is required (e.g. inflammatory genes in response to a pro-inflammatory stimulus (Kondrashov et al. 2012)). Housekeeping genes, on the other hand, may have a transcription rate that is sufficiently low to not be limited by the availability of 3’ processing factors or inefficient recycling of transcription factors.

The above represents just three possible explanations of how cordycepin could affect gene expression by inhibiting polyadenylation. As discussed in section 1.1.3, poly(A) polymerases are diverse in their functions and polyadenylation is a varied process. With polyadenylation existing in nuclear, cytoplasmic, and mitochondrial forms, cordycepin may have multiple effects. Additionally, it may affect polyadenylation in the context of nuclear polyadenylation-mediated decay. Indeed, treatment of human cells with cordycepin led to nuclear accumulation of stable transcripts with shorter tails that, under control conditions, are hyperadenylated and degraded (Bresson and Conrad 2013).

1.3 Inflammation

Inflammation is a response of the innate immune system to infection and tissue injury. The term refers to a complex biological process whose purpose is to defend the host by eliminating invading pathogens, repairing damaged tissues, and restoring homeostasis. A number of cell types are involved, but I will focus specifically on macrophages, since studies have found this cell type to be sensitive to cordycepin (H. G. Kim et al. 2006; Shin, Lee, et al. 2009).

Inflammation is tightly controlled with large regulatory networks in place. There needs to be a sufficient degree of inflammation to deal with the harmful stimulus, but not so much that the inflammation causes collateral damage to the host.
Improper regulation of inflammation is known to give rise to a host of diseases and conditions, including rheumatoid arthritis, asthma, and Crohn’s disease (Barnes et al. 2010; Bradley 2008; Suzuki and Yamamoto 2015).

1.3.1 Inflammation and pain

The process of inflammation is also tied to the sensation of pain (Kidd and Urban 2001). Nociception is the response of specific sensory neurons (nociceptors) to noxious stimuli, generally resulting in pain sensation. In normal tissues, the feeling of pain generally has to do with the nature of the stimulus. However, in inflamed tissue, pain can arise spontaneously without an external stimulus. When there is an external stimulus, pain in inflamed tissues can be enhanced (hyperalgesia), and pain can even result from innocuous stimuli that do not result in pain in normal tissue (alldynia). There are a number of ways in which inflammation results in pain sensation, some of which I will briefly describe. Tissue injury results in the release of inflammatory mediators of which some can activate peripheral nociceptors directly e.g. bradykinin, while others, e.g. neural growth factor (NGF), activate inflammatory cells and trigger the release of pain-inducing (algogenic) agents. Furthermore, release of inflammatory mediators recruits cells of the immune system that, in turn, release more inflammatory mediators and further contribute to the establishment of an inflammatory environment. Inflammation in peripheral tissues can also lead to the phenomenon of central sensitisation in the spinal dorsal horn, whereby changes, including altered neurotransmitter production, result in increased excitability of CNS neurons and persistent pain. Finally, neurotrophic growth factors, including NGF and brain-derived neurotrophic factor (BDNF), are produced in greater quantities during inflammation (Woolf et al. 1997; Cho et al. 1997). These play roles in central sensitisation, and cause hyperalgesia (through directly activating nociceptors and also indirectly through activation of mast cells) (Kerr et al. 1999; Lewin, Rueff, and
In short, inflammation is closely linked to pain sensation.

1.3.2 Macrophages

Macrophages are white blood cells derived through the myeloid lineage from haematopoietic stem cells (HSCs). They are mononuclear, and often defined by their capacity for phagocytosis. They play roles in host defence against tissue injury and infection, as well as tissue repair and homeostasis (Wynn, Chawla, and Pollard 2013). Macrophages are found in all tissues. Formerly, macrophages were thought to arise predominantly from recruitment of circulating monocytes in the blood and their subsequent differentiation into macrophages (van Furth and Cohn 1968). However, it has more recently been found that the majority of tissue-resident macrophages originate during embryonic development (Epelman, Lavine, Beaudin, et al. 2014; Hashimoto et al. 2013; Epelman, Lavine, Randolph, et al. 2014). During inflammation, circulating monocytes that are recruited to tissues and differentiated into macrophages may behave differently to embryonically-derived tissue-resident macrophages. For instance, in cardiac tissue, embryonic macrophages seem to serve a more reparative role while macrophages derived from HSCs are more inflammatory in nature (De Wit et al. 2003; Epelman, Lavine, Randolph, et al. 2014; Aurora et al. 2014).

Definition and classification of macrophages becomes difficult when considering the specialisation of tissue-resident macrophages in distinct anatomical sites and the fact that macrophages are remarkably plastic cells. They are involved in the induction as well as the resolution of inflammation, and can change their activity and gene expression programmes to exhibit different phenotypes depending on the microenvironmental context and the specific stimuli that they encounter. Indeed,
transcriptional profiling of tissue-resident macrophages from different organs done through the Immunological Genome Project revealed highly diverse profiles (Gautier et al. 2012). For this reason, it can be dangerous to think of them as a single cell type. Rather, macrophages are cells that are capable of occupying a large range of biological states depending on a number of factors (Hume 2015).

Macrophages are thought to be activated in two ways. Classical activation produces the M₁ macrophage subtype, and alternative activation produces the M₂ activated subtype (which has the M₂a, M₂b, and M₂c subcategories) (Italiani and Boraschi 2014; Laskin 2009). M₁ macrophages are activated by signals including lipopolysaccharide (LPS) and TNF (following priming by IFNγ (IFNG)), have a pro-inflammatory phenotype, and are associated with tissue destruction. Factors produced by M₁ macrophages include reactive oxygen/nitrogen species, TNF, IL-1, IL-6, and chemokines. They also have increased cell surface MHC class II expression through which they display antigens to helper T cells, thereby playing a role in adaptive immunity. M₂ macrophages, which are activated by signals including IL-4, IL-13, and transforming growth factor beta 1 (TGF-β1, TGFB1), generally have a more anti-inflammatory phenotype, and are associated with wound healing and tissue repair. Factors produced by M₂ macrophages include IL-10, TGFβ, and epidermal growth factor (EGF). These classifications, which have been greatly simplified, here, can be useful. However, it should be remembered that macrophages, in an organism-wide context, are too complex and diverse to fit into these two categories and macrophage biologists are working on a common framework for macrophage-activation nomenclature (Murray et al. 2014).
1.3.2.1  Macrophage receptors and signaling

Macrophages can sense infection and sterile tissue damage, and, in response, mediate inflammatory processes to remove the threat and restore homeostasis. Pattern recognition receptors (PRRs) recognise particular molecular structures that broadly fit into two categories: pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Examples of macrophage PRRs include Toll-like receptors (TLRs), capable of interacting with PAMPs and DAMPs, retinoic acid-inducible gene 1 (RIG-I) which detects viral dsRNA, and nucleotide-binding oligomerisation domain-containing protein 2 (NOD2) which detects the muramyl dipeptide structure found in certain bacteria (Hayden, West, and Ghosh 2006).

PAMPs represent molecular structures that are unique to pathogens and are subject to surveillance by the innate immune system of the host via PRRs (Tang et al. 2012). They are therefore exogenous signals. Examples include LPS (more detail in section 1.3.2.1.1) and flagellin (part of the bacterial flagellum).

DAMPs, by contrast, are the host’s own endogenous molecular structures whose detection by PRRs signals danger and damage (Piccinini et al. 2010). Some DAMPs are intracellular molecules that are normally absent from the extracellular environment, and therefore are not ‘seen’ by extracellular PRRs (Tang et al. 2012). As a result of cellular stress or tissue injury, or cell necrosis, such DAMPs are released into the extracellular space where they can be recognised by extracellular PRRs and elicit sterile inflammation (G. Y. Chen and Nuñez 2010). Examples of DAMPs include mitochondrial DNA, nuclear proteins, and histones. While DAMPs have roles in immunity and tissue repair, excessive levels of DAMPs are implicated in diseases. The DAMP high mobility group box 1 (HMGB1) is present at elevated
concentrations in the serum and plasma of patients with sepsis (H. Wang et al. 1999). Antibodies against HMGB1 increased the survival of septic mice, suggestive of a causal relationship.

1.3.2.1 LPS signalling through TLR4

Lipopolysaccharide (LPS) is an archetypal PAMP found on the surface of gram-negative bacteria. It can trigger the innate immune system through the TLR4 receptor. TLR4 requires carriers and co-receptors to recognise LPS. In the extracellular space, LPS interacts with the soluble, shuttle protein LPS-binding protein (LBP). LBP in the bloodstream forms a complex with LPS (Jack et al. 1997) and transfers monomeric units of LPS to CD14 (a co-receptor of TLR4 expressed in immune cells) (Wright et al. 1990). CD14 – a GPI-anchored cell surface protein (which also exists in a soluble form) – facilitates the transfer of LPS to the TLR4/MD-2 receptor complex. The importance of LBP and CD14 is illustrated in mouse studies – deficiency in either protein led to a shift in sensitivity to LPS by 2-3 orders of magnitude (Haziot et al. 1996; Moore et al. 2000; Wurfel and Wright 1997), and LBP was essential for a rapid inflammatory response to LPS challenge or gram-negative bacterial infection (Jack et al. 1997). MD-2 is a soluble protein, which forms part of the receptor complex with TLR4. It can exist in soluble form (and bind LPS), or in a pre-formed complex with TLR4 (as described above). LPS binding occurs with a higher affinity for the TLR4-MD-2 complex than for soluble MD-2 alone (Akashi et al. 2003). The TLR4-MD-2-LPS complex forms a dimer, as confirmed by a crystal structure (B. S. Park et al. 2009). Downstream signalling is mediated through the intracellular Toll/IL1R homology (TIR) domain of TLR4, involving the recruitment of adapter proteins. These adapter proteins include myeloid differentiation primary response gene 88 (MyD88), TIR domain-containing adapter protein (TIRAP), TIR domain-containing adapter inducing IFN-β (TRIF), TRIF-related adapter molecule
(TRAM), and sterile α and HEAT-Armadillo motifs-containing protein (SARM). TLR4 is the only TLR member able to activate both the MyD88-dependent and TRIF-dependent pathways.

1.3.2.1.1.1 MyD88-dependent pathway

The MyD88-dependent pathway (Figure 1.7) leads to activation of transcription factors such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and activator protein 1 (AP1). Three mitogen-activated protein kinases (MAPKs) are phosphorylated in the MyD88-dependent pathway. These are p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK 1/2). Pro-inflammatory cytokines are induced by this pathway.

Following recognition of TLR4 as described above, MyD88 and TIRAP are recruited to the intracellular domain of TLR4. This leads to the recruitment of IL-1 receptor-associated kinase (IRAK) 4 and 1, and TNF receptor-associated factor 6 (TRAF-6). TRAF-6, in complex with ubiquitin-conjugating enzyme 13 (UBC13) and ubiquitin-conjugating enzyme variant 1 isoform A (UEV1A) activates mitogen-activated protein kinase kinase kinase 7 (MAP3K7 aka TAK1). TAK1 activates IκB kinase (IKK), which phosphorylates inhibitor of kappa B alpha (IκBa), leading to its dissociation from NF-κB, ubiquitination and proteasomal degradation, allowing nuclear translocation of NF-κB. TAK1 also activates mitogen activated protein kinase (MAPK) pathways, namely JNK, p38, and ERK 1/2, all of which contribute to the inflammatory process. A conserved sequence UUAUUUAU is found in the 3’ UTR of a number of human and murine inflammatory mRNAs including TNF (Caput et al. 1986). As mentioned in section 1.1.4, this sequence is bound by TTP and mediates instability of the TNF mRNA. The role of TTP in regulating TNF mRNA stability is discussed in section 1.3.2.1.3. This sequence mediates translational repression, and
derepression occurs in response to endotoxin (LPS) (Han, Brown, and Beutler 1990). Dexamethasone specifically inhibits LPS-induced JNK activity in macrophages and led to decreased TNF production, but no change in TNF mRNA accumulation (Swantek, Cobb, and Geppert 1997). Overexpression of MAPK10 (JNK3, Stress activated protein kinase beta (SAPKβ)) was able to overcome the dexamethasone-mediated translational repression of TNF. A kinase-dead mutant of JNK3 mimicked the effect of dexamethasone, with no translational derepression of TNF observed after LPS stimulation (while TNF mRNA accumulation was unaffected). These data highlight an important role of JNK signalling in facilitating the inflammatory response. p38 phosphorylates and activates several transcription factors, including activating transcription factor 2 (ATF2), and a number of downstream kinases including MAP kinase activated protein kinase 2 (MAPKAPK2) (MK2) (Guha and Mackman 2001). The role of p38-induced MK2 activation in inflammation is discussed in section 1.3.2.1.3. Experiments done in monocytes show that inhibition of MAPK Erk kinase (MEK), which phosphorylates ERK 1/2, led to a decrease in LPS-induced production of a number of inflammatory cytokines including TNF and IL-1β (Scherle et al. 1998). Activation of the MAPK pathways also contributes to pro-inflammatory gene activation through the induction of the transcription factor AP-1.

In addition to the above, the MyD88 pathway also involves induction of IκBζ and interferon regulatory factor 5 (IRF5). IκBζ is a member of the IκB family that is localised in the nucleus. It is important for the induction of the pro-inflammatory cytokine IL-6 (Yamamoto et al. 2004), the antimicrobial protein LCN2 (Kohda, Yamazaki, and Sumimoto 2016), and also the anti-inflammatory cytokine IL-10 (Hörber et al. 2016). IRF5, which interacts with and appears to be activated by MyD88 and TRAF-6, is important for the induction of TNF, IL-6, and IL-12B (Takaoka et al. 2005).
1.3.2.1.2 TRIF-dependent pathway

TLR4 activation of the TRIF-dependent (or MyD88-independent) pathway occurs later when the receptor is endocytosed and trafficked to the endosome, where the TIR domain of TLR4 forms a complex with other adapter molecules such as TRIF and TRAM (Kagan et al. 2008). The activation of this pathway is responsible for the late-phase activation of NF-κB and MAPKs and the production of inflammatory cytokines and Type I interferons, which serve roles in the host response to bacterial and viral infections (Perry et al. 2005). Transcriptional activation of Type I interferons is accomplished through joint action of IRF3 (which is phosphorylated in the pathway) and NF-κB.
The TRAM and TRIF adapters are recruited and TRIF is able to interact with receptor-interacting protein 1 (RIP1). RIP 1 mediates the late-phase activation of NF-κB and MAPKs (Cusson-Hermance et al. 2005; Ofengeim and Yuan 2013). In addition to NF-κB and MAPKs, IRF3 is activated (T. Kawai et al. 2001). This occurs through TRAF-3, which can associate with TRAF family member-associated NF-κB activator (TANK), TANK binding kinase 1 (TBK1) and IKKi (Oganesyan et al. 2006). Once activated, IRF3 and NF-κB activate transcription of target genes, including Type I interferons (Moynagh 2005).

Endotoxin stimulation of MyD88-deficient macrophages still activates MAPKs and NF-κB, albeit with delayed kinetics (Taro Kawai et al. 1999), ostensibly through the TRIF-dependent pathway. However, such macrophages did not experience an induction of pro-inflammatory cytokine production following LPS challenge. This suggests that, aside from NF-κB and MAPK activation, other MyD88-dependent events are prerequisites for the induction of inflammatory gene expression.

### 1.3.2.1.2 NF-κB signalling in inflammation

The NF-κB transcription factor family comprises five members (Oeckinghaus and Ghosh 2009):

- p105 (produced from NFKB1 gene), which is constitutively processed to p50
- p100 (produced from NFKB2 gene), which is processed to p52 under tight control
- p65 (aka RelA, produced from RELA gene)
- RelB (produced from RELB gene)
- c-Rel (produced from REL gene)

Heterodimers and homodimers of this family constitute NF-κB transcription factors that are able to bind to the NF-κB consensus binding sequence and regulate gene
expression by either activating or repressing transcription. NF-κB-responsive genes are numerous and diverse, but many are pro-inflammatory, and so NF-κB is an important mediator in the inflammatory process and a potential therapeutic target. Target genes whose expression is driven by NF-κB include TNF, IL-1, and IL-6 (Oeckinghaus and Ghosh 2009). A lack of proper control in NF-κB signalling can give rise to disease (Courtois and Gilmore 2006; Ben-Neriah and Karin 2011).
Signals that activate NF-κB include PAMPs e.g. LPS through TLR4 (see section 1.3.2.1.1), DAMPs e.g. HMGB1 through TLR4 (S. Kim et al. 2013), and cytokines e.g. TNF through TNF receptor-1 (TNFR1) (Wajant and Scheurich 2011) or IL-1β through IL-1 receptor, type I (IL1R). The NF-κB pathway downstream of TLR4 signalling is shown in Figure 1.8. As mentioned in previous sections, NF-κB is kept inactive in the cytoplasm by members of the IκB family (May and Ghosh 1997; Whiteside and Israël 1997). IκB family members have ankyrin repeats that allow them to bind the N-terminal Rel homology domain (RHD) of NF-κB family members. In binding NF-κB, IκBs can mask the nuclear localisation signal (NLS), thereby excluding NF-κB from the nucleus (and target genes).

Nuclear vs cytoplasmic localisation only represents one level of control, however. NF-κB is also regulated through modulation of its capacity to bind DNA and its transcriptional activity (Guan, Hou, and Ricciardi 2005). NF-κB proteins can be subjected to several post-translational modifications (PTMs) that can affect these properties (Karin and Ben-Neriah 2000; Christian, Smith, and Carmody 2016). All NF-κB proteins have an N-terminal RHD. p65, c-Rel, and RelB all have a C-terminal transactivation domain (TAD), also. p105 and p100 (the precursors from which p50 and p52 are formed, respectively) have an N-terminal RHD, and also ankyrin repeats closer to the C-terminus that give the proteins an inhibitory IκB-like function in the cytoplasm. This inhibitory action is lost upon processing of p105 and p100 to p50 and p52 which retain only the N-terminal RHD. p50 and p52 have DNA-binding activity, but do not have a TAD. As such, they function as transcriptional repressors when homodimeric (Bohuslav et al. 1998; Guan, Hou, and Ricciardi 2005).]

Phosphorylation at S276 in p65 is one of the best studied examples of NF-κB regulation by phosphorylation. The catalytic subunit of protein kinase A (PKAc) is kept in an inactive cytoplasmic complex with IκBα and p65 (Zhong et al. 1997).
Signals that lead to IκB degradation then allow PKAc to phosphorylate p65 at S276. This modification both promotes interaction of p65 with the p300/CBP (cAMP response element-binding protein (CREB) binding protein) coactivators, thus enhancing transcriptional activity, and also leads to acetylation at K310 which also increases transcriptional activity (Zhong et al. 1998; L.-F. Chen et al. 2005). IL-1β stimulation in liver cancer cells led to PI 3-kinase-dependent phosphorylation and transactivation of p65 (Sizemore, Leung, and Stark 1999). Inhibition of PI 3-kinase decreased p65 phosphorylation and caused a decrease in NF-κB-dependent gene expression with no effect on IκB degradation, NF-κB nuclear translocation, or even NF-κB binding to DNA. This demonstrates the importance of PTMs as an independent modulator of NF-κB activity.

1.3.2.1.3 Regulation of inflammatory cytokine mRNA stability

A number of mRNAs involved in the immune response and inflammation such as TNF and prostaglandin-endoperoxide synthase 2 (PTGS2 or COX-2) contain AU-rich elements (AREs) in their 3’ UTRs (P. Anderson 2008; Caput et al. 1986; Tudor et al. 2009). ARE sequences can confer instability upon the mRNA through interactions with ARE-binding proteins (ARE-BPs) that promote its turnover. One such protein is tristetraprolin (TTP), which binds its targets and mediates their rapid decay through recruitment of Not1 and Caf1 deadenylase subunits (Brooks and Blackshear 2013). Xrn1 exonuclease and decapping complex proteins and the exosome are also possibly recruited (Hau et al. 2007). Under normal, unstimulated conditions, TTP causes the rapid degradation of its ARE-containing target mRNAs, and so those mRNA levels are kept low. The amount of ARE content in inflammatory genes’ 3’ UTRs is said to direct the course and kinetics of the inflammatory response, as genes are expressed in three distinct temporal phases (Hao and Baltimore 2009). mRNAs expressed earlier had greater ARE content, while those expressed in later phases
had less. In this study by Hao & Baltimore, it is interesting to note that using TNF as a stimulus in fibroblasts had little or no effect on the measured half-lives of mRNAs with high ARE content. Using LPS to stimulate bone marrow derived macrophages, however, resulted in a marked increase in the stability of such mRNAs. It may be, therefore, that regulation at the level of mRNA stability in inflammation is dependent on the cell type (or possibly just the stimulus).

**Figure 1.9. Simplified p38 signalling pathway overview.** p38 activation leads to phosphorylation of TTP via MAP kinase activated protein kinase 2 (MAPKAPK-2) (MK2). Phosphorylated TTP is bound by 14-3-3 proteins and localises in the cytoplasm but remains inactive, unable to destabilise mRNAs like TNF with AREs in their 3' UTR, allowing such mRNAs to accumulate. Phosphorylated TTP can later be dephosphorylated by protein phosphatase 2A (PP2A) whereupon it regains its ability to destabilise ARE-containing mRNAs. This contributes to the decline in the levels of such mRNAs.
TNF is a key pro-inflammatory cytokine in the inflammatory response, and plays a large role in rheumatoid arthritis – evidence of this is provided by the fact that many successful therapies for rheumatoid arthritis target TNF (Brennan et al. 1989; P. C. Taylor, Taylor, and Feldmann 2009). A number of its effects are mediated through the activation of NF-κB-dependent gene expression through IκB degradation as described in the previous section. TNF contains AREs in its 3’ UTR, and so levels are kept low by TTP in unstimulated cells. The role of TTP in regulating TNF mRNA levels is shown by TTP deficiency in a mouse model. These mice develop a syndrome whose symptoms include inflammatory arthritis, dermatitis, and autoimmunity, and TNF levels are found to be higher, with mRNA half-life being increased (Carballo 1998). Administration of antibodies against TNF to mice prevents the onset of nearly all symptoms (G. A. Taylor et al. 1996). Other 3’ elements are also responsible for TNF mRNA dynamics, such as the constitutive decay element (CDE), which is bound by Roquin and Roquin2, which recruit the Ccr4-Caf1-Not deadenylase complex to the mRNA (Leppek et al. 2013).

The p38 MAP kinase pathway (Figure 1.9), activated by signals including LPS, causes phosphorylation of TTP by MAP kinase activated protein kinase 2 (MAPKAPK2 or MK2) (Chrestensen et al. 2004). In this first phase of p38-TTP interplay, the phosphorylated TTP is bound by 14-3-3 proteins and becomes localised in the cytoplasm (M. Brook et al. 2006; Johnson et al. 2002). In this form, it is inactive and no longer able to repress ARE-containing mRNAs like TNF (Stoecklin et al. 2004), resulting in a rapid accumulation of such mRNAs. Phosphorylation of TTP by MK2 inhibits its ability to recruit the CAF1 deadenylase complex and deadenylate ARE-containing mRNAs (Marchese et al. 2010). In a second phase, the phosphatase PP2A, which competes with 14-3-3 proteins for phosphorylated TTP, dephosphorylates TTP (L. Sun et al. 2006). At this point, TTP regains its capacity to destabilise ARE-
containing mRNAs and is already localised in the cytoplasm to perform this role. In
this phase, levels of ARE-containing mRNAs decline as part of the resolution of
inflammation. TTP dynamics in p38 signalling is discussed in depth in this review
(Sandler et al. 2008). In addition to regulation of TNF mRNA described above, the
mRNA of other pro-inflammatory mediators including PTGS2, IL-10, IL-6, and IL-1α is
also stabilised by p38 through inhibition of TTP-mediated decay (Tudor et al. 2009).

IL-1β mRNA is also subject to ARE-mediated regulation. Like TNF mRNA, it is a target
of TTP, with TTP destabilising it. TTP-deficient dendritic cells displayed elevated
levels of IL-1β mRNA compared to wild type dendritic cells, both with and without
LPS stimulation (Bros et al. 2010). Stability of IL-1β mRNA is increased, along with
that of several other ARE-containing mRNAs, by p38 signalling (Frevel et al. 2003).

KH-type splicing regulatory protein (KSRP) is an ARE-binding protein that promotes
mRNA decay (Chou et al. 2006). Astrocytes from KSRP null mice displayed increased
levels of IL-1β mRNA both with and without stimulation by TNF, and also an increase
in mRNA stability compared to astrocytes from wild type control mice (X. Li et al.
2012).

1.3.3 Anti-inflammatory effects of cordycepin

A number of studies have shown that cordycepin has anti-inflammatory effects in
Kondrashov et al. 2012; Shin, Lee, et al. 2009). In a system of ASM cells stimulated
with TNF, cordycepin did not prevent degradation of IκB or translocation of NF-κB
into the nucleus (Kondrashov et al. 2012). In RAW 264.7 cells, a murine macrophage
cell line, NF-κB nuclear translocation was reduced by cordycepin (H. G. Kim et al.
2006). In HEK 293 cells, NF-κB nuclear translocation was not prevented by
cordycepin, but, at higher concentrations, NF-κB DNA binding and transcriptional
activities were reduced (Ren et al. 2012). Another group examined rat nucleus pulposus (NP) cells in the context of intervertebral disc degeneration (IDD) (Y. Li et al. 2016). IDD is thought to be a contributing factor to the development of low back pain, and a strong pro-inflammatory environment provided by NP cells is heavily implicated in IDD. Treatment of NP cells with LPS increased expression and production of a number of cytokines, which was reduced by cordycepin treatment. In these cells, phosphorylation of IkBα and p65 was decreased by cordycepin. It was noted that cordycepin did not affect MAPK signalling, however.

The therapeutic potential suggested by these studies has been tested in vivo in animal models of disease. In a study in which mice were infected with *Trypanosoma brucei*, a reduction in cerebral inflammation and pro-inflammatory cytokine levels in the brain was observed upon cordycepin treatment (Vodnala et al. 2009). Anti-inflammatory activity of cordycepin has also been observed in several other animal models of disease, including lung injury, cerebral ischemia/reperfusion injury, and asthma (X. Yang et al. 2015; M. Chen et al. 2012; H. Kim et al. 2011; Cheng et al. 2011).

In a study of nociception in rats, rats had a range of inflammatory mediators injected into their spines a week prior to administration of the hyperalgesic agent prostaglandin E2 (PGE2). The enhancement of pain sensation caused by the inflammatory mediators was significantly relieved by administration of cordycepin (Ferrari et al. 2015).

Microglia are brain-resident macrophages and play an important role in CNS repair and homeostasis (Gehrmann, Matsumoto, and Kreutzberg 1995). Their overactivity and increased production of inflammatory mediators is implicated in the progression of neurodegenerative diseases (González-Scarano and Baltuch 1999; Heneka et al.)
Mounting evidence supporting a role for brain inflammation in Alzheimer’s disease has led to significant interest in targeting inflammation to treat the disease (Heneka et al. 2015). Murine microglia stimulated with LPS exhibited increased production of inflammatory mediators, and typical signalling events including increased phosphorylation of p38, ERK1/2, and JNK MAP kinases; IκB degradation; and NF-κB (p65) translocation to the nucleus (Jeong et al. 2010a). Pretreatment of cells with cordycepin prior to addition of LPS, compared to LPS alone, resulted in decreased production of inflammatory mediators, reduced phosphorylation of aforementioned MAP kinases, stabilisation of IκB, and nuclear exclusion of NF-κB (measured both by Western blotting and immunocytochemistry). A more recent study made similar observations (Jie Peng et al. 2015). With in vivo work already showing that cordycepin protected against cerebral ischaemia/reperfusion injury (Cheng et al. 2011), these findings in microglia further support the therapeutic potential of cordycepin for neurodegenerative conditions.

1.4 Osteoarthritis – a therapeutic application of cordycepin?

Osteoarthritis (OA) is a joint disease that affects about a third of the population over the age of 45 in England. It is characterised by a number of hallmark features that include cartilage damage, synovial inflammation, and bone changes. The breakdown of articular cartilage results from the degradation of extracellular matrix by chondrocytes. OA is largely thought of as a non-inflammatory disorder. However, research has shown that inflammation is an integral component of OA progression contributing to the development of its symptoms (Berenbaum 2013). The inflamed synovium (synovitis) releases pro-inflammatory cytokines that can lead to further cartilage degradation. OA is characterised by an increase in anabolic activity in the subchondral bone. Osteoblastic (bone forming) and osteoclastic (bone degrading)
activities become unbalanced and increased bone deposition results in sclerosis of the subchondral bone (bone beneath the articular cartilage) and formation of osteophytes. Osteophytes (new bone formation) appear at the joint margins, subchondral bone thickens, joint capsule enlarges, mild synovitis and effusion are also observed (Johnston 1997; Sunita Suri and Walsh 2012; Wenham and Conaghan 2010). It remains yet to be confirmed whether subchondral bone sclerosis is a cause or consequence of cartilage loss in OA. The increased thickness and density of the subchondral bone and osteophyte formation may be a result of a disordered repair process to increase joint stability. An overview of these changes in the joint physiology is shown in Figure 1.10.

Articular cartilage is found at the junction between two or more bones. It functions as a shock absorber and facilitates movement at the joint. In the case of a healthy joint, articular cartilage is neither innervated nor does it have a blood supply, while the adjacent bone, on the other hand, has both a blood supply and nerves. It has been shown that blood vessels grow up from the subchondral bone, breaching the tidemark (a transitional zone which marks the division between articular cartilage and calcified cartilage above the subchondral bone) and invading the normally aneural and avascular articular cartilage in OA (Walsh et al. 2010; S. Suri et al. 2007). The route by which they do this is usually within the vascular channels that extend up from the subchondral bone marrow spaces through the calcified cartilage and into the non-calcified articular cartilage. The separation between bone and cartilage is thus lost and both nerves and blood vessels invade the cartilage from the bone, leading to joint pain.

Chondrocytes are the only cell types found in the articular cartilage. These cells are normally responsible for maintaining the cartilage by balancing matrix production
and degradation. In OA, the chondrocytes become hypertrophic and this balance is shifted towards matrix degradation, resulting in a reduction of cartilage, and chondrocytes also die by apoptosis (van der Kraan and van den Berg 2012; Akkiraju and Nohe 2015). In some cases, the cartilage is completely lost, leaving only bone on either side of the joint margin.

The subchondral bone, i.e. the layer of bone directly under the cartilage, undergoes notable remodelling in OA. Normal bone structure is in part maintained through the balance of osteoclasts (bone-degrading cells) and osteoblasts (bone-producing cells). In OA, the balance is disturbed, leading to aberrant bone structure (Sunita Suri and Walsh 2012). Osteophytes are also a common occurrence in OA. These are protrusions of bone that form along joint margins, and can contribute to the disease progression through malalignment of the bones at the joint (Felson et al. 2005).

The synovium encases the synovial fluid within the synovial cavity. This provides the nutrients and external factors required for maintenance of the cartilage. Inflammation of the synovium (synovitis) is one of the hallmark features of OA.

![Figure 1.10. Changes in knee physiology in osteoarthritis.](image)
Synovial inflammation contributes to the disease in part through the activity of synovial macrophages and fibroblast-like synoviocytes (FLS). While the degree of inflammation can vary between patients, pro-inflammatory cytokines such as TNF and IL-1β produced by synovial macrophages can promote degradation of the cartilage (Rahmati, Mobasher, and Mozafari 2016). Macrophages in the synovial lining also have a role in the formation of osteophytes (Blom et al. 2004). FLS cells can also promote a pro-inflammatory environment that leads to cartilage destruction (A. R. Sun et al. 2016; Philp, Davis, and Jones 2016). In OA, synovial fluid may contain calcium pyrophosphate dehydrate (CPPD) crystals which are capable of activating the NLRP3 inflammasome in macrophages which, following caspase-1 proteolytic activation, enhances IL-1β and IL-18 secretion (Jin et al. 2011). Basic calcium phosphate (BCP) crystals, which can also be found in OA synovial fluid, have been shown to induce IL-1β secretion by macrophages through the NLRP3 inflammasome in vitro.

Together, the changes in subchondral bone, cartilage, and the synovium contribute to the pain associated with OA and the progression of the disease. Given that inflammation plays a part in the destruction of the cartilage, cordycepin may have therapeutic benefit in reducing pain in OA patients. In human chondrocytes from OA patients, IL-1β-driven increases in proinflammatory cytokine production were inhibited by cordycepin pretreatment (Ying et al. 2014), and degradation of IκB by IL-1β was also prevented by cordycepin in these cells. Cordycepin was also able to inhibit the impairment of osteogenesis (bone formation) by oxidative stress in bone marrow mesenchymal stem cells (BM-MSCs) (F. Wang et al. 2015). Reactive oxygen species (ROS) are important in the differentiation of osteoclasts (N. K. Lee et al. 2005). Consistent with its role in opposing the effects of oxidative stress in BM-
MSCs, cordycepin was found to scavenge ROS generation and inhibit osteoclastogenesis (Dou et al. 2016).

1.5 Project aims and outcomes

The aim of my PhD project was twofold: to investigate the role of polyadenylation in the inflammatory response, and to gain insight into how cordycepin’s anti-inflammatory effects were mediated. This was to be measured in RAW 264.7 macrophages, using LPS as a stimulus to induce an inflammatory response. Addition of LPS to RAW 264.7 cells did, indeed, result in increased inflammatory gene expression measured over a 2 hour period after addition of LPS. Adding cordycepin either 1 hour before LPS or 10 minutes after LPS led to a pronounced decrease in inflammatory mRNA levels (for both mature transcripts and pre-mRNA). This was confirmed on a genome-wide scale through microarray and cluster analysis. It was found that Tnf mRNA (whose levels are >100-fold increased following LPS treatment) experiences an increase in poly(A) tail size following LPS treatment, while housekeeper mRNA poly(A) tail size is unaffected. Performing this experiment with the nuclear fraction, to assess initial poly(A) tail size of newly synthesised mRNA, also showed an increase in Tnf poly(A) tail size, indicating that nuclear polyadenylation may be dynamic in the inflammatory response. The Tnf poly(A) tail size increase is noticeably reduced in the presence of cordycepin. Inhibition of cordycepin’s import into the cell or its phosphorylation abrogated its anti-inflammatory effects. Taken together, these data suggest that, in a macrophage system, polyadenylation is dynamic in response to an inflammatory stimulus, and that cordycepin has specific anti-inflammatory effects that it elicits intracellularly, possibly through effects on polyadenylation. These data support the case for cordycepin as a potential therapeutic for diseases in which inflammation is involved.
Work done by James Burston (with whom I collaborated) in a rat model of osteoarthritis showed that cordycepin reduced pain behaviour associated with OA, but I was unable to see changes in inflammatory cytokine mRNA in the synovium. This suggests these mRNAs are not the therapeutic target in this case, or at least not in that tissue. However, the effects on pain behaviour still add weight to the therapeutic potential of cordycepin.
2 Materials and methods

2.1 Cell work

2.1.1 Cell culture

RAW 264.7 mouse macrophage cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Sigma, cat no 6429) supplemented with 10% foetal bovine serum (FBS) (Sigma, cat no F9665-500ml). Cells were split into fresh flasks whenever they reached ~80% confluence. All experiments were done on cells between passage 20 and 40.

NIH-3T3 mouse fibroblasts were cultured in DMEM supplemented with 10% newborn calf serum (NBCS). For serum induction experiments, $10^6$ cells were seeded in 10 cm plates (TPP, cat no 93100), then had medium changed to DMEM + 0.5% NBCS after 24 hours. 24 hours after this change of medium, cells were stimulated with addition of 10% NBCS. The experiment using NIH-3T3 cells from which data is presented in this thesis (Figure 3.7) was performed by Cornelia de Moor.

2.1.2 Cell stimulation with lipopolysaccharide (LPS) and treatments with compounds

RAW 264.7 cells were seeded into 15 cm plates (TPP, cat no 93150) 10 cm plates (TPP, cat no 93100), 6 cm plates (TPP, cat no 93060), 6-well plates (TPP, cat no 92006), or 12-well plates (TPP, cat no 92012). Seeding densities ranged from $2\times10^3$-$6\times10^4$ cells/cm$^2$. 24 hours after seeding, the medium was aspirated, cells were washed in the same volume of phosphate-buffered saline (PBS) as the medium, and then DMEM + 0.5% FBS was added. ~24 hours after this, the experiment would take
place, with LPS (Sigma, cat no L6761) being added at a final concentration of 1 μg/ml for the desired duration. For some experiments, the LPS was added ~24 hours after seeding, without any change of medium.

For samples that were to be treated with cordycepin (≥98% pure) from *Cordyceps militaris* (Sigma, C3394), the cordycepin dissolved in DMSO (stock concentration 20 mM) was added to all plates (20μM final concentration unless otherwise indicated) 1 hour before, at the same time as, or 10 minutes after the addition of LPS to any plate. Fungal extracts (preparation described below) were treated as 1000-fold concentrated stocks, and so were added at 1/1000 of the volume of medium in which the cells were seeded. Pentostatin (Sigma, cat no SML0508) was added at the same time as cordycepin at 1nM concentration. Adenosine (Sigma, cat no A4036) was added at the same time and concentration as cordycepin. The adenosine transporter inhibitor S-(4-Nitrobenzyl)-6-thioinosine (NBTI) (Sigma, cat no N127) and the adenosine kinase inhibitor 5-Iodotubericidin (ITu) (Sigma, cat no I100) were added 15 minutes prior to cordycepin treatment.

2.1.3 Preparation of fungal ethanol extracts for use in cell culture

*Cordyceps militaris* fungi were from Hainan SHUNTIAN Biological Technology Co Ltd; *Ophiocordyceps sinensis* tablets (500 mg biomass per tablet) were from Mycology Research Laboratories Ltd; and *Pleurotus ostreatus*, *Agaricus bisporus*, and *Flammulina velutipes* were purchased from Sainsbury’s supermarket. The fungus or starting material was ground and 1g dissolved in 20 ml ethanol. This suspension was then placed on a tube roller for 1 hour and then allowed to stand for 15 minutes. Supernatant was then divided into several 2 ml tubes, which were centrifuged at 10,000 g at 4°C for 30 minutes. Supernatant was pooled and filtered in a laminar flow hood for sterility. This sterile mix was then divided into several tubes (500 μl
per tube) and spun in a vacuum concentrator until dry. Once all the ethanol had evaporated, 25 µl of DMSO was added to each tube, thoroughly mixed, and then all liquid was combined to obtain a single, homogeneous mixture. This was divided into aliquots and stored at -20°C for further use.

2.1.3.1 Assessing cordycepin and 3’ deoxyinosine concentration in fungal extracts
by liquid chromatography/mass spectrometry (LC/MS) (performed by Wahyu Utami)

LC/MS analysis was performed by Wahyu Utami – the method described below is taken from her PhD thesis (Utami Wahyu 2015):

“Analyses of samples were carried out on an Agilent 1100 HPLC system (Agilent, Santa Clara, CA, USA) with auto sampler maintained at 8°C. Separations were achieved on a Luna C-18, 3 µm (2 × 150 mm) column with Security Guard (4 × 2 mm) (Phenomenex, Macclesfield, UK) at 40°C. The standards and the samples were eluted using a gradient mobile phase containing of 5 mM DMHA in water:methanol (95:5 v/v) (A), and 5 mM DMHA in methanol: water (80:20 v/v) (B). Mobile phase A was adjusted to pH 7 using acetic acid. The gradient condition was: 0-5 min, 10-20% B; 5-10 min, 20-28 % B; 10-22, 28-40 % B; 22-25, 40-10 % B; 25-35 min, 10 % B. The volume of sample injected to the column was 5 µL. The flow rate was set at 200 µL/min.

MS data were acquired on Waters Quattro Ultima triple quadrupole mass spectrometer (Waters, Milford, MA, USA) in negative electrospray ionisation (ESI) mode. Source temperature was at 125°C, with nitrogen as drying and nebulising gas and argon as collision gas. Multiple reactions monitoring (MRM) scan was used with dwell time 0.1 s. The MS system and data were processed by Waters MassLynx™ Software.”
2.1.4 Statistical tests for comparing cell treatments

Statistical tests were performed using GraphPad Prism version 6 for Windows (GraphPad Software, La Jolla California USA). 2-way ANOVA was performed with means between different conditions compared to each other within each group. For Figure 5.5, this means comparing the mean values for 0 nM pentostatin to the mean values for 1 nM pentostatin within each separate cordycepin concentration tested. For Figure 5.9, it means comparing the mean values for both C+10 and C-60 to the control mean (DMSO) within each separate timepoint. Default options were left unchanged, and recommended tests were used following the ANOVA. For Figure 5.5, the recommended test was Sidak’s multiple comparisons test, and for Figure 5.9, it was Dunnett’s multiple comparisons test.

2.2 RNA work

2.2.1 RNA isolation

At the end of any experiment, cells were harvested as follows:

<table>
<thead>
<tr>
<th>Cells in 10cm/15cm plates</th>
<th>Cells in 6-well or 12-well plate</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Put plates on ice, aspirate medium from cells, and wash twice with ice-cold PBS (Oxoid, cat no BR0014G)</td>
<td>• Add lysis buffer from RNA isolation kit* directly to cells on plate, then transfer lysate to fresh tube</td>
</tr>
<tr>
<td>• Add 5 ml ice-cold PBS and scrape cells using cell scraper (Greiner Bio-One, cat no 541070)</td>
<td></td>
</tr>
<tr>
<td>• Transfer cell suspension to fresh 15 ml tube and spin at 775 g for 2 minutes</td>
<td></td>
</tr>
<tr>
<td>• Aspirate supernatant and add lysis buffer from RNA isolation kit* to cell pellet</td>
<td></td>
</tr>
</tbody>
</table>
RNA was then isolated from the lysates using an RNA isolation kit, following manufacturer’s protocol (except DNase treatment was done for 1 hour rather than 15 minutes), and stored at -20°C. *All experiments done before November 2015 used the NucleoSpin RNA kit (Macherey Nagel, cat no 740955), while experiments done thereafter used the ReliaPrep™ kit (Promega, cat no Z6012). The two kits performed equally well in our experience – the switch was made purely due to the ReliaPrep™ kit being cheaper.

2.2.2 RNA isolation from nuclear and cytoplasmic fractions

Fractionation experiments were done using a 15 cm plate for each timepoint. At the end of the experiment, cells were washed twice with ice-cold PBS, and then scraped in 5 ml ice-cold PBS with a cell lifter (Corning, cat no 07-200-364). All centrifugation was done at 4°C. The cell suspension was spun at 700 g for 5 minutes, the supernatant was discarded, and the pellet resuspended in 1 ml PBS. This suspension was centrifuged at 500 g for 5 minutes and supernatant was discarded. The pellet was resuspended in 400 µl of buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF) and incubated on ice for 15 minutes. 25 µl of 10% NP-40 was then added to the suspension which was vortexed for 10 seconds and placed on ice for 5 minutes. This mix was then centrifuged at 16,000 g for 1 minute, resulting in pelleted nuclei and a cytoplasmic supernatant.

Approximately 60% of the supernatant was collected in a new tube (in order to avoid nuclear contamination by trying to collect all of the supernatant), and had an equal volume of 100% isopropanol added. This was then centrifuged at 16,000 g for 30 minutes. While spinning, the remaining supernatant was discarded, and the nuclear pellet was washed three times with 400 µl buffer A to remove remaining cytoplasmic material. When the cytoplasmic centrifugation was complete,
supernatant was aspirated yielding a cytoplasmic pellet. Cytoplasmic and nuclear pellets then had the appropriate amount of lysis buffer added from the RNA isolation kit. For the NucleoSpin kit, the lysis buffer volume used was 350 µl. For the ReliaPrep™ kit, the volume used was 100 µl for up to 5×10^5 cells, 250 µl for 5×10^5-2×10^6 cells, and 500 µl for any more than that. RNA was isolated from lysates following the manufacturer’s protocol but with a 1 hour DNase treatment rather than the stated 15 minutes. Once eluted from the isolation kit, nuclear RNA was subjected to another DNase digestion using TURBO™ DNase (Ambion™, cat no AM2238), following manufacturer’s protocol. RNA was then extracted by a phenol/chloroform extraction and precipitated with ethanol and sodium acetate. After washing and redissolving the nuclear pellet, cytoplasmic and nuclear RNA isolation was complete. Fractionation was validated by RT-qPCR to check for enrichment of pre-mRNA in the nuclear RNA sample.

2.2.3 4-thiouridine labelling for nascent mRNA capture performed by Richa Singhana

Labelling transcripts in the cells: 250 µM 4-thiouridine (4SU) was added to RAW 264.7 cells 15 minutes before harvesting the cells.

To harvest, cells were placed on ice, washed twice with ice-cold PBS, and immediately lysed with 10 ml TriPure reagent and transferred to a fresh tube. 4SU-labelled yeast RNA was added at this point as a spike-in for later analysis purposes (see below). 2 ml chloroform/isoamyl alcohol (24:1) was added and the tube was incubated on ice for 10 minutes before being centrifuged at >18,000 g for 10 minutes. The top aqueous layer was removed and subject to an ethanol/sodium acetate precipitation, after which the pellet was redissolved in water, subjected to a TURBO DNase treatment following manufacturer’s protocol.
**Biotinylating 4-thiouridine labelled RNA:** DNase-treated RNA, having been cleaned up, was then heated at 65°C for 5 minutes before being placed on ice. The following were then added (final concentrations are indicated) to the RNA for a final volume of 400 µl per 40 µg RNA: Tris-HCl pH 7.4 (10 mM), EDTA (1 mM), EZ-Link™ HPDP-Biotin (0.2 mg/ml) (Thermo, cat no 21341). This was then rotated at room temperature in the dark for 1 hour and 30 minutes, after which an equal volume of chloroform/isoamyl alcohol (24:1) was added and the aqueous phase was then collected using MaXtract column (Qiagen, cat no 129046). RNA was precipitated using isopropanol and NaCl, and pellet redissolved in water.

**Fractionating the RNA:** Streptavidin paramagnetic beads (Promega, cat no Z5482) were pipetted into a tube (200 µl per 70 µg RNA), placed into a magnetic rack, and the buffer was replaced with 200 µl of fresh MPG buffer (1M NaCl, 10 mM EDTA, 100 mM Tris-HCl pH 7.4). A known quantity of thiouridine-labelled RNA from *S. pombe* was added to the total RNA as a spike-in for data analysis purposes later (see below). RNA was heated at 65°C for 10 minutes, and then added to the beads and rotated at room temperature for at least 20 minutes. The tube was then placed on the magnetic rack – biotinylated nucleic acids are bound to the beads, while non-labelled RNA is contained in the supernatant. Supernatant (unlabelled fraction) was transferred to a fresh tube and kept on ice. Beads were washed for 5 minutes with 750 µl MPG buffer four times. The fourth wash was collected as a control fraction which should be free of RNA. 100 µl of 0.1 M DTT was added to the beads and rotated for 10 minutes to elute the bound, labelled RNA. The tube was placed onto the rack and supernatant (labelled RNA) collected in a fresh tube on ice. This was repeated and the second labelled RNA elution pooled with the first.
Final cleanup: the unlabeled fraction was precipitated with ethanol and sodium acetate and then redissolved in water. The labelled fraction was purified using RNeasy MinElute cleanup kit (Qiagen, cat no 74204).

Yeast spike-in and analysis: fixed amounts of 4SU-labelled RNA isolated from *S. pombe* were added to the cell lysate in TriPure reagent prior to isolating total RNA and performing the fractionation, as mentioned previously. RNA samples were then sent for RNAseq on the NextSeq platform. Raw reads from the sequencer then had adapter sequences and low quality base calls trimmed. Remaining reads were mapped to the joined mouse and *S. pombe* genomes – the best matches were returned and ambiguous mappings were discarded. For both the 4SU-labelled RNA and the total RNA, the number of reads mapping to features in the genome was counted. In order to compare the numbers of transcripts between 4SU-labelled and total RNA samples, the numbers must be adjusted so that they are on the same scale. This was accomplished using the *S. pombe* RNA spike in – since this was of a known, fixed amount, the fraction of 4SU-labelled RNA relative to the total could be calculated. The resulting scaling factor was used to scale the fragments per kilobase per million mapped reads (FPKM) values of the 4SU-labelled fraction. The FPKM values could then be used to calculate transcription rates (4SU-labelled FPKM) and decay rates (4SU-labelled FPKM divided by total FPKM).

2.2.4 Reverse transcription quantitative PCR (RT-qPCR)

RNA was reverse transcribed to cDNA using SuperScript™ III reverse transcriptase (Invitrogen, cat no 18080-044). For each sample, 500 ng of RNA was used with 120 ng of random hexamers (Invitrogen, cat no 48190-011), 0.5 mM dNTP mix (nucleotides supplied in separate tubes from Thermo, cat no R0182), 1x first strand buffer (supplied with kit), 5 mM DTT, and 0.5 μl of SuperScript™ III enzyme, in total
volume of 20 μl. Incubations were done as per the protocol. At the end of the reaction, 180 μl of water was added to dilute the cDNA 10-fold. The cDNA could then be used as template for qPCR.

In later experiments, SuperScript™ IV (Invitrogen, cat no 18090050) was used. Reaction was performed as above, but first strand buffer was replaced with SSIV buffer. Incubations were done as per manufacturer’s protocol.

Earlier qPCR was done on an Agilent MX3005P qPCR machine (Agilent, cat no 401513-64000), while later work was done on a Qiagen Rotor-Gene Q qPCR machine (Qiagen, cat no 9001560).
MX3005P

qPCR was done using Promega SYBR Green GoTaq® qPCR master mix (Promega, A6002). Reactions were done in a volume of 20 µl with 4 µl of cDNA, a final primer concentration of 0.25 µM, and 1X GoTaq® qPCR master mix. PCR programme:

10 mins at 95°C

30 seconds at 95°C  
30 seconds at 58°C  
30 seconds at 72°C  \[ \times 50 \]

60 seconds at 95°C  
30 seconds at 55°C  
30 seconds at 95°C

Options selected in the MxPro software, when setting up the above programme:

SYBR Green with dissociation curve, ‘SYBR’ box ticked.

Rotor-Gene Q

Reactions were done with 2 µl of cDNA, a final primer concentration of 1 µM, and 1X GoTaq® qPCR master mix in 10 µl total reaction volume. PCR programme:

5 mins at 95°C

10 seconds at 95°C  
20 seconds at 60°C  
20 seconds at 72°C  \[ \times 40 \]

Melt segment (default)

Gain optimisation was performed at 60°C at start of run, and before melt.

qPCR data were analysed using the $2^{\Delta\Delta Ct}$ method.
2.2.5 Microarray analysis (data analysis performed by Graeme Thorn)

RNA was analysed from RAW 264.7 cells exposed to four treatment conditions (full details are given below): LPS stimulated and unstimulated cells both with and without a cordycepin pre-treatment (cells that were not pre-treated with cordycepin were pre-treated with DMSO instead).

Four wells of a 6-well plate were seeded with RAW 264.7 cells in DMEM + 10% FBS. Cells were washed and medium replaced with DMEM + 0.5% FBS after 24 hours. A further 24 hours later, one pair of wells had DMSO added, and the other pair of wells had 20 µM cordycepin added. After a 60 minute incubation, two wells (one DMSO-treated well and one cordycepin-treated well) had LPS added at 1 µg/ml. Nothing was added to the other two wells. 60 minutes later, all cells were lysed and RNA extracted as described in section 2.2.1. To summarise, cells were pre-treated with DMSO or cordycepin and then either stimulated with LPS or not. Cell conditions were named ‘D0’, ‘D60’, ‘C0’, and ‘C60’ – D means DMSO pre-treated, C means cordycepin pre-treated, 0 means NOT stimulated with LPS, 60 means LPS-stimulated.

This experiment was performed in biological quadruplicate (16 RNA samples in total), and these were then analysed on a SurePrint G3 Mouse Gene Expression 8x60K microarray kit (Agilent, cat no G4852A). Each slide for the microarray has 8 array slots. As we had 16 samples, 2 slides were used with 2 biological replicates on each.

Raw data were processed using limma (Ritchie et al. 2015) and affy R packages to read the data directly from the microarrays. Each individual microarray was then normalised using the ‘qspline’ option which matches the quantiles of intensities for each microarray. Estimates of measurement errors were taken from replicate arrays.
using an empirical Bayes procedure, which calculates an estimated error based on duplicates on individual arrays. Probes for which intensity was greater than the background + error estimate were retained, while probes for which this criterion was not met were marked as “not above background”. Differences between the mean values were calculated between pairs of conditions: D0 vs D60, C0 vs D0, and C60 vs D60. Individual tests were performed if difference between conditions was significantly non-zero. P-values were corrected from individual p-values by Bonferroni procedure: p-values were multiplied by the number of comparisons made between conditions and capped at a maximum value of 1 (corrected p-val = max(1, p-val * #tests)).

Gene ontology (GO) analysis for lists of genes generated from microarray data was performed using DAVID (https://david.ncifcrf.gov). The list of genes was uploaded to DAVID functional annotation tool along with a background list (containing all measurable genes on the microarray chip). The proportion of genes within a GO term out of the total number of genes in the list of interest was compared to the proportion of genes within the same GO term in the background list. The ratio between these two proportions represents the fold enrichment. The test for significance is based on Fisher’s exact test with p-values then adjusted by Bonferroni procedure (the raw p-value is multiplied by the number of comparisons being made) to correct for multiple comparisons.

2.2.6 Poly(A) tail measurement

3’ end labelling using [5’-32P]Cytidine 3’,5’-bis(phosphate) (32P-pCp) and RNA ligase was performed as described (Minvielle-Sebastia et al. 1991). Briefly, 32P-pCp was
ligated to the 3’ end of total RNA, following which the RNA and ligase mixture was subjected to RNase and proteinase K treatment to digest the enzyme and all non-poly(A) RNA. A phenol/chloroform extraction and ethanol precipitation was done to then purify the remaining non-digested RNA (just poly(A) tails). These RNA samples were then run on a TBE-urea PAGE gel. The gel was then placed in a cassette with a phosphor screen and incubated at -80°C for 3-5 days before being imaged on a GE Storm 825 phosphorimager.

The poly(A) tail test (PAT) assay is done to assess poly(A) tail length. 3 different types of PAT were used – RL1-PAT, RL2-PAT, and sPAT (I/T). RL1-PAT was an older method that was supplanted by RL2-PAT. sPAT (I/T) was tested against RL2-PAT for potential improvements, but was found to be an inferior method, and so RL2-PAT was kept as the method in use.

For RL1-PAT, the 3’-blocked anchor oligo (‘PAT-R1 anchor’) was ligated to the 3’ end of an RNA sample. 50 pmol of anchor and 2 µg of RNA were combined in an 8 µl volume. This mix was incubated for 5 minutes at 65°C, and then had 10 units of T4 RNA ligase 1 (NEB, cat no M0204S) added together with the supplied reaction buffer for a final concentration of 1X. The ligation mix was incubated at 37°C for 2 hours, then 15 minutes at 65°C to heat inactivate the enzyme. After this, reverse transcription was done directly on the resulting mix using SuperScript III. Reaction was done using 1 µM PAT-R1 (complementary to the ligated anchor oligo), 0.2 mM dNTP mix, 1x first strand buffer, 5 mM DTT, and 1 µl of SuperScript™ III enzyme, in total volume of 50 µl. Incubations done as per manufacturer’s protocol.

During the ligation, the oligo receives a 5’-5’ adenylation (catalysed by the enzyme using ATP in the reaction buffer) to form an intermediate species (Figure 2.1). T4 RNA ligase 1 used in RL1-PAT is capable of generating this intermediate, which can
then be ligated to the 3’ end of an acceptor RNA molecule. For **RL2-PAT**, T4 RNA ligase 2 truncated KQ (NEB, cat no M0373S) was used, which is incapable of generating the intermediate. It requires the donor oligo to already have the modification made. The enzyme can only ligate the pre-formed intermediate to an acceptor RNA molecule. The 5’-5’ adenylation can be done using Mth RNA ligase from the 5’ DNA adenylation kit (NEB, cat no E2610S), or oligos can be ordered with this modification already made. Since T4 RNA ligase 2 truncated KQ requires its substrates to be 5’-5’ adenylated already, and is incapable of ligating 5’-phosphorylated substrates (Ho et al. 2004; Ho and Shuman 2002), endogenous RNA cannot supply the 5’ end for the RL2-PAT ligation reaction and endogenous RNAs are not ligated to each other by this enzyme. Additionally, RL2-PAT ligation is ATP-independent. The ligation reaction used in RL2-PAT will be referred to as L2T.
Step one – linking AMP to the ligase enzyme

ATP

Enzyme

Pyrophosphate release

AMP-linked enzyme

Step two – transfer of AMP from the enzyme to the 5’ phosphate of the donor oligo

Enzyme release

5’-5’ adenylation

5’ adenylate oligo intermediate

Rest of oligo

Rest of oligo
Step three – formation of phosphodiester bond between the donor oligo 5’ end and acceptor oligo (or mRNA) 3’ hydroxyl group

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Step 1</th>
<th>Step 2</th>
<th>Step 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>T4 RNA ligase 1</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Mth RNA ligase</td>
<td>✓</td>
<td>✓</td>
<td>x</td>
</tr>
<tr>
<td>T4 RNA ligase 2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>T4 RNA ligase 2 truncated (KQ)</td>
<td>x</td>
<td>x</td>
<td>✓</td>
</tr>
</tbody>
</table>

Figure 2.1. Mechanism of RNA ligation. The ligation of an ssRNA or ssDNA oligo to ssRNA is completed in 3 steps. The table shows the ability of different enzymes to perform each step. An ssRNA donor oligo is depicted here, but is mechanistically interchangeable with ssDNA.
When assessing RL2-PAT as an alternative to RL1-PAT, Mth RNA ligase was used to perform the 5’-5’ adenylation on the PAT-R1 anchor oligo. After determining that RL2-PAT was superior to RL1-PAT, a new anchor was ordered with the modification already made. This anchor was termed ‘PAT-R1 anchor oligo (L2T)’ (Table 2.1). The RL2 ligation was performed using 0.5 µg RNA, 20 pmol 5’-rApp PAT anchor oligo, 15% PEG 8000, and 10 units T4 RNA ligase 2 truncated KQ, with 1X supplied buffer in a 20 µl reaction volume. Note that this ligation is done in the absence of ATP. The ligation mix was incubated at 16°C overnight, following which a reverse transcription was done in the same way as is done for RL1-PAT, but all quantities were doubled, since the ligation mix volume for RL2-PAT is double that of RL1-PAT.

Splint mediated PAT (sPAT) involves the use of a DNA ‘splint’ oligo, which is supposed to contribute to the sensitivity and accuracy of the assay. An overview of the ligation used in sPAT is shown in Figure 2.2. It uses a 3’-blocked RNA anchor oligo (whereas RL1-PAT and RL2-PAT both use a DNA anchor oligo) and a DNA splint which has a 5’ sequence complementary to the anchor followed by a string of T bases, designed to base pair to the poly(A) tail of mRNA. The splint, RNA sample, and the RNA anchor are mixed, heated, and then gradually cooled to room temperature. Under these conditions, the RNA anchor first base pairs to the splint. The non-paired T bases of the splint in this RNA-DNA hybrid then serve to guide the splint to the 3’ ends of mRNA, by base pairing with the last A bases in poly(A) tails. At this point, T4 RNA ligase 2 is added, which repairs nicks in double-stranded RNA. This is not the same enzyme as that used in RL2-PAT (T4 RNA ligase 2 truncated). T4 RNA ligase 2 ligates 5’-phosphorylated oligos and can perform all steps of the ligation process (Figure 2.1). Once the ligation incubation is complete, the ligation mix is subjected to a DNase I treatment to remove the DNA splint. The ligated RNA is then cleaned up
by a phenol/chloroform extraction and ethanol precipitation, whereupon it can be reverse transcribed to PAT cDNA and used for PCR.

Figure 2.2. Overview of sPAT ligation. Total RNA is mixed with a 3’-blocked RNA anchor oligo and a splint. The splint has a 3’ stretch of T bases that are complementary to the poly(A) tail, and a 5’ stretch (red) that is complementary to part of the anchor oligo. After an initial melt phase in the thermocycler, the temperature is cooled enough to favour hybridisation between the splint and anchor only. The temperature is then cooled enough to favour hybridisation between the splint’s T stretch and poly(A) tails. The splint thus guides the anchor to the 3’ ends of mRNAs. The ligation reaction is then performed, a DNase treatment done to remove the splint, and the RNA is cleaned up, whereupon reverse transcription and PCR can be done as in RL1-PAT.
The version of sPAT we tested deviated from the published protocol (Minasaki, Rudel, and Eckmann 2014). The RNA oligo sequence was adapted so that we could use our existing PAT-R1 primer to do the reverse transcription and PCR. The DNA splint sequence was modified to be complementary to our modified RNA oligo. In addition to a DNA splint with a stretch of T bases, a second splint was designed in which the T bases were replaced with an equal number of inosine bases. This was in order to avoid biasing against mRNAs with terminal uridylation. sPAT using the oligo (dT) splint is abbreviated to sPAT (T) and sPAT using the oligo(dI) splint is abbreviated to sPAT (I). The last change made was to not only perform the ligation as it was done in the original publication, but also to test sPAT with the L2T ligation method. Written below is the method using the L2T ligation. For the original sPAT ligation, details are in the original publication.

1 µg of RNA was mixed with 20 pmol DNA splint and 3 pmol anchor in a 10 µl volume. This was then heated to 70°C for 5 minutes, then 60°C for 5 minutes, then 42°C for 5 minutes, then 25°C for 5 minutes, and then held at 15°C. This programme should favour first the hybridisation of the splint to the anchor, and then the hybridisation of the overhanging splint-anchor hybrid to the 3’ end of mRNA. 10 units of T4 RNA ligase 2 truncated KQ was then added to the mix, with 1X reaction buffer and 15% PEG 8000 in a total reaction volume of 20 µl, and this was incubated overnight at 15°C. Following this, the ligation mix was subjected to a DNase digestion using TURBO™ DNase (Ambion™, cat no AM2238), following manufacturer’s protocol, to remove the DNA splint. Following DNase treatment, the mix was subjected to a phenol/chloroform extraction and ethanol precipitation. The RNA pellet was redissolved in 20 µl water, and then subjected to reverse transcription using SuperScript III, in the same was as is done for RL2-PAT.
For all PAT types, once the reverse transcription was complete, the PCR step was done in the same way, using GoTaq G2 polymerase (Promega, cat no M7801).

Reactions were done in a 50 µl volume with 1 µl PAT cDNA, 1X supplied buffer, 1.5 mM MgCl₂, 0.2 mM dNTP mix, 0.4 µM forward PAT primer, 0.4 µM reverse PAT primer (PAT-R1), and 1.25 units of GoTaq G2 polymerase. PCR programme: 5 minutes initial denaturation at 95°C, followed by 40 cycles of 1 minute at 95°C, 1 minute at 58°C, and 2 minutes at 72°C, and ending with a 10 minute final extension at 72°C. PCR products were then run on an agarose gel pre-stained with SYBR Safe (Invitrogen™, cat no S33102) at 4V/cm for 2.5-3 hours.

<table>
<thead>
<tr>
<th>Gene name</th>
<th>Primer name</th>
<th>Sequence (5'-3')</th>
<th>Expected deadenylated product size/bp</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cxcl2</td>
<td>Cxcl2 PAT 1</td>
<td>TGGGGGTGGGGGACAAATAGA</td>
<td>339</td>
</tr>
<tr>
<td>Fosb</td>
<td>Fosb 3F1</td>
<td>ATTAGCTCCATAGCCCTCAC</td>
<td>189</td>
</tr>
<tr>
<td>Rpl28</td>
<td>Rpl28 3F1</td>
<td>GCCACTTCTATGTGAGGAC</td>
<td>259</td>
</tr>
<tr>
<td>Tnf</td>
<td>TNF PAT 1</td>
<td>CTCTACCTTGCTCCTCTT</td>
<td>215</td>
</tr>
<tr>
<td></td>
<td>PAT-R1 anchor (RL1)</td>
<td>GGTCACCTTGATCTGAAGC-NH₂</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>PAT-R1 anchor (L2T)</td>
<td>/rApp/GGTCACCTTGATCTGAAG/ddC/</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>sPAT anchor</td>
<td>/5Phos/GGUCACCUUUGACUGAAGC-NH₂</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>sPAT I splint</td>
<td>TCAGATCAAGGTGAGCCIIIIIIII-NH₂</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>sPAT T splint</td>
<td>TCAGATCAAGGTGAGCTTTTTTTTTTTTT-NH₂</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>PAT-R1</td>
<td>GCTTCAGATCAAGGTGACCTTTTT</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 2.1. List of PAT primers. Note sPAT anchor is entirely RNA. All other primers are DNA. Expected PCR product sizes resulting from PAT using cDNA synthesised from deadenylated RNA samples is shown.
After imaging the agarose gels on a Chemidoc XRS UV transilluminator (Biorad, cat no 1708265), the image was analysed using Quantity One 1-D analysis software (Biorad, cat no 1709602). Lanes in the image were framed and scanned, yielding a plot of physical distance migrated vs intensity for each lane, including one empty lane to measure background intensity. These data were exported and processed in Microsoft Excel as described below.

Firstly, physical distance was plotted against the log$_2$(base pairs) of the DNA fragments in the ladder (100 bp ladder, NEB cat no N3231S). Since the ladder fragments are of defined sizes, they can be used to derive a relationship between physical distance migrated and DNA length (bp). A fourth order polynomial trendline was fitted to the plot of physical distance vs log$_2$(base pairs) for the ladder lane. The equation of the trendline was then used to convert physical distance migrated to DNA length (bp). Note that this was only done within the range of the data available i.e. the smallest and largest fragment sizes in the ladder (100 bp and 1517 bp respectively). All data points outside this range were removed.

Secondly, the column representing background intensity values down the lane were subtracted from the intensity values for all sample lanes. The resulting background-corrected intensity values were then all divided by their corresponding DNA size (bp) to account for the fact that longer DNA molecules will produce a stronger signal.

Lastly, these intensity values in each lane were divided by the average intensity value of their respective lanes. This was done in order to normalise the data and be able to plot them on the same scale (in case more product was loaded in one lane compared to another). These were the final values to plot on the y-axis as ‘relative frequency’. The x-axis values at this point are ‘DNA size (bp)’. By subtracting the expected deadenylated PAT product size (Table 2.1) for whichever primer was used
from the DNA size (bp) values, the resulting x-values represent poly(A) tail length (bp). Thus, the final plot of poly(A) tail length vs relative frequency is obtained.

2.2.7 High throughput poly(A) tail measurement: TAIL-seq

Figure 2.3. Overview of the TAIL-seq library generation procedure. Total RNA is subjected to 2 rRNA-removal steps and then has a biotinylated adapter ligated to the 3’ end of RNAs. This is then subjected to a partial RNase T1 digest, following which the 3’-most fragment of all digested RNAs (which has the biotinylated sequence) is purified by streptavidin pulldown, 5’-phosphorylated, and run on a gel for size selection (300-1000 nt). This size-selected, 5’-phosphorylated RNA then has the 5’ adapter ligated and is reverse transcribed to cDNA. PCR is then done using primers that have overhanging index sequences.
TAIL-seq, originally developed by the Kim lab (Chang et al. 2014), allows for a global assessment of poly(A) tail lengths. An overview of the process is shown in Figure 2.3. Work was done to establish a working protocol for this technique, since the original group’s protocol was not producing results, in our experience. Below is the method we used, deviations from the original protocol are indicated.

**rRNA depletion:** 50 µg of total RNA was subjected to 2 rounds of rRNA depletion using Ribo-Zero Gold kit (MRZH11124C, Epicentre) following manufacturer’s protocol with 10 µl rRNA removal solution used per round. 50 µg exceeds the capacity of the rRNA removal solution, which is why 2 rounds are used.

**3’ adapter ligation:** After redissolving the RNA (now rRNA-depleted), the biotinylated 3’ adapter (RA3_biotin4) was ligated to the 3’ ends of all the RNA using T4 RNA ligase 2 truncated KQ, 20 pmol of the adapter, and 15% PEG 8000 in a 20 µl reaction volume. The ligation was done at 16°C overnight. This step differs from the original protocol, which used T4 RNA ligase 2 truncated (NEB, cat no M0242S), 10 pmol of the 3’ adapter, no PEG 8000, a 10 µl reaction volume and the ligation temperature profile was 28°C for 1 hour, 25°C for 6 hours, 22°C for 6 hours, and then hold at 4°C.

**Partial digestion:** Following the ligation, the RNase T1 (Ambion, cat no AM2283) partial digest was done by assembling the 3’ adapter ligated RNA in 100 µl reaction volume with 1X sequencing buffer (supplied with kit). This mixture was incubated at 50°C for 5 minutes then paused at 22°C, at which point 2 µl of RNase T1 was added. This digestion mixture was incubated at 22°C for 5 minutes in the original protocol, which we found to be insufficient, so we increased the duration (discussed in section 3.4). After the digestion, precipitation/inactivation buffer was added to the mixture
and RNA was precipitated following manufacturer’s instructions and redissolved in 50 µl water.

Optimisation of the duration of the RNase T1 treatment (discussed in section 3.4) involved the use of synthetic RNA as a substrate. The synthetic RNA used (‘T3CAT-xxsB1-M2’) was produced by in vitro transcription from a construct containing the chloramphenicol acetyltransferase gene under the control of a T3 promoter. Further details are available in the methods section of the publication for which it was made (de Moor and Richter 1999).

**Biotin/streptavidin pulldown, 5′-phosphorylation, and size selection:** The 3′ most RNA fragments were purified using Dynabeads M-280 Streptavidin (Invitrogen, cat no 11206D). 50 µl of Dynabeads were used per 10 pmol biotinylated oligo. Manufacturer’s protocol was used up until the bead washing following binding of RNA to beads. At this point, a PNK (polynucleotide kinase) reaction was done while the RNA was still bound to the beads to phosphorylate the 5′ ends of the RNAs. This was done by preparing a 50 µl mix containing 2 µl of T4 PNK (NEB, cat no M0201S), 1X PNK buffer (50 mM Tris-Cl pH 7.4, 10 mM MgCl₂, 0.5% NP-40), and 0.4 mM ATP. This mix was then mixed with the beads and incubated at 37°C for 30 minutes. Note that the PNK buffer is NOT the buffer supplied with the kit. Following the PNK reaction, the beads were washed twice with 100 µl PNK buffer, and then had 13 µl of RNA loading dye (95% formamide, 10 mM Tris-HCl) added. This was mixed, heated at 95°C for 3 minutes, placed on the magnetic rack, and supernatant immediately collected. This elution step was repeated and the two 13 µl elution volumes pooled. Eluted RNA was then run on a TBE-urea PAGE gel and stained with SYBR gold (Invitrogen, cat no S-11494). A size selection was done by cutting the gel between 300 nt and 1000 nt (in the original protocol, this was 450-1500 nt), placing
the gel slice into a gel breaker tube (IST engineering, cat no 3388-100) stacked into a 2 ml centrifuge tube and centrifuging at >16,000 g for 5 minutes. In the original protocol, the size selection was At the end of this, 800 µl of 0.3 M NaCl solution was added to the gel slice debris and rotated overnight at 4°C. The following day, the gel debris suspension in NaCl was divided between 2 Spin-X columns (Corning, cat no 8162) and centrifuged at >16,000 g for 5 minutes. The flow through was then precipitated with 2-3 volumes of 100% ethanol and 0.3 M sodium acetate. The pellet was redissolved in 4.2 µl water.

5' adapter ligation: This RNA (now with the 3’ adapter in place, and 5’-phosphorylated) then had the 5’ adapter ligated. T4 RNA ligase 1 (NEB, cat no M0204S) was used for this with 0.8 µl of the enzyme, 1mM ATP, 1X T4 RNA ligase buffer (supplied with kit) and 5 pmol of the 5’ adapter (RA5) in an 8 µl reaction volume. In the original protocol, the temperature profile for the ligation incubation was 28°C for 1 hour, 25°C for 6 hours, 22°C for 6 hours, and hold at 4°C. We changed this to a single incubation temperature of 16°C overnight.

Reverse transcription (RT): The RNA was reverse transcribed using SuperScript III (Invitrogen, cat no 18080093). Manufacturer’s protocol was followed using 4 pmol of the reverse transcription primer (RTP).

PCR: When the library is generated, the fewest cycles that results in successful amplification should be used – this is because amplification becomes non-linear at higher cycle numbers. A small-scale PCR at several different cycle numbers was performed to find out what the ideal number of cycles was. PCR was done using Phusion polymerase (Thermo, cat no F-530L), RP1 forward primer, and RPI X reverse primer (where X denotes. The reaction was done in a 4 µl volume with 0.4 µl of RT
product, 0.2 mM dNTP mix, 0.5 µM primers and 0.04 μl of enzyme. 13-21 cycles were used with the following cycling conditions:

<table>
<thead>
<tr>
<th>Temperature</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>98°C</td>
<td>30s</td>
</tr>
<tr>
<td>98°C</td>
<td>10s</td>
</tr>
<tr>
<td>60°C</td>
<td>30s</td>
</tr>
<tr>
<td>72°C</td>
<td>45s</td>
</tr>
<tr>
<td>72°C</td>
<td>5 min</td>
</tr>
</tbody>
</table>

13-19 cycles

After running the PCR products on the gel to determine what the lowest cycle number was that resulted in amplification, this number of cycles was used for a full-scale PCR. The same cycling conditions were used as above, the volumes were all scaled up by a factor of 12.5 so that the reaction volume was 50 µl.

**Purification of DNA library:** Once the PCR was complete, the library was purified by AMPure XP beads (Beckman Coulter, cat no A63880) following manufacturer’s protocol.

<table>
<thead>
<tr>
<th>Primer name</th>
<th>Primer sequence (5’-3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA 5’ Adapter (RA5)</td>
<td>GUCAGAGUCUCAGUCCGACGAUC</td>
</tr>
<tr>
<td>RNA 3’ Adapter (RA3 biotin 4)</td>
<td>/5App/CTGACNNNNNNNNNNNTGGAATTCTCG GGTCGAAGGC/iBiodT//iBiodT//3ddC/</td>
</tr>
<tr>
<td>RNA RT Primer (RTP)</td>
<td>GCCTTGCCAACCCGAATTTCCA</td>
</tr>
<tr>
<td>RNA PCR Primer (RP1)</td>
<td>AATGATACGGCGACCACCGAGATCTACACGTTCAGAGTTCTACAGTTCCGA</td>
</tr>
<tr>
<td>RNA PCR Index Primers (RPIX)</td>
<td>Any of Illumina’s proprietary TruSeq small RNA RNA PCR index primers between RPI 1 and RPI12</td>
</tr>
</tbody>
</table>

**Table 2.2. List of TAIL-seq primers.**
<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer name</th>
<th>Sequence (5’-3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acod1</td>
<td>Irg1-F1</td>
<td>ACTCTGAGCCAGTTACCT</td>
</tr>
<tr>
<td></td>
<td>Irg1-R1</td>
<td>CTGTGACAGACTTGAGCATCAT</td>
</tr>
<tr>
<td>Acod1</td>
<td>un Irg-F</td>
<td>TTCTCCAATGCCAGCAATCA</td>
</tr>
<tr>
<td></td>
<td>un Irg1-R</td>
<td>CAGAAACTTGGAGCGACAGCAG</td>
</tr>
<tr>
<td>Cxcl2</td>
<td>Cxcl2-F</td>
<td>TGAACAAAGGGCAAGTACTAATG</td>
</tr>
<tr>
<td></td>
<td>Cxcl2-R</td>
<td>ACATCAGTGATACCCAGGC</td>
</tr>
<tr>
<td>Gapdh</td>
<td>Mouse GAPDH F</td>
<td>AAGAAGGTGGTGAAGCGAGG</td>
</tr>
<tr>
<td></td>
<td>Mouse GAPDH R</td>
<td>ATCGAAGTGGAAGATGGGG</td>
</tr>
<tr>
<td>Hprt</td>
<td>Mouse HPRT F</td>
<td>GGTGTCTAGTCTGTGGCC</td>
</tr>
<tr>
<td></td>
<td>Mouse HPRT R</td>
<td>AGTGCATAACTGAAGCTGGGG</td>
</tr>
<tr>
<td>Il1b</td>
<td>Mouse Il1b-F1</td>
<td>AGATGAAGGGCCTGCTCCAAAA</td>
</tr>
<tr>
<td></td>
<td>Mouse Il1b-R1</td>
<td>GGAAGGTCCACGGGAAAGAC</td>
</tr>
<tr>
<td>Ptgs2</td>
<td>Ptgs2 F</td>
<td>GGGTGATACACCTCCACCAAT</td>
</tr>
<tr>
<td></td>
<td>Ptgs2 R</td>
<td>GGGGGATACACCTCCACCAAT</td>
</tr>
<tr>
<td>Rpl28</td>
<td>Rpl28 Fw</td>
<td>TACAGCACGGGAGCAATGGC</td>
</tr>
<tr>
<td></td>
<td>Rpl28 Rev</td>
<td>ACGGTCTTGCGTGAGATTAG</td>
</tr>
<tr>
<td>Rpl28</td>
<td>Rpl28 Fw2</td>
<td>CATCGTACACTAATCCCTCC</td>
</tr>
<tr>
<td></td>
<td>Rpl28 Rev</td>
<td>ACGGTCTTGCGTGAGATTAG</td>
</tr>
<tr>
<td>Rpl28</td>
<td>Rpl28 Rdthr 500 F1</td>
<td>ACATTCTGGTGCTGTCAGC</td>
</tr>
<tr>
<td></td>
<td>Rpl28 Rdthr 500 R1</td>
<td>TCTAAGGTCAGCAATTCACACTGA</td>
</tr>
<tr>
<td>Rpl28</td>
<td>Rpl28 PAS F1</td>
<td>ACACGCCCAGCAATGAAAAG</td>
</tr>
<tr>
<td></td>
<td>Rpl28 PAS R1</td>
<td>CAACCCTCACCTAGAAGCA</td>
</tr>
<tr>
<td>Tnf</td>
<td>TNF Fw1</td>
<td>CTATGGCCAGAGCCTCACA</td>
</tr>
<tr>
<td></td>
<td>TNF Rv1</td>
<td>CACCTGGTGGGTGGCTACGA</td>
</tr>
<tr>
<td>Tnf</td>
<td>Mouse un Tnf-F1</td>
<td>ACACTGACTAATCCTCCC</td>
</tr>
<tr>
<td></td>
<td>Mouse un Tnf-R1</td>
<td>AGCCTGTGCCTGAAGAGA</td>
</tr>
<tr>
<td>Tnf</td>
<td>Tnf Rdthr 750 F1</td>
<td>ATCCAAAGCTGCATATGTGATTA</td>
</tr>
<tr>
<td></td>
<td>Tnf Rdthr 750 R1</td>
<td>TATGGAGGTGGTGATGGAAA</td>
</tr>
<tr>
<td>Tnf</td>
<td>Tnf PAS F1</td>
<td>TTTTGTTCCAGGCGTGTTTTT</td>
</tr>
<tr>
<td></td>
<td>Tnf PAS R1</td>
<td>GGGAGCCCTGACCTGTAATCG</td>
</tr>
</tbody>
</table>

Table 2.3. List of qPCR primers. Primers are stacked as pairs. The top primer in each stack is the forward primer, the bottom is the reverse.
2.3 Protein work

2.3.1 Western blot analysis

At the end of the experiment, cells were placed on ice and washed twice with chilled PBS, and then scraped in 5 ml PBS with a cell lifter (Corning, cat no 07-200-364). This cell suspension was then centrifuged at 10,000 g for 1 minute at 4°C. The supernatant was discarded and the pellet resuspended in 500 µl ice-cold PBS, centrifuged as above, and supernatant discarded. To this pellet, 125 µl of ice-cold lysis buffer (1xPBS, 0.5% Igepal, 0.5% deoxycholate, 0.05% SDS, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 mM PMSF) was added, and pipetted up and down. This was centrifuged at 20,000 g for 10 minutes at 4°C and supernatant collected in a new tube. 10 µl of the supernatant was used for determining protein concentration by Bradford assay, and the rest had 3X SDS-PAGE loading buffer (0.2 M Tris-HCl pH 6.8, 9%SDS, 30% glycerol, 2.1 M β-mercaptoethanol, 0.0125% bromophenol blue) added for a final concentration of 1X. 45 µg of protein in 1X SDS-PAGE loading buffer was loaded per well on a 1mm 12% minigel (8.6cm × 6.8cm).

After running the gel, proteins were blotted onto a PVDF membrane (Thermo, cat no 88518). Membrane was rinsed twice with TBST (10 mM Tris/HCl, 150mM NaCl, 0.05% Tween 20), incubated for 1 hour at room temperature while rocking in TBST containing 5% milk, rinsed three times with TBST, and then sealed in a small pouch with the primary antibody in milk. Primary antibodies used were mouse anti-IκBα (Cell signalling technology, cat no 4814) and mouse anti-symplekin (BD Biosciences, cat no 610644). This was then incubated for 1 hour at room temperature, with the pouch regularly rubbed to mix. The blot was then removed, rinsed three times with TBST, and then incubated with polyclonal goat anti-mouse secondary antibody (Dako, cat no P0447) in milk for 1 hour at room temperature in another small, sealed
pouch. The blot was then recovered, rinsed three times with TBST, and incubated for 20 minutes in TBST on a rocker at room temperature. Chemiluminescence solution (GE, cat no RPN2106) was prepared and, after placing the blot onto a glass plate (protein side up), pipetted onto the blot just enough to cover the surface. After approximately 5 minutes, the blot was imaged on the LAS-4000 imager (GE, discontinued, cat no 28-9558-10).

2.4 Animal work

2.4.1 Rat osteoarthritis model pain behaviour assessment by James Burston

The monosodium iodoacetate (MIA) model of osteoarthritis was used. On day 0, animals had either saline (one group) or MIA (two groups) injected into the knee of one hind leg. One MIA group had cordycepin mixed with food at 2 mg/kg every other day over the course of the experiment while the other MIA group and the saline group had DMSO (vehicle) mixed with food, instead. Pain behaviour was assessed on a number of days during this period, measured as weight bearing asymmetry between hind legs, and paw withdrawal thresholds when paws were pressed with Von Frey filaments of increasing force until the animal withdrew its paw. On day 14 post injection, animals were killed and tissues obtained for later use.

2.4.2 RNA isolation from rat synovia

A number of strategies were attempted to isolate RNA from synovia (discussed in results). The method that worked was the use of TRI Reagent (Sigma, cat no T9424) at 2 ml per 50 mg tissue. TRI Reagent was added to the synovium in a tube and immediately processed using a rotor-stator homogeniser for 15-30 seconds at room temperature, until a homogeneous suspension was obtained. The homogenates
were incubated at room temperature for 5 minutes after which 0.2 ml of 1-bromo-3-chloropropane was added per 1 ml of monophasic lysis reagent. Samples were mixed by shaking and then centrifuged at 10,000 g for 15 minutes at 4°C. The aqueous layer was then transferred to a fresh tube and subjected to an isopropanol/sodium acetate precipitation. Pellet was redissolved in water.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer name</th>
<th>Sequence (5'-3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actb</td>
<td>Actb-F</td>
<td>AGGCCATGTACGTAGCCATCCA</td>
</tr>
<tr>
<td></td>
<td>Actb-R</td>
<td>TCTCCGGAGTCCATCAATG</td>
</tr>
<tr>
<td>Il1b</td>
<td>Il1b-F</td>
<td>CACCTCTCAAGCAGACACAG</td>
</tr>
<tr>
<td></td>
<td>Il1b-R</td>
<td>GGGTTCCATGTGAAGTCAC</td>
</tr>
<tr>
<td>Tnf</td>
<td>Rat Tnf-F</td>
<td>CCAGGAGAAAGTCAGCTCCT</td>
</tr>
<tr>
<td></td>
<td>Rat Tnf-R</td>
<td>TCATACGAGGTGCTGCTCA</td>
</tr>
<tr>
<td>Ptgs2</td>
<td>Cox2-F</td>
<td>GGCACAAATATGATGTTGCA</td>
</tr>
<tr>
<td></td>
<td>Cox2-R</td>
<td>CCTCGGCTTCTGTCTGTTGA</td>
</tr>
</tbody>
</table>

**Table 2.4. List of rat qPCR primers used.** Primers are stacked as pairs. The top primer in each stack is the forward primer, the bottom is the reverse.
3 Optimising and developing methodologies for poly(A) tail measurements

The poly(A) tail test (PAT) offers a means for assessment of the distribution of poly(A) tail sizes for a specific mRNA within an RNA sample. There are several varieties of the PAT method, but the types that this chapter is concerned with all include ligation of an oligonucleotide adapter to the 3’ end of RNA, reverse transcription to generate cDNA, and PCR using primers that flank the poly(A) tail. The method that was in use in our research group when this project began was RNA ligation-mediated PAT (RL1-PAT) (Rassa et al. 2000). RL1-PAT requires a large input quantity of RNA, which was not always possible for samples with low yields. I sought to make improvements to RL1-PAT, as it was. Additionally, RL1-PAT was compared to two alternative PAT methods in case they offered superiority – RL2-PAT and splint-mediated PAT (sPAT) (Minasaki, Rudel, and Eckmann 2014).

Lastly, in collaboration with the Deep seq facility at the University of Nottingham, we attempted to establish the recently published TAIL-seq method for high-throughput poly(A) tail analysis (Chang et al. 2014).

3.1 Deadenylation by oligo (dT)/RNase H treatment

To determine if the correct product is amplified, RNA samples are used that have been subjected to an oligo (dT)/RNase H treatment to remove poly(A) tails. This should result in all PAT cDNAs that get amplified having a uniform poly(A) tail size close to zero. This means a single band will be observed on the gel, or 2 or more discrete, distinct bands in the case of alternative polyadenylation. Doing the oligo (dT)/RNase H treatment is therefore essential for testing new primers (to check that the expected deadenylated product is being amplified, and not an off-target product). In the event that different PAT products are yielded from different RNA
samples, repeating PAT on the samples’ deadenylated counterparts should yield the same product(s) as 1 or more discrete, distinct band(s), thus proving that differences observed are exclusively due to poly(A) tail size differences. For this reason, the oligo (dT)/RNase H treatment is a crucial part of the PAT methodology.

After switching supplier of RNase H from Promega to NEB, our lab group was experiencing incomplete, unsatisfactory deadenylation with the oligo (dT)/RNase H treatment (Figure 3.1A). I tested multiple different permutations of the treatment to see if this could be rectified to yield complete deadenylation (Figure 3.1B). The treatments were all carried out under the same conditions, with the only differences being the quantity of oligo (dT) and RNase H enzyme used. Using 4 µg of oligo (dT) and 5U of enzyme consistently yielded properly deadenylated RNA, and so this combination of concentrations was adopted. The lowest combination of oligo (dT) and enzyme concentration (2 µg and 2.5 U respectively) appears to result in the same degree of deadenylation as using 4 µg of oligo (dT) and 5 U of enzyme in Figure 3.1B. However, such results were not consistent in further experiments, whereas 4 µg of oligo (dT) and 5 U of RNase H reliably caused deadenylation. Unexpectedly, the result of using 4 µg of oligo (dT) and 2.5 U of enzyme was less deadenylation than for the lowest combination of concentrations. This was probably an anomalous result.
Figure 3.1 Incomplete deadenylation using NEB RNase H was addressed by increasing oligo (dT) and RNase H quantities. RL1 PAT was performed using the Rpl28 3F1 primer with various cDNA samples and PAT products were run on agarose gels. (A) DA and non-DA denote deadenylated and non-deadenylated PAT cDNA of RNA isolated from unstimulated RAW 264.7 cells. The deadenylation was performed using Promega or NEB RNase H (1.5 U of enzyme, 2 µg oligo (dT)). (B) NEB RNase H deadenylation was performed on RNA from RAW 264.7 cells stimulated with LPS at 1 µg/ml for 30 minutes using a range of different oligo (dT) and NEB RNase H quantities. * indicates artefactual bands.

Deadenylated Rpl28 product size: 259 bp
3.2 Appraising different ligation strategies

As part of the PAT optimisation, different ligation strategies were used and compared to each other. I compared RL1-PAT, which uses the T4 RNA ligase 1 enzyme, to RL2-PAT, which uses the T4 RNA ligase 2 truncated enzyme. The ligation in the RL2-PAT workflow is referred to as L2T. The sPAT method was also tested both with the original ligation and using the L2T ligation. Full details are in section 2.2.6.

In order to see whether RL2-PAT offered advantages over the RL1-PAT method in use, reactions were incubated in parallel with 3 different input RNA quantities (2 µg, 1 µg, and 0.5 µg). PAT anchor was 5’-adenylated using a 5’ DNA adenylation kit prior to use in the RL2-PAT workflow, while the normal, unaltered, PAT anchor (5’-phosphorylated) was used for RL1. Following the ligation step, the reverse transcription was done in the same way, but all volumes were doubled for RL2-PAT, since the ligation reaction volume was double that of RL1-PAT. PAT-PCR was then done in exactly the same way for both, with 1 µl of cDNA. RL2-PAT was found to yield consistent PAT products across the 3 different input RNA quantities, while the distribution of PAT products generated with RL1-PAT appeared to vary between the different input RNA quantities (Figure 3.2A). qPCR on all the PAT cDNA samples was performed, and demonstrated that cDNA generation was consistent for RL2-PAT for all input RNA quantities used (Figure 3.2B). This consistency was not seen for RL1-PAT, which also yielded considerably less cDNA than RL2-PAT, suggesting better ligation efficiency with L2T. Taken together, these data indicate that using the L2T ligation represents a significant improvement of the PAT method over the RL1 method that had been in use before. For this reason, RL2-PAT using L2T ligation replaced the RL1-PAT procedure, and a new PAT anchor oligo was ordered with the 5’-5’ adenylation modification already made.
Figure 3.2. RL2 PAT yields more consistent results with a range of input RNA quantities, and more efficient cDNA generation. (A) RL1 and RL2 PAT tests were performed for Tnf using RNA from RAW 264.7 cells stimulated with LPS at 1 µg/ml for 30 minutes. Three input RNA quantities were used (2 µg, 1 µg, and 0.5 µg) for each ligation method (RL1 and RL2). PAT products were run on an agarose gel. The gel image was scanned using Quantity One software and profiles represented graphically. * indicates artefactual bands. (B) The PAT cDNA samples were also subjected to qPCR for Tnf, and the raw Ct value was measured. qPCR was performed on the Qiagen Rotor-Gene Q platform. Error bars represent standard deviations across three technical replicates.

Deadenylated Tnf product size: 215 bp
After implementing the RL2 ligation in the PAT procedure, the sPAT method was published, which was tested against our newly adopted RL2-PAT method. In order to see if a combination of amplification ligation and the ligation method used in RL2-PAT ligation could improve the ligation efficiency even further, the RNA anchor oligo was subjected to a 5′-5′ adenylation step prior to use in some samples i.e. sPAT using RL2 ligation with 5′-5′ adenylated RNA anchor instead of the standard sPAT using T4 RNA ligase 2 with 5′-phosphorylated RNA anchor. sPAT using the RL2 ligation method will be referred to as L2T sPAT, while standard sPAT using T4 RNA ligase 2 with 5′-phosphorylated RNA anchor will be referred to as T4 Rnl2 sPAT.

Both types of sPAT were done (L2T and T4 Rnl2), and the gel image (Figure 3.3) shows that the L2T method produced a stronger signal. It was later noted that the DNase treatment had been accidentally omitted in this experiment, and so it was repeated alongside RL2-PAT for direct comparison. However, having observed that L2T ligation appeared to improve sPAT, we only compared RL2-PAT to L2T sPAT – T4 Rnl2 sPAT was not included in the experiment. RL2-PAT produced results that were either similar to those for L2T sPAT or showed higher signal (Figure 3.4). qPCR was done on RL2-PAT and L2T sPAT cDNAs for a number of mRNAs across a range of different levels of abundance. RL2-PAT consistently resulted in a greater efficiency of cDNA generation (Figure 3.4). It was thus concluded that RL2-PAT was superior to L2T sPAT, and so the method was retained.
Figure 3.3. The L2T ligation improves sPAT compared to the T4 Rnl2 sPAT ligation. sPAT protocol was followed with two different ligation strategies: the L2T ligation with a 5’-5’ adenylated RNA anchor oligo (L2T sPAT) or the standard sPAT ligation using T4 RNA ligase 2 with 5’-phosphorylated RNA anchor oligo (T4 Rnl2 sPAT).

Both the I and T splints were used with 3 different input quantities of RNA: 1 µg, 0.5 µg, and 0.2 µg. RNA was from RAW 264.7 cells that had been stimulated for 30 minutes with LPS at 1 µg/ml. PAT products (Tnf) were run on an agarose gel. Note that the DNase treatment was forgotten. * indicates artefactual bands.

Deadenylated Tnf product size: 215 bp
Figure 3.4. RL2-PAT results in greater efficiency of cDNA generation. (A) PAT was performed for Tnf using RNA from RAW 264.7 cells stimulated with LPS at 1 µg/ml for 30 minutes with three distinct methodologies: RL2-PAT, L2T sPAT using an oligo (dT) splint (sPAT T), and L2T sPAT using an oligo(dI) splint (sPAT T). PAT products were run on an agarose gel. The gel image was scanned using Quantity One software and profiles represented graphically. (B) The PAT cDNA samples were subjected to qPCR for 4 genes of varying abundance levels, and the raw Ct values were plotted on a graph. qPCR was done on the Qiagen Rotor-Gene Q platform. Error bars represent standard deviations across three technical replicates.

3.3 Identifying artefacts

Very large, unexpected, PAT products are routinely observed when running the products on agarose gels, in addition to the products that appear around the expected size (Figure 3.7). Possible explanations for the presence of these unexpected species were that they were products with very large poly(A) tails, products with a downstream poly(A) site (i.e. alternative polyadenylation) and therefore longer 3’ UTR, or some sort of artefactual species. If these higher bands are due to alternative polyadenylation, then doing PAT on the samples’ deadenylated counterparts should yield a correspondingly large deadenylated PAT product in addition to the expected one. However, this is generally not observed (e.g. Figure 3.1A), and so this was unlikely. If the higher bands represented some sort of artefact formed through secondary structure, then running them on a gel under denaturing conditions should remove them. I attempted this by mixing different quantities of a PAT product with formamide buffer (49.5% final concentration for all samples loaded), heating, and running on a TBE-urea PAGE gel (Figure 3.5). This was done for 2 different PAT products (Rpl28 and Tnf), and the relative proportion of the higher bands increased with increasing PAT product being loaded, even though it was the exact same PAT product for each of the 3 quantities loaded. This was highly suggestive of the higher band representing an artefact whose formation was favoured by increasing concentration of the product.
Figure 3.5. An increase in PCR product:formamide ratio increases the prevalence of suspected multimeric bands. RL2-PAT was performed for Rpl28 and Tnf using RNA from RAW 264.7 cells stimulated with LPS at 1 µg/ml for 30 minutes. PAT products were run on a TBE-urea PAGE gel. Samples were in 49.5% formamide buffer and were heated at 90°C for >10 minutes then placed on ice prior to loading and running. Gel images were scanned using Quantity One software and profiles represented graphically. * indicates artefactual bands.

I ran those same products, again, on a TBE-urea PAGE gel, but with only 1 µl of PAT product loaded in 90% formamide buffer, and with heated running buffer in the electrophoresis tank to maximise the denaturing potential of the system. Doing this completely removed the appearance of the higher bands which were observed on agarose and when using 49.5% formamide buffer on TBE-urea PAGE (Figures 3.5 and 3.6). A working model for the formation of these higher bands was conceived (Figure 3.7B), wherein the repetitive melting and reannealing in later stages of PCR leads to mispairing of strands with different poly(A)/poly(T) lengths, and looping out of excess A or T bases. Loops of excess A can then facilitate base pairing with loops of excess T from other mismatched duplexes to form a multimeric artefact. This model is consistent with the findings of an experiment in which oligo (dT) was able to remove higher bands. PAT cDNA from serum-stimulated NIH-3T3 cells were used for PAT to amplify Fosb – PAT for this mRNA in this cell type routinely results in higher bands. PAT products then had varying quantities of oligo (dT) added, were heated at 95°C, and then were run on an agarose gel. The gel photo and graphical scan show that the addition of oligo (dT) leads to disappearance of the higher bands (Figure 3.7A). Ostensibly this occurs by ‘titrating’ A loops, preventing their association with T loops.
Artefactual species are multimers and can be removed through fully denaturing PAGE. RL2-PAT was performed for Rpl28 and Tnf using RNA from RAW 264.7 cells stimulated with LPS at 1 µg/ml for 30 minutes. PAT products were run on an agarose gel, and on a TBE-urea PAGE gel. For PAGE, samples were in 95% formamide buffer, TBE in the gel tank was heated to 50 °C prior to running, and samples (in formamide buffer) were heated at 90 °C for >10 minutes immediately prior to loading and running. Gel images were scanned using Quantity One software and profiles represented graphically. * indicates artefactual bands.

Figure 3.7. Addition of oligo (dT) to PAT-PCR products can remove multimer species. (A) RL2 PAT was performed for Fosb on RNA samples from NIH-3T3 cells stimulated with DMEM + 10% NBCS for 110 minutes (following a 24 hour incubation in DMEM + 0.5% NBCS). 15 µl of PAT-PCR products were mixed with the indicated amount of oligo (dT), heated at 95°C for 10 minutes then placed on ice prior to loading and running. Gel images were scanned using Quantity One software and profiles represented graphically. * indicates artefactual bands. (B) Working model for formation of the PAT multimer species.

Dedenylated Fosb product size: 189 bp.
3.4 High-throughput poly(A) tail measurements – TAIL-seq

TAIL-seq is a method that allows for the high-throughput measurement of poly(A) tail lengths, and other 3’ terminal modifications, within an RNA sample. We sought to establish the technique within our group in conjunction with the Nottingham deep sequencing facility. However multiple attempts to follow the TAIL-seq protocol (provided by Narry Kim’s group) failed to generate a library, and so we tried to troubleshoot the procedure by assessing how well individual steps within the protocol were working. An overview of the process is shown in Figure 2.3.

By the point of eluting RNA from the streptavidin beads, the expected RNA recovered would be the 3’-most fragment yielded from the partial RNase T1 digest with the biotinylated 3’ adapter (RA3_biotin4) ligated to its 3’ end, and phosphorylated at its 5’ end (since a PNK reaction is performed on the beads after the wash steps and before eluting). As shown in Figure 3.8, only the unligated 3’ adapter (RA3_biotin4) was being recovered following the streptavidin pulldown. The RA3_biotin4 oligo can be seen in the ligation mix along with the rRNA-depleted NIH 3T3 RNA – this indicates that at least some of the oligo did not ligate to the NIH 3T3 RNA. If the ligation had been successful, I would have expected the bands for the rRNA-depleted NIH 3T3 RNA to shift up between the two lanes on the gel (before and after ligation). The RA3_biotin4 adapter is 45 nt in length, and the ladder shows clear separation of the 30 nt and 50 nt RNA fragments, and so a 45 nt change in RNA length should be clearly observable, at least around this lower part of the gel. This suggests a possible failure of the 3’ adapter ligation. Moreover, only a single band is observed on the gel after the streptavidin pulldown, corresponding to the RA3_biotin4 oligo. This strongly suggests that the 3’ adapter ligation did indeed fail,
since ligation products would have otherwise been recovered in the pulldown (irrespective of whether the RNase T1 digest had been successful or not).

Figure 3.8. Only unligated RA3 oligo is recovered after the streptavidin pulldown. Total RNA from unstimulated NIH 3T3 cells was isolated and subjected to rRNA removal. The resulting ribodepleted RNA was then used for the 3’ adapter (‘RA3 oligo’) ligation step, following original protocol (T4 RNA ligase 2 truncated, 10 pmol of the 3’ adaptor, no PEG 8000, a 10 µl reaction volume, 28°C for 1 hour, 25°C for 6 hours, 22°C for 6 hours, and then hold at 4°C). Once the ligation step was complete, the RNA was subjected to a partial RNase T1 digest (5’ digestion time), and a streptavidin pulldown performed. A PNK reaction was completed prior to eluting bound RNA from the streptavidin beads. Samples of RNA from multiple points in this procedure were run on a TBE-urea PAGE gel alongside the 3’ adapter (‘RA3_biotin4’) alone.
Our PAT protocol uses a very similar ligation step under different conditions that works well, so we sought to compare the efficiencies of the TAIL-seq ligation versus the L2T ligation used in the RL2-PAT method (see section 2.2.6 for details). After doing the ligation in both ways, the RNA ligation mixes were divided into two halves – one half was reverse transcribed using random hexamers, while the other was reverse transcribed using the “RT primer” (primer complementary to the 3’ adapter). Using random hexamers was expected to produce similar amounts of cDNA for all RNA ligation mixes, while reverse transcription (RT) using the RT primer would depend on the efficiency of the ligation. Comparison of the ratio of the Ct value for the two RT methods will give an indication of how well the ligation has worked between the different ligation methods.

Surprisingly, the Ct values for the TAIL-seq ligation method and random hexamer RT were very high (Table 3.1). As a result, I was not able to directly compare the ligation efficiencies, but, since I obtained reasonable Ct values from all cDNAs made from our PAT ligation method, we elected to use this method for the TAIL-seq, also.
**Table 3.1.** The ligation used in the PAT workflow successfully generated cDNA for TAIL-seq. 3 µg or 0.5 µg of total RNA from unstimulated RAW 264.7 cells had RA3_biotin4 3’ adapter ligated to the 3’ end of RNA in one of two ways: T4 RNA ligase 2 truncated KQ, 20 pmol of RA3_biotin4, and 15% PEG 8000 in a 20 µl reaction volume incubated overnight at 16°C overnight ('L2T'); or T4 RNA ligase 2 truncated, 10 pmol of RA3_biotin4, and no PEG 8000 in a 10 µl reaction volume incubated at 28°C for 1 hour, 25°C for 6 hours, 22°C for 6 hours, and then held at 4°C ('TAIL-seq'). Ligation mixes were then reverse transcribed using either random hexamers or the RT primer specific to RA3_biotin4 (the ligated 3’ adapter). qPCR was done in technical triplicate for each reverse transcription mix for Gapdh, Tnf, and Fosb. Average Ct values are shown.

<table>
<thead>
<tr>
<th>RT method used</th>
<th>Input RNA quantity</th>
<th>Gapdh (high abundance)</th>
<th>Tnf (mid-high abundance)</th>
<th>Fosb (low abundance)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3 µg</td>
<td>14.02</td>
<td>35.08</td>
<td>19.37</td>
</tr>
<tr>
<td>Random hexamers</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.5 µg</td>
<td>18.62</td>
<td>32.34</td>
<td>23.60</td>
</tr>
<tr>
<td>RT primer (RTP)</td>
<td>3 µg</td>
<td>16.28</td>
<td>23.46</td>
<td>23.97</td>
</tr>
<tr>
<td></td>
<td>0.5 µg</td>
<td>20.29</td>
<td>34.06</td>
<td>28.34</td>
</tr>
</tbody>
</table>
Following the RNase T1 partial digest, bands from the NIH-3T3 RNA are clearly visible (Figure 3.8). The quantity of RNA run on the gel at this point was very low compared to that of the previous two lanes, and so the signal is faint, but the bands between 50 nt and 80 nt, as well as the band just under 150 nt, can be observed at the same size as in the previous two lanes (undigested sample), possibly indicating limited digestion. For deep sequencing using Illumina technology, longer fragments of nucleic acids (>1,000 nt) experience a decreased efficiency of amplification during the process of cluster generation relative to that of shorter fragments (Quail et al. 2009). This can lead to an underestimation of longer fragments compared to shorter ones, since shorter ones will amplify more efficiently and result in proportionately more reads. For this reason, we wanted to ensure the digestion was not limited and sought to optimise it by testing different digestion durations. Using multiple aliquots of NIH-3T3 RNA that had been subjected to rRNA removal (the normal substrate for the RNase T1 partial digest step) to test multiple digestion durations was not viable, since the rRNA removal reactions were very expensive. For this reason, we used a synthetic RNA (‘T3CAT-xxsB1-M2’, henceforth referred to simply as ‘synthetic RNA’) as a substrate, instead, since this was expendable RNA from older work that was no longer required. The synthetic RNA was ~800 nt in length.

The RNase T1 enzyme cleaves single-stranded RNA after G residues, and so poly(A) tails are impervious to RNase T1 digestion. Therefore, in order to avoid the problem mentioned above (longer fragments that do not amplify efficiently during cluster generation), we aimed to ensure that the RNase T1 would cleave non-poly(A) RNA approximately every 400 nt. In this way, the fragments obtained after the ligation and RNase T1 digestion would have a length amounting to ~400 nt plus the length of their poly(A) tails. This would allow for even RNAs with long poly(A) tails (>250 nt) to
still fall below the 1,000 nt limit (after RNase T1 digestion). For our synthetic RNA (~800 nt total size), we aimed to achieve an extent of digestion which yields a distribution of products with a peak around 400 nt. **Figure 3.9** shows that a 10’ RNase T1 treatment of the synthetic RNA yielded a spread of products, with most RNA appearing to fall in the range of 300 nt to ~800 nt (just below the undigested 0’ control). The 30’ digestion duration resulted in a greater degree of digestion than the 10’ duration. Compared to the 10’ digestion, no significant amount of RNA is observed above the 500 nt band, RNA between 300 nt and 500 nt is fainter, and more RNA appears below the 300 nt band. For the 60’ RNase T1 digestion, the longest RNA fragments yielded are below the 300 nt band – a much greater extent of digestion than desired. The 10’ digestion was not quite extensive enough (significant signal observed just under the undigested RNA band), and the 30’ digestion appeared to be slightly too extensive (significantly fainter signal observed between 300 nt and 500 nt marker bands and more intense smear of shorter products below the 300 nt band compare to the 10’ digestion). Ultimately, a digestion duration of 15’ was chosen for the workflow.
Our attempt to generate a library for TAIL-seq using the original ligation strategy and RNase T1 duration was unsuccessful, as shown in Figure 3.10A – the only product observed in the small-scale PCR is a band is observed below the 100 bp marker band, possibly due to primer dimer. After implementing the L2T ligation (to ligate the RA3_biotin4 3’ adapter to the end of rRNA-depleted NIH-3T3 RNA) and the 15’ RNase T1 digestion in the TAIL-seq workflow, the library generation was reattempted and 13-17 cycles of PCR was sufficient to successfully generate a library, with products corresponding to the library ranging from 100 bp to >1,000 bp (Figure 3.10B). The fact that products larger than 1,000 bp were amplified suggests that the RNase T1 digestion duration may need further optimisation.
Figure 3.10. Changing the 3’ adapter ligation strategy and increasing the RNase T1 digest duration resulted in successful amplification of a library.

(A) The original TAIL-seq workflow was followed with NIH 3T3 RNA, using the original protocol. 3’ adapter ligation conditions: T4 RNA ligase 2 truncated, 10 pmol of the 3’ adaptor, no PEG 8000, a 10 µl reaction volume, 28°C for 1 hour, 25°C for 6 hours, 22°C for 6 hours, and then hold at 4°C. RNase T1 digest duration: 5 minutes. After the small scale PCR, samples were run on an agarose gel after completing the indicated number of PCR cycles to assess whether a library had been amplified. (B) As above except for 15 minute RNase T1 digest and altered 3’ adapter ligation conditions: T4 RNA ligase 2 truncated KQ, 20 pmol of the adaptor, 15% PEG 8000 in a 20 µl reaction volume, 16°C overnight. After the small scale PCR, samples were run on a TBE-urea PAGE gel after completing the indicated number of PCR cycles to assess whether a library had been amplified.
3.5 Discussion

Significant improvements were made to the PAT methodology through the identification of working deadenylation reaction conditions and use of the L2T ligation reaction in the RL2-PAT workflow. RL2-PAT was also superior to the sPAT method, even when it was combined with the L2T ligation. This is a beneficial outcome since sPAT is a longer and more expensive method than RL2-PAT, due to the need for an RNA oligo and DNase treatment step. RL2-PAT was implemented in the research group as the standard PAT method to use. Unless otherwise stated in the figure legends, all PAT presented in chapter 4 onwards is RL2-PAT and all products are run on agarose gels. Higher, unexpected bands that often appeared on PAT gels were identified as artefacts, and ways to remove them were found. It should be noted that the addition of oligo (dT) did not reliably and reproducibly remove these artefacts, but fully denaturing TBE-urea PAGE did. None of the PAT data in chapter 4 onwards use TBE-urea PAGE, however, as those data were all generated before TBE-urea PAGE was shown to remove artefacts. Progress was made on establishing TAIL-seq for use by our research group. We were unable to obtain usable data, so further adjustments to the workflow are necessary. However, a library was successfully created and data generated validated the technique in principle, which shows progress from the initial experience of not being able to even generate the library before steps in the workflow were altered. Further work should lead to the proper establishment of the technique, which would provide a means to analyse poly(A) tails on a genome-wide scale.
4 Inflammation and polyadenylation in RAW 264.7 cells

Our group previously reported that inhibiting polyadenylation results in a decrease in inflammatory gene expression (Kondrashov et al. 2012). Many mRNAs involved in inflammation are inherently unstable due to regulatory cis elements in their 3’ UTRs, with AU-rich elements (AREs) being a well-studied example of such elements (P. Anderson 2010; Stumpo, Lai, and Blackshear 2010; Hao and Baltimore 2009). Part of ARE function includes recruitment of deadenylase machinery via trans-acting factors that removes the poly(A) tail. This is often regarded as the first and rate-limiting step of mRNA decay (C.-Y. A. Chen and Shyu 2011), and so a model can be conceived wherein the time taken to remove the poly(A) tail represents a delay before the mRNA can be degraded. Thus, regulation of poly(A) tail size could be particularly important for those mRNAs that are inherently unstable (like inflammatory mRNAs) and thus “depend” on the delay to exist long enough to be translated.

Previous experiments in our group studying polyadenylation and inflammation were done in human airway smooth muscle (ASM) cells, and we sought to further investigate the importance of polyadenylation in inflammatory gene induction using a macrophage-like cell type. I used the RAW 264.7 murine macrophage cell line and stimulated with lipopolysaccharide (LPS) to induce an inflammatory response. While primary macrophages may have been an ideal choice for being more representative of true macrophage biology, the RAW 264.7 cell line was chosen for two main reasons. Firstly, at the time of beginning the project, the poly(A) tail test (PAT) protocol required high input RNA quantities, especially if a deadenylated counterpart of a sample needed to be generated (in excess of 20 µg of RNA). Such high yields of RNA are more manageable and feasible with a cell line. Secondly, cell lines offer greater reproducibility across different types of experiments. When trying
to assemble and integrate data from multiple different experiments into an overall picture of how polyadenylation is important in the overall process of inflammation, and how cordycepin’s effects are mediated (the subject of the next chapter), such reproducibility is very important.

Experiments in this chapter aimed to establish a working inflammatory system using LPS as a stimulus in the RAW 264.7 macrophage-like cell line. The inflammatory response would be assessed by RT-qPCR to monitor mRNA levels of inflammatory genes. Polyadenylation over the course of the inflammatory response was assessed by using the poly(A) tail test (PAT). This was done on both total RNA samples and also nuclear RNA, to examine whether the initial poly(A) tail size was the subject of regulation.

4.1 Developing the inflammatory system

I used the RAW 264.7 murine macrophage cell line and stimulated with lipopolysaccharide (LPS) to induce an inflammatory response. The cells were cultured in DMEM + 10% FBS, which contributes to growth factor signalling in the cells. In order to determine to what extent this signalling (and other effects of the serum) would have on the inflammatory dynamics, I performed LPS stimulations on cells still in the growth medium, and also on cells whose medium was changed to DMEM + 0.5% FBS. RT-qPCR data shows that serum starvation leads to a stronger degree of induction of the inflammatory genes by LPS compared to cells for which medium was not changed (Figure 4.1). The degree of induction refers to the difference in mRNA levels between unstimulated and stimulated conditions. This can result from either a lowering of mRNA levels in unstimulated conditions or an increase in mRNA levels in stimulated conditions (or some combination of the two). For Tnf mRNA, the greater degree of induction in serum-starved cells was mainly
due to a decrease of mRNA levels under unstimulated conditions. For Cxcl2, however, higher mRNA levels in stimulated conditions were the main contributor to the stronger induction in serum-starved cells. I decided to use the method involving serum starvation for subsequent experiments due to the stronger induction.

Figure 4.1. Serum withdrawal prior to LPS stimulation results in a more pronounced response. 24 hours after seeding RAW 264.7 cells, one set of cells was stimulated with LPS for 2 hours (serum-replete), while a second set of cells had medium changed to DMEM + 0.5% FBS (serum-starved). A further 24 hours later, serum-starved cells were stimulated with 1 µg/ml LPS for 2 hours. RT-qPCR was done, error bars represent standard deviations across 3 technical replicates.
4.2 Time courses and poly(A) tails

With a working inflammatory system established, I then did time course experiments to observe the expression profiles of inflammatory genes over time, after induction with LPS. To this end, RT-qPCR was done on samples from the time course in addition to PAT to assess the distribution of poly(A) tails (Figures 4.2 and 4.3). Over a 2 hour period, all genes assessed showed an increase of 2-3 orders of magnitude in expression levels which remained elevated at the end of this period. RT-qPCR was also done for Tnf and Acod1 using primers specific for unspliced mRNA in order to gauge pre-mRNA levels (and thereby estimate transcription levels). Tnf pre-mRNA levels appeared to increase and plateau by 30 minutes for the entire 2 hour period and mature mRNA levels followed a similar profile, with a slight decrease by 90 minutes. Acod1 pre-mRNA levels, in contrast, rose to peak at 70 minutes and then declined greatly by 120 minutes. Although the Acod1 pre-mRNA levels had decreased greatly by 90 minutes (and further still by 120 minutes) from the peak at 70 minutes, the levels of mature Acod1 mRNA continued to increase throughout the whole 2 hour period. Hprt is shown as a control mRNA whose expression levels did not change, validating Rpl28 as a reference mRNA.

Performing PAT on the RNA samples showed that Cxcl2 and Tnf have relatively long poly(A) tails that coincide with their induction, and steadily get shorter over time (Figure 4.3). This could reflect a situation in which a pulse of transcription produces a population of mRNAs with long, freshly produced poly(A) tails which are gradually deadenylated over time. In the case of Tnf, the PAT data show the highest proportion of mRNAs with long poly(A) tails at 30 minutes, an approximately equal spread of mRNAs over a range of tail sizes at 50 minutes, and then most mRNAs are deadenylated from 70 minutes onwards. However, the Tnf pre-mRNA levels remain
elevated at these later timepoints, indicating that transcription is ongoing. This suggests that new *Tnf* transcripts produced at later timepoints may be made with shorter poly(A) tails.

**Figure 4.2.** LPS stimulation of RAW 264.7 cells induces expression of inflammatory genes. RAW 264.7 cells were stimulated with 1 µg/ml LPS for the indicated durations. RT-qPCR data obtained on the Qiagen Rotor-Gene Q platform show expression levels over the time course. Error bars represent standard deviations across 3 technical replicates. Data for 2 biological replicates are shown in separate graphs for each mRNA. *Acod1* data was only obtained for one biological replicate.
Figure 4.2. (cont) LPS stimulation of RAW 264.7 cells induces expression of inflammatory genes.
Figure 4.3. Tnf and Cxcl2 poly(A) tails change in size over the course of their inductions by LPS. RAW 264.7 cells were stimulated with 1 µg/ml LPS for the indicated durations. RNA samples are the same as those analysed in Figure 4.2 (replicate 2). (A) RT-qPCR data obtained on the Qiagen Rotor-Gene Q platform showing expression levels over the time course. These are the same data as those shown in Figure 4.2. (B) RNA samples were used for RL2-PAT, and products were run on an agarose gel. (C) Gel images were scanned using Quantity One software and profiles represented graphically. All data (including qPCR) are shown for a single biological replicate. qPCR error bars represent standard deviation across three technical replicates. * indicates artefactual bands.

To test whether initial poly(A) tail size was variable over the course of the inflammatory response, I performed another time course experiment but nuclear and cytoplasmic fractions were separated prior to RNA isolation. Doing PAT on nuclear RNA should show the poly(A) tail distribution of newly synthesised RNA. PAT for Tnf shows that the poly(A) tail of cytoplasmic RNA is longer at 30 minutes and shorter afterwards (Figure 4.4), as had been observed in total RNA (Figure 4.3B and 4.3C). PAT done for Tnf on nuclear RNA appeared to generate very little product, leading to weak signal on the gel.

Figure 4.3. (cont) Tnf and Cxcl2 poly(A) tails change in size over the course of their inductions by LPS. (D) The Tnf PAT gel was loaded in the wrong order, so the image was altered to reorder the lanes. The original is shown alongside the altered image. * indicates artefactual bands.
Qualitatively, it appears that there is a band at 30 minutes corresponding to newly made RNA with a longer poly(A) tail compared to the PAT product for the 70 minute timepoint (Figure 4.4). This suggests that Tnf mRNA is made with a poly(A) tail whose length varies depending on what stage of the inflammatory response the cell is in. Notably, while PAT for cytoplasmic and total RNA samples shows that the poly(A) tail becomes shorter, and stays short, after 30 minutes of LPS treatment, this does not appear to be the case for nuclear RNA PAT. Tnf poly(A) tails of newly made mRNA appear to be long and short at 30 minutes, short only at 70 minutes, and long and short, again, at 120 minutes. This may indicate an oscillatory nature of the polyadenylation state of Tnf over the course of the inflammatory response.

Figure 4.4. Initial Tnf poly(A) tail size is variable. RAW 267.4 cells were stimulated with 1 µg/ml LPS for the indicated durations. Nuclear and cytoplasmic RNA was isolated from cells and RL2-PAT was done. PAT products were run on one agarose gel but different exposures were used for imaging cytoplasmic and nuclear lanes (images separated by a gap). PAT gel images were scanned using Quantity One software and profiles represented graphically.

Deadenylated Tnf product size: 215 bp.
4.3 Discussion

A working inflammatory model was established in the RAW 264.7 cells, as measured by levels of unspliced and mature mRNA of inflammatory genes. The poly(A) tails of Tnf and Cxcl2 were shown to change over the course of their inductions. For Tnf, the fact that the poly(A) tail becomes progressively shorter after the 30’ timepoint (Figure 4.3) even though unspliced levels of Tnf (i.e. pre-mRNA) remains elevated until at least 90’ (Figure 4.2) suggests that the initial tail size is changing. Indeed, PAT done for Tnf on nuclear RNA (representing newly transcribed mRNA) showed that Tnf mRNA made at 30’ had a greater proportion of long poly(A) tails than mRNA made at 70’ (Figure 4.4). I was unable to obtain data for Cxcl2 mRNA either for unspliced mRNA levels or nuclear PAT, and so there is insufficient data to make the same argument for Cxcl2. Additional replicates are needed for the nuclear PAT to confirm whether the initial Tnf poly(A) tail size is dynamic, and more mRNAs should be tested, particularly control mRNAs e.g. Rpl28 to verify that their initial poly(A) tail size remains constant while that of Tnf (and perhaps also those of other inflammatory mRNAs) are dynamic.

However, the RAW 264.7 inflammatory system was successfully established and allowed reproducible inductions between replicates and measurement of poly(A) tails. While more data may be needed to validate the Tnf initial poly(A) tail size result, the idea that the initial poly(A) tail size varies is consistent with the qPCR data for mature and unspliced mRNA levels (which was shown across two biological replicates and validated against a control mRNA whose levels did not change). This represents a possibility of polyadenylation being involved in the regulation of such mRNAs.
5 Cordycepin and macrophages

The caterpillar fungi *Cordyceps* or *Ophiocordyceps* are prized in Far Eastern traditional medicine and are used for the treatment of many ailments including kidney and heart conditions (Winkler 2010). The adenosine analogue cordycepin is derived from *Cordyceps* fungi and has been shown to have clear biological activities, including anti-inflammatory properties (H. Kim et al. 2011; Kondrashov et al. 2012; Ying et al. 2014; Jeong et al. 2010b). See section 1.3.3 for more detail.

Our group previously observed anti-inflammatory effects of cordycepin in human airway smooth muscle (ASM) cells (Kondrashov et al. 2012). Having established the inflammatory system in RAW 264.7 cells, we sought to test cordycepin in these cells. Time courses were done as in the previous chapter with and without cordycepin and the effects of cordycepin on mRNA levels and polyadenylation were both assessed. Proper cleavage and polyadenylation is needed for efficient transcription termination. In ASM cells, cordycepin was found to cause defective cleavage and transcription termination, consistent with a role in interfering with polyadenylation.

We sought to test whether such effects were also present in the RAW 264.7 cells. Experiments were also done to gain insight into cordycepin’s mechanism of action. In some studies, cordycepin has been reported to be active intracellularly (Kondrashov et al. 2012; Wong et al. 2010), while others report that effects of cordycepin on adenosine receptors are important. This was tested by assessing whether cordycepin’s effects were altered by inhibiting its import into the cell.

Another experiment was done in which, prior to LPS stimulation, cells were either preincubated with cordycepin for a given time or preincubated for part of that time and then had the medium replaced with cordycepin-free medium. In the event that cordycepin’s effects are mediated extracellularly through adenosine receptors, any
effects of cordycepin should be lost or significantly reduced in cells for which the medium was replaced (whereas intracellular effects would persist). Cordycepin is metabolised by adenosine deaminase (ADA), resulting in its deamination to 3’-deoxyinosine. The ADA inhibitor pentostatin was used to see whether inhibition of deamination of cordycepin would potentiate its effects (which would imply that 3’-deoxyinosine is an inactive metabolite). LPS binding to Toll-like receptor 4 (TLR4) results in signalling that causes degradation of IκBα (NFKBIA). This then allows nuclear translocation of NF-κB, an important inflammatory transcription factor, and switching on of target genes (Lu, Yeh, and Ohashi 2008), as discussed in section 1.3.2.1.3. It has been reported by several groups that cordycepin interferes with this process, while the data of other groups (including our own ASM data) suggests that this does not happen. To assess this, the degradation of IκBα was monitored in the presence and absence of cordycepin.

5.1 *Cordyceps* fungal extracts

Cordycepin is one of the metabolites present in *Cordyceps* fungi with a number of reported biological activities. We tested *Cordyceps militaris* and *Ophiocordyceps sinensis* ethanol extracts for anti-inflammatory potential, and also measured the concentration of cordycepin in the extracts. Both extracts were able to replicate the repressive effects of cordycepin on inflammatory gene expression in RAW 264.7 cells (*Figure 5.1A*) while control extracts from other fungi were not, with no reduction in *Tnf* or *Il1b* levels observed for treatments with *P. ostreatus*, *A. bisporus*, or *F. velutipes* extracts (*Figure 5.1B*). The level of cordycepin in the *C. militaris* extract was very similar to the stock concentration of cordycepin used for the cordycepin treatment, and both the cordycepin stock and *C. militaris* extract were used as 1000-fold concentrates (so the same volume of each was used in the respective cell.
treatments). Taken together, these findings strongly imply that cordycepin is the bioactive component of *C. militaris*. Strikingly, however, the level of cordycepin in the *O. sinensis* extract was 5 orders of magnitude lower (Table 5.1), despite exhibiting repressive effects on inflammatory gene expression. This clearly demonstrates that cordycepin is not the sole component that contributes to the anti-inflammatory potential of at least one of these fungi.

<table>
<thead>
<tr>
<th>Extract</th>
<th>[Cordycepin]</th>
<th>[3'-deoxyinosine]</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Coryceps militaris</em></td>
<td>22.72 ± 1.59 mM</td>
<td>12.37 ± 1.57 µM</td>
</tr>
<tr>
<td><em>Ophiocordyceps sinensis</em></td>
<td>0.13 ± 0.01 µM</td>
<td>0.04 ± 0.003 µM</td>
</tr>
</tbody>
</table>

Table 5.1. *Cordyceps militaris* extract contains significant quantities of cordycepin while *Ophiocordyceps sinensis* extract does not. Concentration of cordycepin and 3'-deoxyinosine was determined in the two fungal extracts by LC/MS.

Figure 5.1. Ethanol extracts from *C. militaris* and *O. sinensis* exhibited similar repressive effects to those of cordycepin. RAW 264.7 cells were treated with the indicated compound or extract for 1 hour prior to stimulation with LPS at 1 µg/ml for 1 hour. RT-qPCR was performed, error bars represent standard deviations across 3 technical replicates. Extracts used: *Cordyceps militaris* (CM), *Ophiocordyceps sinensis* (OS), *Pleurotus ostreatus* (PO), *Agaricus bisporus* (AB), and *Flammulina velutipes* (FV).
5.2 Effects of purified cordycepin

Our lab group previously observed anti-inflammatory effects of cordycepin in airway smooth muscle cells (Kondrashov et al. 2012). To assess whether these effects were also present in macrophages, we incubated RAW 264.7 cells with DMSO (control) or cordycepin prior to stimulating the cells with LPS to provoke an inflammatory response. Expression of inflammatory genes was then measured by RT-qPCR at a number of timepoints over a course of 2 hours. Inflammatory gene expression of assessed genes was found to be repressed by cordycepin (Figure 5.2), while housekeeping gene expression (Hprt and Gapdh) was unaffected. A third set of cells was also used in which cordycepin was added 10 minutes after LPS stimulation, in order to assess how fast or slow the effects of cordycepin were (Figure 5.3). The repressive effects of cordycepin for cells pretreated with cordycepin and cells treated with cordycepin after LPS addition were identical. Cordycepin’s observed effects are clearly very fast, and are thus likely to be primary in nature.

The previous work on ASM cells indicated that cordycepin did not affect the unspliced mRNA levels of most inflammatory mRNAs assessed (Kondrashov et al. 2012). In the RAW 264.7 cells, cordycepin was found to affect unspliced mRNA levels (Figure 5.4). Only two genes were assessed (Tnf and Acod1), but the result was observed over two replicates.
Figure 5.2. Cordycepin represses inflammatory gene expression. RAW 264.7 cells were treated with DMSO or 20 µM cordycepin for an hour (DMSO and C-60 respectively) prior to 1 µg/ml LPS addition for the indicated durations. Data for DMSO series are the same as those shown in Figure 4.2. RT-qPCR was performed, error bars represent standard deviations across 3 technical replicates. Acod1 data was only obtained for one biological replicate.
Figure 5.2. (cont) Cordycepin represses inflammatory gene expression.
RAW 264.7 cells were treated with DMSO or 20 µM cordycepin for an hour (DMSO and C-60 respectively) prior to 1 µg/ml LPS addition for the indicated durations. Cells in the C+10 series had 20 µM cordycepin added 10 minutes after addition of 1 µg/ml LPS. The 0’ timepoint for DMSO and C+10 was a single cell treatment, shared between both series. RT-qPCR was performed, error bars represent standard deviations across 3 technical replicates.

Figure 5.3. Administering cordycepin 10 minutes after LPS causes the same repression as a 1 hour pretreatment.
Figure 5.4. Cordycepin represses at the transcriptional level. See Figure 5.2 legend for experimental description. Error bars represent standard deviations across 3 technical replicates. Acod1 data are only available for 1 replicate.
Figure 5.5. Pentostatin potentiates cordycepin’s repressive effect on inflammatory gene expression. (A) RAW 264.7 cells were seeded in DMEM + 10% FBS. After 24 hours, cells were treated with the indicated concentrations of cordycepin, with or without 1 nM pentostatin for 1 hour, at which point 1 µg/ml LPS was added to cells for a further 2 hours. RT-qPCR was performed, error bars represent standard deviations across 3 technical replicates.

(B) As above, but 24 hours after seeding, medium was changed to DMEM + 0.5% FBS. The experiment was then done 24 hours later. Error bars represent standard deviations across 3 biological replicates.

Significant differences assessed by 2-way ANOVA followed by Sidak’s multiple comparisons test. *p<0.05, **p<0.01, ***p<0.001
The deamination of cordycepin by adenosine deaminase produces 3’-deoxyinosine as the breakdown product. To assess whether cordycepin (or a non-deaminated metabolite) was the active compound rather than 3’-deoxyinosine (or a metabolite of this compound), RAW 264.7 cells were incubated with cordycepin in the presence or absence of 1 nM pentostatin – an inhibitor of adenosine deaminase – prior to LPS stimulation. Pentostatin potentiated the repressive effects of cordycepin for all concentrations of cordycepin tested when cells were in DMEM + 10% FBS (Figure 5.5A), suggesting that deamination of cordycepin reduces or may even abolish its anti-inflammatory capacity. However, when this was repeated with biological replicates in cells for which serum was withdrawn (i.e. cells for which the medium was changed to DMEM + 0.5% FBS 24 hours after seeding cells in DMEM + 10% FBS, and 24 hours prior to the experiment), significant differences were only observed for Il1b and not for Tnf (Figure 5.5B). It should also be noted that a significant decrease in Il1b levels was observed when treating with pentostatin in the absence of cordycepin, suggesting possible additive, independent effects.

Stimulation of adenosine receptors with adenosine is known to cause anti-inflammatory effects in macrophages (Haskó and Cronstein 2013), and it has been reported that some of cordycepin’s biological effects are also mediated through these receptors (Takahashi et al. 2012; Kadomatsu et al. 2012; Nakamura et al. 2006). As an adenosine analogue, it is conceivable that cordycepin can act extracellularly as an adenosine receptor agonist. Our group has previously shown that inhibiting cordycepin import into the cell, by using an inhibitor of the adenosine transporter, abrogates its anti-inflammatory effects in airway smooth muscle cells (Kondrashov et al. 2012). Work in the Centre for Bioanalytical Science (Nottingham) showed that cordycepin itself is short-lived intracellularly, while it persists as cordycepin triphosphate in tissue culture cells and liver (Wahyu Utami and David
Barrett, unpublished data). Moreover, inhibition of the phosphorylation of cordycepin through inhibition of adenosine kinase also abrogates its anti-inflammatory effects (Kondrashov et al. 2012). To address the question of whether cordycepin can act extracellularly, possibly through adenosine receptors, or whether it must be imported and phosphorylated, as is the case for airway smooth muscle cells, we performed similar experiments. RAW 264.7 cells were incubated with NBTI (adenosine transport inhibitor) or ITu (adenosine kinase inhibitor) or nothing (control) prior to addition of LPS together with DMSO, adenosine, or cordycepin. As had been the case with airway smooth muscle cells, it was found that NBTI or ITu treatment completely abolished cordycepin’s repressive effects on inflammatory gene expression in RAW 264.7 cells (Figure 5.6). These data indicate that cordycepin must be imported and phosphorylated to have its effects, and does not act extracellularly.

The NBTI/ITu experiment also demonstrates distinct activities of cordycepin and adenosine. While adenosine was seen to repress \( \text{Il1b} \) mRNA levels, its repression of other mRNAs was much less than that of cordycepin, if there was even any repression at all. The repression of \( \text{Il1b} \) by adenosine was not relieved by NBTI or ITu, either. These data indicate that cordycepin and adenosine do not act in the same manner, and so cordycepin is unlikely to merely act as an adenosine analogue that mimics the effect of adenosine.
To further distinguish the effects of cordycepin from those of adenosine, 2 sets of RAW 264.7 cells were briefly exposed to DMSO, adenosine, or cordycepin before being washed with PBS and having medium replaced. 1 set then had DMSO, adenosine, or cordycepin added back to the original concentration (non-washed) while the other set did not (washed). 2 hours after this point, cells were stimulated with LPS. Cordycepin that is intracellular and stable should still be able to exert its effects on the cells, while any extracellular action, e.g. that of adenosine on adenosine receptors, should be lost. While effects of adenosine were lost, the repressive effects of cordycepin were retained, albeit to a lesser degree, in the cases of Acod1 and Tnf, but not for Cxcl2 (Figure 5.7). These data show that the effects of...
cordycepin are more persistent than those of adenosine, making effects through adenosine receptors even less likely. This experiment, alone, cannot rule out a distinct extracellular mode of action, since it could be the case that extracellular effects had already triggered long-acting signalling pathways within the cell by the time the washing was done. However, when taken together with the results of the inhibition of cordycepin import and phosphorylation experiment (Figure 5.6), an intracellular mechanism of action becomes likely. It is possible that washed cells had lower levels of intracellular cordycepin than non-washed cells, which may account for the loss of repression of Cxcl2, rather than because extracellular effects were lost. Adenosine did not display particularly strong repression of inflammatory gene expression, but for Tnf and Cxcl2, the modest repression observed in non-washed cells was lost in the washed counterparts. It should be noted that Acod1 shows higher expression levels for DMSO treatment in washed cells than in non-washed cells. This highlights potential limitations of this experiment as a means for assessing changes in repressive capacity.
It is known that cordycepin is a polyadenylation inhibitor, and so effects on polyadenylation must be considered when assessing its mechanism. For this reason, I did PAT for *Tnf* – an inflammatory gene whose poly(A) tail size changes over the inflammatory response, and whose expression is repressed by cordycepin – on samples from the LPS time course in the presence and absence of cordycepin. It was found that the poly(A) tail is, indeed, shortened by cordycepin (Figure 5.8). While this does not indicate causality, it is clear that the effects of cordycepin on polyadenylation are present.

**Figure 5.7.** Cordycepin effects can be persistent. RAW 264.7 cells were treated with DMSO, 50 µM adenosine (ado), or 50 µM cordycepin (cordy), with 2 sets of cells per group, for 30 minutes. All cells then had medium removed and were washed with PBS. 1 set of cells had fresh DMEM + 0.5% FBS added (termed ‘washed’), while the other set of cells also had the respective compound (DMSO, ado, or cordy) added at the original concentration (these cells were termed ‘non-washed’). A further 2 hours later, cells were stimulated with LPS at 1 µg/ml for 1 hour. RT-qPCR was performed, error bars represent standard deviations across 2 biological replicates.
Figure 5.8. Cordycepin shortens the Tnf poly(A) tail. RAW 264.7 cells were treated either with DMSO or 20 µM cordycepin (C-60) for 1 hour prior to addition of 1 µg/ml LPS for the indicated durations. RNA was isolated and RL2 PAT performed to assess polyadenylation. Agarose gels were scanned in Quantity One and data presented graphically.

N.B. Tnf (DMSO) gel image has been altered to reorder lanes – see Fig 4.3D for original image. * indicates artefactual bands.

Deadenylated Tnf product size: 215 bp.
Figure 5.9. Cordycepin causes defects in transcription termination and mRNA

3' cleavage. (A) RAW 264.7 cells were treated with DMSO or 20 μM cordycepin for an hour prior to 1 μg/ml LPS addition for the indicated durations (DMSO and C-60 respectively), or 20 μM cordycepin 10 minutes after 1 μg/ml LPS addition for the indicated durations (C+10). The 0’ timepoint for DMSO is used as the calibrator for both DMSO and C+10 series (the C+10 series does not have its own 0’ timepoint). RNA was isolated and RT-qPCR performed. Error bars represent standard deviations across 3 biological replicates. Significant differences assessed by 2-way ANOVA followed by Dunnet’s multiple comparisons test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001

(B) RT-qPCR primer locations for uncleaved and unterminated mRNA.
Proper mRNA 3’ cleavage and polyadenylation is thought to be essential for efficient transcription termination (Luo, Johnson, and Bentley 2006; West, Proudfoot, and Dye 2008; Richard and Manley 2009). If cordycepin’s effects on polyadenylation include interfering with mRNA 3’ cleavage, it would be expected to lead to defective transcription termination. In order to measure this, we performed RT-qPCR using primers that amplified a region spanning the cleavage site, and primers that amplified a region 500-750 nt downstream of the cleavage site (Figure 5.9). These levels were then represented relative to the unspliced levels of the mRNA to gauge cleavage and termination efficiencies. Cordycepin caused an increase in the relative proportions of uncleaved transcripts for Rpl28 and an increase in both uncleaved and unterminated transcripts for Tnf (Figure 5.9). These data support a model for an intracellular mode of action of cordycepin, involving impairment of and interference with mRNA 3’ processing. The timepoints that were chosen (0’, 15’, 30’, 90’) allowed for assessment of both newly or recently made mRNA and also mRNA in the later stages of the induction.

Assessment of cleavage and termination efficiencies also showed differences in cordycepin and adenosine treatments (Figure 5.10). Adenosine treatment, whether in washed or non-washed cells, did not change measured cleavage and termination efficiency. Cordycepin treatment, however, caused a significant decrease in cleavage and termination efficiencies – an effect that was still clearly observed in washed cells. In the time course, cordycepin affected both cleavage and termination for Tnf but only cleavage for Rpl28 (Figure 5.9). Data from the washing experiment, however, showed changes in both cleavage and termination efficiencies for both Tnf and Rpl28 in cordycepin-treated cells. Rpl28 expression levels are insensitive to cordycepin, but these data show that cordycepin, while having specific effects on final mRNA levels, may have more generalised effects on 3’ processing and
transcription termination, as was previously observed in airway smooth muscle cells (Kondrashov et al. 2012).

Figure 5.10. The effects of cordycepin on mRNA 3’ processing are not shared by adenosine and are unlikely to be mediated extracellularly. RAW 264.7 cells were treated with DMSO, 50 µM adenosine (ado), or 50 µM cordycepin (cordy), with 2 sets of cells per group, for 30 minutes. All cells then had medium removed and were washed with PBS. 1 set of cells had fresh DMEM + 0.5% FBS added (termed ‘washed’), while the other set of cells also had the respective compound (DMSO, ado, or cordy) added at the original concentration (these cells were termed ‘non-washed’). A further 2 hours later, cells were stimulated with LPS at 1 µg/ml for 1 hour. RT-qPCR was performed, error bars represent standard deviations across 2 biological replicates.
To test whether cordycepin affected NF-κB signalling, an LPS time course was done in RAW 264.7 cells over a 30 minute period. Cells were treated with either DMSO or cordycepin for 1 hour prior to addition of LPS. Western blotting was then done on cell lysates for total IκBα. The DMSO series shows a band for IκBα in unstimulated cells and for a 5 minute LPS treatment (Figure 5.11). This band is almost completely lost, indicating degradation, in the 15 minute timepoint, and then reappeared in the 30 minute sample. The degradation of IκBα was not at all prevented by cordycepin pretreatment. Further replicates are needed for verification, but these data suggest that cordycepin does not interfere with IκBα degradation.

**Figure 5.11. IκBα degradation is not prevented by cordycepin.** RAW 264.7 cells were treated with DMSO or cordycepin for an hour prior to LPS addition at 1 µg/ml for the indicated durations. Cells were then lysed and Western Blot performed. Relative IκBα levels for timepoints in each series (DMSO and cordy) are shown with the respective 0’ timepoint set to 1. Symplekin was used as a loading control.
5.3 Discussion

Data in this chapter demonstrated the anti-inflammatory effects of cordycepin in RAW 264.7 cells. In general, more replicates are needed in order to be able to perform statistical analysis and confirm the conclusions that have (tentatively) been made here.

Cordycepin is likely to be the main bioactive component (as far as anti-inflammatory effects are concerned) of *C. militaris* ethanol extract. *O. sinensis* extract, however, contained 5 orders of magnitude less cordycepin than the concentration of cordycepin in the *C. militaris* extract or purified cordycepin stock in DMSO. This suggests that other metabolites are more important in *O. sinensis* for mediating its anti-inflammatory effects. Data in Table 5.1 and Figure 5.1 are only for one biological replicate, however. To confirm these findings and further investigate, more replicates would be needed, and perhaps fungal samples from multiple sources. Additionally, a treatment of pure cordycepin should be used that matches the low cordycepin concentration in the *O. sinensis* extract to show that the low level of cordycepin in *O. sinensis* alone cannot account for its anti-inflammatory properties.

Cordycepin decreased the expression of the assessed inflammatory genes and had identical effects when administered to cells ten minutes after addition of LPS rather than 1 hour beforehand (Figures 5.2 and 5.3). The fact that unspliced mRNA levels were decreased (Figure 5.4) suggests a transcriptional level of control by cordycepin. Since NF-κB is a key inflammatory transcription factor whose activation is downstream of LPS/TLR4 signalling in macrophages (see sections 1.3.2.1.1 and 1.3.2.1.2), we assessed whether cordycepin interfered with the NF-κB pathway, as
others have reported (H. G. Kim et al. 2006; Y. Li et al. 2016; Jie Peng et al. 2015; Ying et al. 2014). This was done by detecting IκBα degradation following LPS stimulation in the presence and absence of cordycepin. Cordycepin did not impede the degradation of IκBα (Figure 5.11). Further replicates are needed to confirm this finding, however.

Experiments with adenosine highlighted distinct activities of adenosine and cordycepin, showing that cordycepin is unlikely to simply act by mimicking the effect of adenosine. Cordycepin is likely to act intracellularly and require phosphorylation, since inhibition of the adenosine transporter and adenosine kinase abrogated its effects (Figure 5.6). The results of the washing experiment were entirely clear and seemed to sometimes contradict the results of the NBTI/ITu experiment. However, if cordycepin does act intracellularly, it is possible that non-washed cells accumulated more cordycepin within them than the washed cells. To monitor this variable, the experiment could be repeated with parallel sets of cells. At the end of the experiment, one set could be used for RT-qPCR (as we did), and the other set could be subjected to liquid chromatography-mass spectrometry analysis to determine cordycepin concentrations in washed and non-washed cells. Effects on polyadenylation by cordycepin were clearly observed (Figure 5.8), and were consistent with the observation that cordycepin caused defective mRNA cleavage and transcription termination (Figures 5.9 and 5.10). As such, valuable information was obtained for understanding molecular effects of cordycepin.
6 High-throughput analysis of cordycepin-treated RAW 264.7 cells

Having observed by RT-qPCR that cordycepin treatment in RAW 264.7 cells led to downregulation of a number of inflammatory mRNAs (see previous chapter), we elected to perform high-throughput analysis to reveal genome-wide changes brought about by cordycepin. To assess changes in gene expression, a microarray analysis was performed followed by cluster analysis on the lists of RNAs whose levels were changed by cordycepin. In order to see whether cordycepin sensitivity correlated with mRNA stability or transcription rates, RNA-seq was performed on newly transcribed RNA (generated by pulse labelling) from RAW 264.7 cells.

6.1 LPS and cordycepin treatments

With polyadenylation implicated in inflammatory gene expression, and cordycepin, as a polyadenylation inhibitor, shown to inhibit expression of a number of inflammatory genes, we sought to assess the effect of cordycepin in a genome-wide manner through microarray analysis. RAW 264.7 cells were either pre-treated with DMSO or 20 µM cordycepin for an hour prior to either no further treatment or addition of 1 µg/ml LPS for one hour. At the end of the two hour period (1 hour DMSO/cordycepin plus 1 hour LPS/no LPS) RNA was isolated from cells and analysed by microarray. Cell conditions were named ‘D0’, ‘D60’, ‘C0’, and ‘C60’ – D means DMSO pre-treated, C means cordycepin pre-treated, 0 means NOT stimulated with LPS, 60 means LPS-stimulated. We compared expression in D60 vs D0 (i.e. LPS-stimulated vs unstimulated, both without cordycepin) to show expression changes caused by LPS stimulation, and then compared C60 vs D60 (i.e. LPS-stimulated with cordycepin to LPS-stimulated without cordycepin) to show how those expression changes are affected. These two comparisons were then plotted against each other,
with genes whose expression levels were at least 2-fold changed in both comparisons considered, while other genes were disregarded (Figure 6.1). A Chi-squared test showed that LPS and cordycepin treatments are not independent (p<2.2×10^{-16}). Specifically, it appears that proportionately more RNAs that upregulated by LPS treatment are downregulated by cordycepin (94) than upregulated (30). Similarly, proportionately more RNAs that are downregulated by LPS treatment are upregulated by cordycepin (49) than downregulated (1). Additionally, performing gene ontology analysis on the list of genes most strongly downregulated in the LPS with cordycepin treatment compared to LPS alone revealed that immune and inflammatory gene clusters are the most significantly enriched (Table 6.1).
<table>
<thead>
<tr>
<th>Gene Ontology Term</th>
<th>Count</th>
<th>Bonferroni-corrected P-value</th>
<th>Gene names</th>
<th>Fold Enrichment</th>
</tr>
</thead>
<tbody>
<tr>
<td>mmu04060:Cytokine-cytokine receptor interaction</td>
<td>17</td>
<td>5.41E-08</td>
<td>CSF3, IL6, TNF, CCL2, PDGFB, TNFRSF12A, CSF1, CCL5, IL7R, CCL4, CCL7, CCL10, OSM, LOC100045000, IL12RB1, LOC100044675, IFNB1, IL10RA, IL1B</td>
<td>7.0</td>
</tr>
<tr>
<td>cytokine</td>
<td>13</td>
<td>7.07E-06</td>
<td>CSF3, IL6, TNF, CCL2, CSF1, CCL5, CCL4, CCL7, CXCL10, OSM, LOC100045000, IFNB1, IL1B, CMTM5</td>
<td>8.4</td>
</tr>
<tr>
<td>GO:0005125~cytokine activity</td>
<td>13</td>
<td>2.16E-05</td>
<td>CSF3, IL6, TNF, CCL2, CSF1, CCL5, CCL4, CCL7, CXCL10, OSM, LOC100045000, IFNB1, IL1B, CMTM5</td>
<td>7.8</td>
</tr>
<tr>
<td>GO:0006955~immune response</td>
<td>22</td>
<td>4.56E-04</td>
<td>CSF3, IFIH1, IL6, CCL2, TNF, RSAD2, NLRP3, CCL5, IL7R, CCL4, CCL7, FOXP1, POLR3D, CXCL10, OSM, LOC100045000, ZGPAT, CLEC4E, SQSTM1, TICAM1, OASL1, IL1B, LIME1, CD300LB</td>
<td>3.7</td>
</tr>
<tr>
<td>GO:0006954~inflammatory response</td>
<td>14</td>
<td>8.83E-04</td>
<td>NFKBIZ, IL6, TNF, CCL2, CCL5, NLRP3, CCL4, CCL7, CXCL10, LOC100045000, CD44, TICAM1, IL1B, NOS2, PTAFR</td>
<td>5.8</td>
</tr>
</tbody>
</table>

Table 6.1. Immune and inflammatory GO terms are the most significantly enriched in genes downregulated by cordycepin.

RAW 264.7 cells were treated with 1 µg/ml LPS for 1 hour after a 1 hour pretreatment with DMSO or cordycepin (D60 and C60 respectively). Gene expression levels from microarray data were then compared between the two treatments. Those genes whose levels were >2-fold decreased in C60 compared to D60 were compiled into a list which was uploaded to DAVID for functional annotation. The 5 most significantly enriched GO terms are shown in the table.
Figure 6.1. 94 RNAs with a >2-fold increase after LPS treatment are >2-fold downregulated by cordycepin. RAW 264.7 cells treated with DMSO for 2 hours (D0), or treated with 1 µg/ml LPS for 1 hour after a 1 hour pretreatment with DMSO or cordycepin (D60 and C60 respectively). Gene expression levels from microarray analysis were compared between D60 and D0 (showing the effect of LPS) and between C60 and D60 (showing the effect of cordycepin in LPS-treated cells), and log$_2$(fold change) values calculated. These values were then plotted against each other for all expressed genes. Grey dots indicate RNAs that did not show a significant >2-fold change in one or both comparisons. Red dots are RNAs that are >2-fold changed in both comparisons, with numbers indicating the number of such RNAs in each quadrant.

A Chi squared test showed that the two treatments are not independent (p<2.2×10$^{-16}$).
6.2 Cordycepin sensitivity and mRNA kinetics

Cordycepin inhibits both polyadenylation and transcription of inflammatory genes (Figures 5.4 and 5.8). In response to the inflammatory stimulus (LPS), inflammatory genes experience a large increase in transcription, and transcripts may be made with longer poly(A) tails for transient stabilisation of mRNAs that are otherwise unstable, as many inflammatory mRNAs are (P. Anderson 2010; Sanduja et al. 2012). If cordycepin’s inhibitory effects on polyadenylation and transcription, possibly through defective termination and mRNA 3’ processing, are responsible for its inhibition of inflammatory genes, then it may be the case that genes that have a high transcription rate and produce unstable mRNAs are sensitive to cordycepin. Information on which genes are cordycepin-sensitive is contained in the microarray data. RNA-seq data using 4-thiouridine-labelled RNA – i.e. RNA that was freshly transcribed within a short labelling period – from unstimulated RAW 264.7 cells (assumed to be at steady-state) was used to make inferences about mRNA transcription rates and stability. Consolidating the microarray and RNA-seq data allowed us to look for correlations between cordycepin-sensitivity and transcription rate or mRNA stability. No such correlation was observed, however (Figure 6.2).
Figure 6.2. Cordycepin sensitivity is independent of mRNA stability and transcription rate. RAW 264.7 cells treated with 20 µM cordycepin (C0) or DMSO (D0) for 2 hours. Gene expression levels were compared between the two treatments and log₂(fold change) values calculated. In a separate experiment, untreated RAW 264.7 cells (in DMEM + 0.5% FBS) were exposed to a 15 minute 4-thiouridine labelling. RNA-seq was then performed and log₂(fold change) values from the microarray plotted against the 4SU-labelled FPKM (transcription rate) and 4SU-labelled FPKM/total FPKM values from the RNA-seq data. Linear regressions (red lines) were fitted to all plots, and r² values calculated. No significant correlation was observed.

6.3 Cordycepin and long noncoding RNAs

Long noncoding RNAs (lncRNAs) are RNAs longer than 200 nt that do not code for protein, but can have regulatory roles and implications for health and disease (Wapinski and Chang 2011; Kung, Colognori, and Lee 2013). It has been reported that there exists a class of lncRNAs whose turnover is promoted by PABPN1 in a polyadenylation-dependent manner (Beaulieu et al. 2012). If cordycepin inhibits polyadenylation, it would be expected to stabilise these lncRNAs, which should therefore be enriched in the set of RNAs upregulated by cordycepin. To test this hypothesis, I looked at the changes in RNA levels from the microarray data between
the cordycepin-treated and non-cordycepin-treated cells (both in the absence of LPS). The RNAs were categorised into 3 classes: significantly upregulated by cordycepin, significantly downregulated by cordycepin, and unchanged. Significantly upregulated and downregulated RNAs were those that were at least 2-fold changed in the appropriate direction, and had an adjusted p-value < 0.01. All other RNAs were placed in the ‘unchanged’ category. The vast majority of RNAs were in the unchanged category (>20,000), while the upregulated and downregulated categories had 547 and 146 RNAs, respectively. In order to perform the comparison between categories with similar numbers of RNAs, a random selection of 500 RNAs were taken from the unchanged category. The numbers of lncRNAs in each category was determined and a Chi-squared test done to see whether the proportion of lncRNAs in a category is independent of cordycepin treatment. The test revealed that lncRNA proportion and cordycepin treatment are not independent, with a much higher proportion of lncRNAs observed in the upregulated category (Figure 6.3). These data support the hypothesis that cordycepin stabilises a class of lncRNAs whose degradation is enhanced by polyadenylation. It may be that some or all of these RNAs are involved in mediating cordycepin’s effects (i.e. they may regulate inflammation).
Figure 6.3. IncRNAs are enriched in RNAs that are upregulated by cordycepin treatment. RNA expression fold changes were calculated from microarray data between RAW 264.7 cells treated for 2 hours with 20 µM cordycepin (C0) or DMSO (D0). RNAs that were >2-fold increased or decreased in expression, with an adjusted p value < 0.01, were placed in the up and down categories respectively. From the remaining RNAs, a random selection of 500 RNAs with a log$_2$(fold change) between -0.1 and 0.1 formed the unchanged category.
6.4 Discussion

Data in this chapter showed that cordycepin did indeed cause widespread repression of inflammatory mRNAs, as seen in the cluster analysis of the microarray data (Table 6.1). In section 1.2.3.1, some possible models by which cordycepin might act were proposed. One was that inherently unstable mRNAs may depend on a poly(A) tail more for the limited stability they do have, and that inhibition of polyadenylation would have a particularly strong destabilising effect on such mRNAs. The lack of a correlation between stability and cordycepin sensitivity, however (Figure 6.2), does not support this model. Another suggested possibility was that cordycepin may arrest the cleavage complex, as observed in vitro (Zarkower and Wickens 1987), thereby sequestering 3’ processing factors. Genes for which transcription is taking place at a high rate (such as genes activated in the inflammatory response) would have high requirements for processing factors. A shortage of processing factors would affect transcription of such genes more than genes that are transcribed at a low rate (such that the availability of processing factors is not rate-limiting). However, the lack of a correlation between transcription rate and cordycepin (Figure 6.2) suggests this model does not apply. In the second model mentioned above, if a high need for processing factors arises through ‘weaker’ cis elements defining the poly(A) site rather than simply due to high rates of transcription, then cordycepin-sensitive genes may be enriched in such cis elements. This could be investigated through further bioinformatic analysis of the data sets.

Interestingly, IncRNAs are significantly enriched in RNAs upregulated by cordycepin treatment. There is a class of IncRNAs whose degradation is dependent on polyadenylation and whose levels are increased by PABPN1 knockdown (Beaulieu et
al. 2012). If cordycepin inhibits the polyadenylation of such IncRNAs, this would be expected to have a stabilising effect, which could account for the enrichment of IncRNAs in cordycepin-treated cells. If one or more of these IncRNAs affects the process of inflammation, cordycepin-mediated stabilisation of this/these IncRNA(s) could constitute part of the mechanism by which its anti-inflammatory effects are mediated. It would be interesting to assess whether the IncRNAs that are stabilised by cordycepin are the same as those whose levels are increased by PABPN1 knockdown, ostensibly through reduced polyadenylation-dependent degradation. This assessment was not carried out in this thesis as the work done by Beaulieu et al was performed in human cells while my data were generated from experiments in murine cells.

While data in this chapter did not support any of the proposed hypotheses to explain cordycepin’s effects, a clear genome-wide anti-inflammatory effect of cordycepin was shown to exist in RAW 264.7 cells.
7 Cordycepin in a rat model of osteoarthritis

Osteoarthritis (OA) is a degenerative joint disease. While classically viewed as a non-inflammatory form of arthritis, evidence shows that inflammation can play a role in disease progression. Key features of the disease include remodelling of subchondral bone (bone under the cartilage) and degradation and loss of articular cartilage. As the previous two chapters show, cordycepin has widespread anti-inflammatory effects in RAW 264.7 cells. Furthermore, it has been reported that cordycepin shifts the balance of bone formation and degradation (F. Wang et al. 2015; Dou et al. 2016), and that it also reduced overactive cytokine production in chondrocytes from OA patients (Ying et al. 2014). For these reasons, cordycepin treatment was used in a rat model of osteoarthritis in order to see if it had any effect on pain behaviour in affected animals (this work was done by James Burston in Victoria Chapman’s research group at the University of Nottingham). In order to see whether cordycepin affected mRNA levels of inflammatory genes or had effects on polyadenylation, RNA was isolated from the synovia of rats in the OA model and analysed by RT-qPCR and 3’ end labelling.

7.1 Pain behaviour – work done by James Burston

Using the monosodium iodoacetate (MIA) chemically induced model of osteoarthritis in rats, cordycepin (administered orally) was assessed for its capacity to alter the pain behaviour of the animals. Animals had a saline (control) or MIA injection into the knee of a hind limb (day 0), and were then fed with DMSO (vehicle) or cordycepin every other day over the course of 14 days, during which time pain behaviour was assessed. Pain associated with the site of damage was measured through weight bearing asymmetry – animals were placed in a chamber that forced them to stand on their hind limbs, and the difference in weight borne by the leg with
the injury (ipsilateral) and the other leg (contralateral) was measured. Allodynia (pain caused by stimuli that do not normally cause pain) was measured by paw withdrawal threshold (PWT) – animals were placed in a cage in which the bottoms of their paws could have force applied by Von Frey filaments. The force applied was increased until the PWT was reached i.e. the force that caused the animal to withdraw its paw. The saline + vehicle group showed equal weight bearing over the course of the 14 days, while the MIA + vehicle group placed much more weight on their uninjured (contralateral) side (Figure 7.1). The MIA + cordycepin group also placed more weight on the contralateral limb than the saline + vehicle group, but placed significantly more weight on their ipsilateral side than the MIA + vehicle group in 3 of the 4 timepoints after day 0. The PWT of the saline + vehicle group remained constant over the 14 day period, while that of the MIA + vehicle group had dropped markedly by day 3, with no recovery observed over the remaining period. The MIA + cordycepin group experienced the same drop in PWT, with no differences between these groups at day 3 or day 7. At days 10 and 14, however, the PWT of the MIA + cordycepin group was significantly higher than that of the MIA + vehicle group. Together, these data show that cordycepin reduces pain behaviour in the MIA rat model of osteoarthritis.
Figure 7.1. Cordycepin alters pain behaviour in a rat osteoarthritic model. MIA or saline was injected into the knee of one hind limb of rats on day 0. MIA rats were then fed 20 mg/kg cordycepin or DMSO (vehicle) every other day. Saline rats were fed DMSO every other day. Pain behaviour was then assessed through weight bearing asymmetry and paw withdrawal threshold upon application of pressure to the paw using Von Frey filaments.

p<0.05, ** p<0.01, *** p<0.001 between MIA groups and saline control.

# p<0.05, ## p<0.01, ### p<0.001 Between MIA + vehicle group and MIA + cordycepin group.

N = 6-8 animals per group.

Data courtesy of James Burston and Victoria Chapman (University of Nottingham, School of Life Sciences)
7.2 Analysing rat RNA

At the end of the 14 day period over which the pain behaviour experiments were done, the rats were killed and tissues chilled. Since cordycepin affects RNA levels in cell culture, we sought to assess expression of inflammatory genes between the different treatment groups. In order to do this, we had to first isolate the RNA from the tissues. Using a column based kit was unsuccessful and resulted in the synovia being wasted. We therefore decided to use spare synovia from animals in other experiments (which would otherwise have been discarded) as our tissues on which to test different RNA isolation methods. Using TRIzol yielded enough RNA to work with, but, when run on a gel, it was found to be degraded. This may have occurred due to contaminating RNases in the workflow or degradation experienced in the lag time between killing the animal and chilling the tissue (in this case, the time was 19 minutes). Another possible explanation was that the decay occurred during the lysis procedure, with the denaturing reagents either being insufficient in quantity or not penetrating the tissue quickly enough. In the case of contaminating RNases being present, incubating the RNA at 37°C should further degrade the RNA. This was carried out, but no further degradation was observed (Figure 7.2). Upon repeating the entire RNA isolation process with a synovium that was chilled much sooner after killing the animal (2 minutes), the RNA was found to be intact, and incubation at 37°C did not lead to any degradation. The degradation that was originally observed was therefore probably due to the tissue not being chilled soon enough after the animal was killed. The amount of lysis reagent (TRizol) was not changed, so this was unlikely to have been the cause of the problem before. RNA was then successfully isolated using TRIzol from the remaining ipsilateral synovia, and RT-qPCR was carried out to measure inflammatory gene expression in the synovia. No significant
differences were observed in the expression levels of the assessed genes between
the three treatment groups (Figure 7.3).

Figure 7.2. After killing the rat, the synovium must be quickly removed
and chilled to avoid RNA degradation. RNA was isolated from the synovia
of rats using TRIzol. 19' and 2' refer to the time elapsed between killing
the rat from which the synovium was taken and removing and chilling the
synovium. Positive control is RNA isolated from RAW 264.7 cells known to
be intact. RNA samples were then either incubated for 30’ at 37°C or not
to check for presence of RNases in the workflow. All RNA samples were
then run on an agarose gel to assess integrity.
Since cordycepin is a polyadenylation inhibitor, and has been shown to shorten global poly(A) tails in a number of cell types (Kondrashov et al. 2012), we decided to determine whether cordycepin was having any such effect on the level of the entire tissue. Briefly, 5’-[32P] pCp was ligated to the 3’ end of RNA samples, a cocktail of RNases was added to digest all non-poly(A) RNA, and resulting RNA was run on a urea-TBE PAGE gel. A phosphor screen was then exposed to the gel and imaged on a phosphorimager. Doing so revealed no differences in global poly(A) tail lengths between the treatment groups (Figure 7.4). While cordycepin inhibits inflammatory gene expression in RAW 264.7 cells and inhibits global polyadenylation in a number of cell types, it appears that its effects on pain behaviour in the rat osteoarthritis model are not dependent on these phenomena occurring within the synovium, unless such effects already took place at an earlier, unobserved time.

**Figure 7.3.** No significant differences observed in assessed inflammatory gene mRNA levels in rat ipsilateral synovia between treatment groups. MIA or saline was injected into the knee of one hind limb of rats on day 0. MIA rats were then fed 20 mg/kg cordycepin or DMSO (vehicle) every other day. Saline rats were fed DMSO every other day. RNA was extracted from rat ipsilateral synovia using TRIzol. RT-qPCR was performed, error bars represent standard deviations across 2 animals per group.
Figure 7.4. No global poly(A) tail length differences were observed between rat groups in ipsilateral synovial RNA samples. MIA or saline was injected into the knee of one hind limb of rats on day 0. MIA rats were then fed 20 mg/kg cordycepin or DMSO (vehicle) every other day. Saline rats were fed DMSO every other day. RNA was extracted from rat ipsilateral synovia using TRIzol. [5'-32P]Cytidine 3',5'-bis(phosphate) was ligated to the 3' end of RNA samples, a cocktail of RNases was added to digest all non-poly(A) RNA, and resulting RNA was run on a urea-TBE PAGE gel. The gel was incubated at -80°C with a phosphor screen for > 5 days and then imaged on a GE Storm 825 phosphorimager.

7.3 Discussion

Data in this chapter show that OA pain behaviour in a rat model of the disease is significantly altered by orally administered cordycepin. When isolating RNA from animal tissues (or at least from the synovium), the tissue must be chilled very soon after killing the animal in order to prevent degradation of RNA. Analysis of RNA from rats in the OA study did not reveal any significant differences in mRNA levels of cytokines assessed, nor did it show any differences in total poly(A) tail sizes between rats in different treatment groups. However, the finding that pain behaviour in the OA rat model is altered by cordycepin is a very promising start to the investigation of cordycepin as a lead compound for new OA therapeutics.
8 Discussion and conclusions

During the course of this project, a working inflammatory model was established in the RAW 264.7 murine macrophage cell line. In this system, the poly(A) tail was found to be dynamic, with the initial poly(A) tail size of Tnf becoming longer following lipopolysaccharide (LPS) stimulation. Anti-inflammatory effects of cordycepin were observed in the system on a genome-wide scale, and mechanistic insight was gained into how cordycepin’s effects are mediated. Pain-alleviating properties of cordycepin in a rat model of osteoarthritis (OA) warrant further investigation into its use as a therapeutic.

8.1 Advances in poly(A) tail measurements

Chapter 3 was concerned with method development and troubleshooting. Previously, the method used for the poly(A) tail test (PAT) involved a high input RNA quantity, an unreliable deadenylation step, and an inefficient ligation. Optimisation was done that addressed all of these issues, resulting in a considerably improved method. In addition, higher PCR bands following PAT that often appeared on gels were identified as artefactual multimers. These could be removed by running the PAT products on a fully denaturing TBE-urea PAGE gel – a finding that should prove useful. Attempts to perform TAIL-seq were not ultimately successful in yielding usable data. Using the starting method, provided to us by the authors of the original TAIL-seq paper (Chang et al. 2014), we were unable to even generate a library. After further attempts and troubleshooting, the method was improved, most notably in the ligation efficiency, and a library was generated. Sequencing data from the library showed poly(A) tails and uridylation but 3’ UTRs were too short (suggesting too great a degree of RNase T1 digestion) and counts were too low. As mentioned, however, considerable improvements were made, and further refinement should
yield usable data. Presently, work is being done in the group to develop an altered version of TAIL-seq termed quanTAIL-seq. The method aims to address inefficiencies in the TAIL-seq workflow that should yield libraries from which better quality data can be obtained. When quanTAIL seq is fully developed, usable poly(A) tail data should be obtainable.

8.2 Polyadenylation in the inflammatory response

An inflammatory system was successfully established in which LPS was used as a stimulus to induce an inflammatory response in RAW 264.7 cells. It was found that withdrawal of serum from the medium 24 hours prior to addition of LPS resulted in a greater degree of induction (Figure 4.1), and so this was done as standard in all experiments thereafter. It should be noted that many other groups do not withdraw serum prior to LPS induction (H. G. Kim et al. 2006; Y. Li et al. 2016; Shin, Lee, et al. 2009), and so the absence of growth factor signalling in our cells cf. the presence of it in theirs should be borne in mind when comparing data.

Once the system was established, the improved PAT procedure was applied to analyse poly(A) tail size changes over the inflammatory response. As can be seen in Figure 4.3, the Tnf and Cxcl2 poly(A) tails change are variable while that of Rpl28 remains constant. The Tnf poly(A) tail shortens much faster than that of Cxcl2. PAT performed on nuclear RNA (Figure 4.4) confirmed that the initial poly(A) tail of Tnf was variable in size at different timepoints. However, the change is relatively modest, only observed in one replicate, and data is needed to show that a control mRNA (e.g. Rpl28 does not change). It should also be noted that the initial poly(A) tail size difference (Figure 4.4) was inferred from PAT performed on nuclear RNA, assumed to be newly synthesised. Using an independent method of isolating newly synthesised RNA, like 4-thiouridine labelling, followed by PAT would support the
idea that initial poly(A) tail size is variable. Also, nuclear PAT was only done for Tnf. PAT data to show that initial tail size does not change for a control mRNA is needed to confirm the validity of the finding. Since the poly(A) tail size of Tnf in total RNA changes so quickly, it may be that a greater proportion of Tnf mRNA is made with a longer poly(A) tail earlier on in the time course. Repeating the time course with more timepoints across multiple replicates and with control mRNAs for reference would be worthwhile. However, the indication that initial poly(A) tail size is variable is interesting and this may represent a means for regulation of the inflammatory response. Regulation at the level of polyadenylation is a phenomenon that we have observed in the serum response in NIH-3T3 mouse fibroblasts (Singhania et al, manuscript under review). A similar phenomenon may exist in the inflammatory response.

8.3 Mechanistic insight into cordycepin’s mode of action

Anti-inflammatory effects of cordycepin are well documented, and a range of mechanisms have been proposed to explain its effects. This project confirms previous findings that cordycepin has anti-inflammatory effects. Given that the effects of C. militaris extract and cordycepin were very similar (Figure 5.1), and that the concentration of cordycepin in the C. militaris was almost the same as in the cordycepin stock (Table 5.1), it stands to reason that cordycepin is likely to be the active component of C. militaris. This was not the case for O. sinensis extract, in which the cordycepin concentration was 5 orders of magnitude lower, but anti-inflammatory effects were still observed, and so cordycepin is unlikely to be the active compound in this fungus.

Contrary to data obtained in ASM cells (Kondrashov et al. 2012), there appear to be effects at the transcriptional level (Figure 5.4). A decrease in transcription may be a
result of interfering with NF-κB signalling, but cordycepin did not impede the degradation of IκBα (Figure 5.11) suggesting that this is not the case. Other explanations include effects on polyadenylation causing decreased transcription termination efficiency (Figure 5.9 and 5.10) leading to inefficient recycling of transcriptional machinery (Mapendano et al. 2010), or that cordycepin may arrest the mRNA 3’ cleavage complex as it does in vitro (Zarkower and Wickens 1987). If the cleavage complex is arrested, thus sequestering processing factors, generation of transcripts with high processing factor requirements could be limited by the availability of factors. In both cases (inefficient recycling of transcriptional machinery or lack of availability of processing factors), genes being transcribed at high rates would be expected to be most affected. However, the idea that cordycepin affects those mRNAs that are transcribed at high rates is inconsistent with the observation that no correlation was observed between transcription rate and cordycepin sensitivity (Figure 6.2). Alternatively (or additionally), cordycepin’s mechanism may include effects on signal transduction – there is evidence that it inhibits AKT phosphorylation (H. G. Kim et al. 2006) which may decrease NF-κB activation (Rajaram et al. 2006; Dan et al. 2008). Co-administration of cordycepin and pentostatin (inhibitor of adenosine deaminase) potentiated cordycepin’s repressive effects on inflammatory mRNA levels (Figure 5.5A), suggesting that deamination of cordycepin reduces its activity. However, such effects were less clear in cells from which serum had been withdrawn (Figure 5.5B). This observation may have arisen due to the presence of adenosine deaminase in the serum, such that potentiation of cordycepin’s effects through prevention of its deamination may become less pronounced in the absence of serum (since there would be less adenosine deaminase available to deaminate the cordycepin). The effects of cordycepin were abrogated by inhibiting either the adenosine transporter or adenosine kinase using
S-(4-Nitrobenzyl)-6-thioinosine (NBTI) or 5-Iodotubericidin (ITu) respectively (Figure 5.6). This outcome strongly suggests that cordycepin must be imported and phosphorylated in order to elicit its anti-inflammatory effects, and therefore that its effects are intracellular. Since effects of cordycepin on adenosine receptors have been reported (Kadomatsu et al. 2012; Kitamura et al. 2011; Nakamura et al. 2006), we sought to test whether extracellular effects of cordycepin in the RAW 264.7 system were present, although the NBTI/ITu experiment suggested that they were not. Repressive effects of adenosine were observed for Il1b, but were much lower than those of cordycepin for other mRNAs (Figure 5.6), suggesting that the two compounds function in different ways. NBTI or ITu should not alter the effects of adenosine if it acts extracellularly, so repression of Il1b mRNA should be maintained in the presence of either inhibitor. The data were too variable to confirm this, however.

To distinguish the effects of cordycepin and adenosine, we conducted the washing experiment (Figure 5.7), but the results were inconclusive. A different experiment could be done in which the effects of cordycepin are simply compared in the presence and absence of adenosine receptor antagonists. The ability or inability of adenosine receptor antagonists to relieve cordycepin-mediated repression of inflammatory gene expression would include or exclude adenosine receptors respectively in cordycepin’s mode of action. The antagonists would need to have a higher affinity for the receptor(s) than cordycepin in order for the experiment to provide an answer, however.

The poly(A) tail size of Tnf was found to be elongated in response to LPS stimulation (Figure 4.3), and a size increase is present in the initial poly(A) tail size (Figure 4.4). Furthermore, cordycepin-treated cells display a much more modest increase in
poly(A) tail size after LPS stimulation. This shows that effects of cordycepin on polyadenylation are present, consistent with an intracellular mode of action. Further work would be required to establish whether the shorter poly(A) tail has a role in mediating cordycepin’s effects, or whether it is merely a consequence of its effects.

Cordycepin was found to have no effect on the breakdown of IκBα (Figure 5.1). This is at odds with findings from Peng et al (Jie Peng et al. 2015). This could be due to the differences in timings – they used a 24 hour incubation with LPS, while my observations of IκBα levels were within a 30 minute window after addition of LPS, and so signalling events would be at different stages. Kim et al, who also used LPS as a stimulus in RAW 264.7 cells, reported that cordycepin treatment decreased phosphorylation of IκB after 2.5 hours of LPS stimulation. Their paper does not show total IκBα levels, which is what my data show, and so I cannot directly compare their data to mine. Also, without knowing total IκBα levels, decreased signal of p-IκBα could be explained either by decreased phosphorylation (as Kim et al conclude) or increased degradation of the protein entirely. My observation that IκBα degradation is not prevented by cordycepin suggests that NF-κB translocation into the nucleus would be unimpeded, while Kim et al show that NF-κB translocation is inhibited by cordycepin (H. G. Kim et al. 2006). When measuring this, Kim et al used a longer LPS stimulation (2.5 hours). It would be interesting to repeat my experiments across a broader range of timepoints in order to better understand the timings of cordycepin’s reported effects. It would also be informative to assess localisation of NF-κB, as well as phosphorylation of IκBα and activation of upstream members of the pathway including IκB kinases (IKKs). In this way, a more complete picture would be obtained regarding the effects of cordycepin on NF-κB signalling (none of which were detected in my experiment). It should be noted that the localisation of NF-κB is not the only means to its regulation. Posttranslational mechanisms including
Phosphorylation and acetylation of NF-κB subunits also play roles (Karin and Ben-Neriah 2000; Christian, Smith, and Carmody 2016) which may be affected by cordycepin. Phosphorylation of p65 is an important activating modification in NF-κB signalling (see section 1.3.2.1.2 for more detail), and Li et al show this to be reduced by cordycepin (Y. Li et al. 2016). Such posttranslational modifications could also be assessed in a broader investigation into the effects of cordycepin on NF-κB signalling.

8.4 High throughput analysis of cordycepin’s effects

Genome-wide analysis by microarray showed that immune and inflammatory gene clusters are the most significantly enriched in the list of genes downregulated by cordycepin treatment compared to LPS alone. If intrinsically unstable mRNAs, which many inflammatory mRNAs are (P. Anderson 2010; Stumpo, Lai, and Blackshear 2010), were made with short poly(A) tails due to cordycepin treatment, this might explain why they are particularly sensitive to cordycepin. Since removal of the poly(A) tail is generally the first and rate-limiting step of mRNA decay (C.-Y. A. Chen and Shyu 2011), the loss of the poly(A) tail could leave unstable mRNAs susceptible to fast decay. However, no significant correlation was observed between mRNA stability and fold change after cordycepin treatment (Figure 6.2). If cordycepin arrests the cleavage complex as it has been shown to do in vitro (Zarkower and Wickens 1987), this could lead to a decreased availability of 3’ processing factors to such an extent that they become rate-limiting for transcripts with high processing factor requirements. High processing factor requirements could arise from genes with such a high transcription rate that the sheer number of transcripts being made requires a correspondingly high number of processing factors. Alternatively, such a requirement could exist in mRNAs with inefficient poly(A) signals (PASs) due to suboptimal cis elements. Figure 6.2 shows that no correlation was observed
between transcription rate and cordycepin sensitivity, and so this model does not fit either. To test whether there is a link between the efficiency or “strength” of poly(A) sites and cordycepin sensitivity from the microarray data, a bioinformatic approach could be used. However, preliminary analysis by project students of microarray data for cordycepin treatment in NIH-3T3 cells indicates that such a link is unlikely to exist. The arrested cleavage complex that forms the basis of the model has only been detected \textit{in vitro}. It would be worthwhile investigating whether the stabilisation of the complex by cordycepin is a phenomenon that occurs in cordycepin-treated cells. Microarray analysis revealed an enrichment of long noncoding RNAs (lncRNAs) in cordycepin-treated cells (\textit{Figure 6.3}). Given that there is a class of lncRNAs whose nuclear degradation is enhanced by polyadenylation (Beaulieu et al. 2012), this enrichment is consistent with a model in which cordycepin inhibits polyadenylation. If cordycepin inhibits polyadenylation of these lncRNAs, such RNAs would be expected to become stabilised (since their degradation is dependent upon polyadenylation). As mentioned previously, cordycepin causes repression of inflammatory genes at the transcriptional level, as inferred from unspliced mRNA levels (\textit{Figure 5.4}). Cordycepin’s anti-inflammatory effects are very fast, since the addition of cordycepin 10 minutes after the addition of LPS or 60 minutes before led to virtually the same degree of repression of inflammatory mRNAs (\textit{Figure 5.3}). This indicates that the anti-inflammatory effects are mediated very quickly, and unlikely to occur through a slow secondary process of altering transcription of a transcription factor. Rather, the effects are likely to be mediated either through a primary effect or through a fast secondary effect. This could be through effects on polyadenylation or effects on signal transduction e.g. AKT inhibition, as Kim et al claim is integral to cordycepin’s activities (H. G. Kim et al. 2006). The observation that a set of lncRNAs are stabilised by cordycepin presents
another explanation: if such lncRNAs regulate inflammation, whether by directly regulating inflammatory gene expression or modulating signal transduction, then their stabilisation by cordycepin could be responsible for the observed effects. Such a secondary effect could be quick enough to fit the data, since, in this model, cordycepin stabilises RNAs that have already been transcribed. Investigation into the potential involvement of the cordycepin-stabilised lncRNAs in mediating anti-inflammatory effects would be worthwhile.

To address the question of whether cordycepin’s acts through effects on polyadenylation or not, inhibition of polyadenylation in other ways would be worth attempting to see whether this replicates cordycepin’s effects. However, our attempts so far to perform knockdown of poly(A) polymerases (PAPs) in RAW 264.7 cells have been unsuccessful. Alternatively, other unrelated polyadenylation inhibitors could be used, or perhaps expression of a dominant negative PAP mutant.

8.5 Demonstrated therapeutic potential of cordycepin in osteoarthritis
Cordycepin has been successfully used as an anti-inflammatory compound in a number of animal models of disease and injury (X. Yang et al. 2015; M. Chen et al. 2012; H. Kim et al. 2011; Cheng et al. 2011). During this project, work done by James Burston (School of Life Sciences, University of Nottingham) showed that orally administered cordycepin alleviated pain behaviour in a rat model of osteoarthritis (Figure 7.1). No differences in poly(A) tail size between rat treatment groups were observed in synovial RNA, however (Figure 7.4), nor were there differences in the mRNA levels of cytokines that were assessed (Figure 7.3). If cordycepin has effects on polyadenylation in vivo, there are several possibilities that would account for our not detecting them. We may have been looking at the wrong time or in the wrong tissue. Also, it could be that total poly(A) tail size is unchanged but specific mRNAs
do experience changes. In this case, a more targeted approach of doing PAT on the
rat RNA for specific mRNAs would be appropriate. *Tnf* may be one such mRNA, since
its poly(A) tail was affected by cordycepin in RAW 264.7 cells (*Figure 5.8*).

Alternatively, a high throughput method like TAIL-seq could be used to observe
genome-wide poly(A) landscape changes between animals, but at much greater expense. If RNA from multiple tissues and at multiple stages in the disease model
were to be analysed, the expense of using TAIL-seq would certainly become prohibitive.

Limited data notwithstanding, the effects of cordycepin on pain behaviour in the rat
OA model represent a promising start into an assessment of cordycepin’s suitability
as a lead compound for the development of new OA treatments. These findings are
complemented by evidence of its anti-inflammatory effects in chondrocytes from OA
patients (Ying et al. 2014). The ability of cordycepin to overcome impairment of
osteogenesis and inhibit osteoclastogenesis (F. Wang et al. 2015; Dou et al. 2016)
suggests a potential to shift the balance of bone destruction and formation. Changes
in subchondral bone over the course of OA in the rat model may therefore be worth
monitoring between cordycepin and non-cordycepin treated animals. Finally, as a
compound with demonstrated anti-inflammatory effects, cordycepin would be
worth testing in rheumatoid arthritis (RA) – a disease with a more inflammatory
nature. Anti-TNF therapies have been highly successful in the treatment of RA (P. C.
Taylor, Taylor, and Feldmann 2009; Brennan et al. 1989), and cordycepin represses
TNF levels, both at the level of mRNA – as has been observed in this project – and
protein (Shin, Lee, et al. 2009; Jie Peng et al. 2015). However, anti-TNF biologics
have their shortcomings, including heightened risk of infections and loss of efficacy
over time (Askling and Dixon 2008; Neovius et al. 2015; P. C. Taylor, Taylor, and
Feldmann 2009). Cordycepin’s broad anti-inflammatory action may mean it has potential for the development of new RA treatment options.

In summary, this project provides insight into the effects of cordycepin, both at the transcriptomic and molecular level. In the context of inflammation, Tnf was found to have a dynamic poly(A) tail size in response to LPS stimulation, and this was true of the initial poly(A) tail size i.e. Tnf was made with a poly(A) tail of different size at different points in the inflammatory response. Cordycepin was shown to be anti-inflammatory and, in addition to reducing levels of inflammatory mRNAs, shortened the Tnf poly(A) tail. This effect, along with a stabilisation of IncRNAs, provide potential leads to be followed to discover the role of inhibiting polyadenylation in mediating cordycepin’s observed effects. Improved and emerging poly(A) tail measurement techniques will doubtless play a role in such investigation. Lastly, promising animal data support further research into the potential use of cordycepin as a therapeutic agent.
9 Bibliography


Beaulieu, Yves B., Claudia L. Kleinman, Anne-Marie Landry-Voyer, Jacek Majewski,


De Wit, Dominique, Sandrine Tonon, Véronique Olislagers, Stanislas Goriely, Michaël


Hafer, Nathaniel, Shuwa Xu, Krishna Moorthi Bhat, Paul Schedl, J. M. Alarcon, R.


Huang, Jingxiang, and Brendan D. Manning. 2009. “A Complex Interplay between Akt, TSC2 and the Two mTOR Complexes.” *Biochemical Society Transactions* 37 (1).


Rajaram, Murugesan V S, Latha P Ganesan, Kishore V L Parsa, Jonathan P Butchar,


Sandberg, Rickard, Joel R Neilson, Arup Sarma, Phillip A Sharp, and Christopher B


Shell, S. A., Candice Hesse, Sidney M. Morris, and Christine Milcarek. 2005. “Elevated Levels of the 64-kDa Cleavage Stimulatory Factor (CstF-64) in


Takagaki, Y., and J. L. Manley. 2000. “Complex Protein Interactions within the Human Polyadenylation Machinery Identify a Novel Component.” Molecular


Weber, M., Curt H. Hagedorn, David G. Harrison, and Charles D. Searles. 2005. “Laminar Shear Stress and 3’ Polyadenylation of eNOS mRNA.” *Circulation*


Wright, S D, R A Ramos, P S Tobias, R J Ulevitch, and J C Mathison. 1990. “CD14, a
Receptor for Complexes of Lipopolysaccharide (LPS) and LPS Binding Protein.” *Science (New York, N.Y.)* 249 (4975). American Association for the Advancement of Science: 1431–33. doi:10.1126/science.1698311.


